22 April 2005 Final Programme - The British Society for Rheumatology

BSR Annual Meeting
19 – 22 April 2005
A joint meeting with the Deutsche
Gesellschaft für Rheumatologie and
the Bone and Tooth Society
Final Programme
Birmingham International Convention
Centre, Birmingham, UK
with the British Health Professionals in
Rheumatology Spring Meeting,
20 – 22 April 2005

The ICC and Symphony Hall plan

BSR Annual Meeting & BHPR
Spring Meeting 2005
FINAL PROGRAMME
CONTENTS
Meeting at a Glance 2 - 3
Scientific Programme; Tuesday 19 April 4 - 8
Scientific Programme; Wednesday 20 April 8 - 15
Scientific Programme; Thursday 21 April 15 - 21
Scientific Programme; Friday 22 April 21 - 23
Additional Meetings 24
Abstracts for oral presentations
BSR Concurrent Oral Sessions; Tuesday 19 April, 17:00 – 18:30 25 - 28
BSR & BHPR Plenary Oral Session; Wednesday 20 April, 14:30 – 16:30 28
BHPR Oral Presentations; Thursday 21 April, 10:30 – 12:30 29
BSR Concurrent Oral Sessions; Thursday 21 April, 14:30 – 16:30 30 - 33
BHPR Oral Presentations; Friday 22 April, 10:00 – 11:00 34
Abstracts for poster presentations
Poster Viewing Session 1; Wednesday 20 April, 08:30 – 10:00 34 - 50
Poster Viewing Session 2; Thursday 21 April, 08:30 – 10:00 51 - 65
Poster Viewing Session 3 (inc. BHPR); Friday 22 April, 08:30 – 10:00 66 - 81
Exhibition Floor Plan 82
Exhibitor’s Details 83
Abstract Reviewers 89
Acknowledgements
Back Cover
1

BSR Annual Meeting & BHPR Spring
Meeting, 19 -22 April 2005
A joint meeting with the Deutsche Gesellschaft für Rheumatologie
and the Bone and Tooth Society
Birmingham International Convention Centre, Birmingham, UK
BSR & BHPR SCIENTIFIC PROGRAMME
Tuesday 19 April 2005
10:30 – 11:00 Coffee Hall 3
11:00 – 13:00 Vasculitis in Europe Hall 1
Chairs: Paul Bacon, Wolfgang Gross
• Environment – are there important risk factors? Prof. David Scott, Norwich, UK
This talk will review the literature on environmental factors in vasculitis and
especially the Norfolk study of 2003 linking for the first time farming exposure to
primary systemic vasculitis.
• Is it really vasculitis? Wolfgang Gross, Lübeck/Bad Bramstedt, Germany
The approach with patients with suspected vasculitis or even established vasculitis
always remains challenging because the condition may mimic infections, neoplasia
and/or drug effects. The diagnostic and therapeutic procedure will be discussed in
these cases.
• Is ANCA useful? Dr. Wilhelm Schmidt, Mannheim, Germany
Despite the close correlation of ANCA with ANCA associated vasculitides, the role
of ANCA-testing in clinical medicine is still controversial. This talk will discuss
strategies to minimize the occurrence of false-positive results and to interpret
changes in ANCA titers.
• Is cyclophosphamide always needed? Dr. David Jayne, Cambridge, UK
From being a revolution in the 1970s, the late toxicity associated with prolonged
cyclophosphamide in vasculitis highlighted the need for alternatives in the 1990s.
Cyclophosphamide usage has now become safer while alternatives, either immune
suppressives or therapeutic monoclonal antibodies, are progressively replacing
cyclophosphamide in the clinic
11:00 – 13:00 BSR Special Interest Groups
EMG/NCS Executive Room 7
Chair: Adam Young
• Carpal tunnel syndrome and thyroid disease. Ian Morris
• Polyneuropathy. Jenny Vaughan
• Proposed carpal tunnel syndrome/EMG research project.
Anna Young, MSc Research Physiotherapist
• How should rheumatologists provide an electrophysiology services. Rupa Bessant
• Clinical governance for EMG services in rheumatology
(competencies and standards). Jumbo Jenner
• Proposed future education courses
4

13:00 – 14:30 Lunch Hall 3
Genetics of Rheumatic Disease Executive Room 2
Convenor: Paul Wordsworth
• Dissection of the major histocompatibility complex component of
susceptibility to ankylosing spondylitis. Anne-Marie Sims
• Dissection of the MHC component of susceptibility to rheumatoid arthritis.
Sinead Harney
• MHC genes and rheumatoid arthritis. Rachel Kilding
• The CRH locus in rheumatoid arthritis. Sophia Steer
• Non-MHC genes in rheumatoid arthritis. Anne Barton
Osteoarthritis Hall 10B
Convenor: Fraser Birrell
• How to disseminate guidelines. Nigel Arden
• How to promote public information. Sophie Edwards, ARMA CEO
• How to implement changes of best clinical practice. Sue Page, NHCT CEO.
• Update in research database and collaborative studies. Fraser Birrell.
Scleroderma; the challenge management in adults and children
Executive Room 1
Chair: Carol Black
• The clinical challenge of childhood scleroderma. Joyce Davidson
• Challenges in epidemiology of adult and childhood scleroderma. Alan Silman
• Assessment of adult scleroderma: functional scores versus skin in
scleroderma assessment. Anita Smyth
• Risk stratification – can screening be targeted yet? Chris Denton
Rheumatology Open Debate/Forum: “Open Access Publishing:
a threat or opportunity for BSR” Hall 9
(Lunch will be available at the meeting.)
Debate speakers:
• Mrs Mandy Hill, Oxford University Press
• Mr Robert Kiley, The Wellcome Trust
The aim of the debate is to inform the rheumatology community about the
recent developments within the publishing industry and the possible impact that
they may have on a medical journal such as Rheumatology and on a learned
society such as the BSR which relies on income from its journal to carry out its
work, in this case to advance knowledge and practice in the field of
rheumatology, and to generate discussion. Each speaker is being asked to give a
20 min presentation after which discussion will be opened up to the audience.
BSR Standards, Guidelines and Audit Working Group
Open Meeting Hall 8
(Lunch will be available at the meeting.)
Come along to see presentations of the latest clinical guidelines in development
5

14:30 – 16:30 Regenerative medicine and gene therapy Hall 4
Chair: Yuti Chernajovsky
• Genetic defects in co-stimulation - lessons for new therapeutic targets in
rheumatology Prof. H-H Peter, Freiburg, Germany
Based on mouse models and human immunodeficiences costimulatory molecules
of the B7-CD28 superfamily (e.g. CTLA-Ig, ICOS) and homeostasis regulating
molecules of the TNF-TNFR superfamilies (BAFF, BAFF-R, TACI) are becoming
increasingly interesting new therapeutic targets for systemic autoimmune disases.
• Tissue engineering: chances and challenges for application in rheumatic
diseases Dr. Michael Sittinger, Berlin, Germany
Autologous chondrocyte transplantation is routinely applied to treat traumatic
cartilage lesions. However, regenerative therapies for chronic joint diseases are
still in an experimental phase. Next generation tissue-engineering therapies
will depend on "smart" delivery concepts based on the regenerative potential
of progenitor cells and tissue forming growth factors
• Targeting cytokines to sites of inflammation Dr. Sandrine Vessillier, London, UK
Latent cytokines have been engineered to increase their half life and target their
activation to disease sites. Promising results have been obtained by DNA injection
in a collagen induced arthritis model.
• Inflammatory signalling and their cross talk during tissue development and
regeneration Dr. Gerhard Gross, Braunschweig, Germany
The downregulation of the inflammatory mediator protein, the MAP3-Kinase TAK1,
significantly enhances TGF-beta/BMP and HLH-transcription factor dependent tissue
regeneration. Signalling mediators leading to tendon/ligament formation in vitro
may be used for a regenerative therapy of tendons in vivo
• Development of regulated vectors for gene therapy application
Dr. David J. Gould, London, UK
Development of gene therapy vectors that permit pharmacological and/or disease
regulated transgene expression. How these vectors can be delivered in the
treatment of disease, and progress that has been made in experimental arthritis
models.
14:30 – 16:30 Current concepts in osteoporosis – a combined session with the Bone and
Tooth Society Hall 1
Chairs: Jon Tobias and Richard Eastell
• High bone mass phenotypes and osteoporosis Prof. Matthew Warman,
Cleveland, USA An overview of the role of the cell surface receptor "low density
lipoprotein receptor related protein 5" (LRP5) and the Wnt signalling pathway in
human disorders of high and low bone mass.
• The role of the RANK/RANKL pathway Prof. Steven Goldring, Boston. USA
The talk will review the role of the RANK/RANKL pathway in the pathogenesis of
bone loss associated with inflammatory arthritis. Potential approaches for
targeting this pathway to prevent articular and systemic bone loss in patients with
rheumatoid arthritis and related forms of inflammatory joint disease will be
discussed."
• Role of anabolic therapy in the treatment of osteoporosis Prof. Robert Lindsay,
New York, USA
Most agents available for osteoporosis treatment are antiresorptive in their action.
That is they reduce remodling rate and stabilize bone density with a subsequent
reduction in fracture rate. So called anabolic agents (such as teriparatide)
stimulate both bone formation and remodeling. The consequence is increased
trabecular size and number as well as increased cortical thickness. These agents
repair at least some of the structural damage that we call osteoporosis. They also
6

16:30 – 17:00 Tea Hall 3
reduce the risk of fractures, but for a variety of reasons are often considered
to be "second line" agents. Such agents, by virtue of their effects on bone
structure, have the potential to produce dramatic fracture benefits, but these
have not been realized yet in clinical trials
• Case selection in osteoporosis Prof. John Kanis, Sheffield, UK
Identification of patients for treatment has centered on the assessment of
bone mineral density. Since low bone mineral density is only one of many
factors that contribute to fracture risk, selection of patients by fracture risk
assessment offers a more efficient strategy.
17:00 – 18:30 Concurrent oral presentations of abstracts
BSR/BATS Hall 4
Chair: Robert Lindsay
• Young Investigator Award Winner: Bone mass in childhood is not related
to measures of parental deprivation. Emma Clark
• Growth in infancy and childhood predicts hip fracture risk in late adulthood.
M Javaid
• Lipid profile is related to bone mineral density in middle aged UK men and
women: the Hertfordshire cohort study. Elaine Dennison
• Prevalent fractures, falls and walking aid use and the risk of future fracture.
Zoe Cole
• Increased IκB levels in patients with Paget’s Disease of bone carrying the
P392L sequestosome 1 gene mutation. Anna Daroszewska
• Comparison of longitudinal changes in BMD in advanced prostate cancer
patients treated with androgen ablation or anti-androgen hormonal therapy.
Asad Hussain
Clinical Genetics Hall 9
Chair: Matt Brown
• Association of the HLA-DRB1 shared epitope with mortality in rheumatoid
arthritis. Derek Mattey
• Association of the TNFα cleavage enzyme (TACE) gene with rheumatoid
arthritis. Catherine Potter
• A role for the protein tyrosine phosphatase N22 PTPN22 gene in autoimmune
disease. Ann Hinks
• Young Investigator Award Winner: Psoriatic arthritis is associated with a
Crohn’s disease gene. Pauline Ho
• Killer immunoglobulin-like receptor (KIR) polymorphism in psoriatic arthritis.
Eleanor Korendowych
• Polymorphisma in CTLA4 and CD28 are associated with systemic lupus
erythematosus. Deborah Graham
Imaging Hall 8
Chair: Philip Conaghan
• Distribution of erosions in early rheumatoid arthritis using macroradiographs.
Nicholas Shenker
• Ultrasound assessment of chronic deforming hand arthritis in SLE.
Stephen Wright
7

• A comparison of clinical versus ultrasound determined synovitis in rheumatoid
arthritis utilizing power Doppler and intravenous sonovue ® microbubble
enhancement. Patrick Kiely
• An audit on the use of magnetic resonance imaging (MRI) to diagnose axial
spondyloarthropathy (SPA). Adrian Gibbs
• Heberden’s nodes: what Heberden didn’t see – a high-resolution positron emission
tomography with 18 F-fluoride study of osteoarthritic and normal hands. Ai Lyn Tan
• Cortical processing of chronic arthritis pain versus acute experimental pain using
18
Flurodeoxygluxose 18 FDG positron emission tomography (PET). Bhavna Kulkami
Therapeutics 1 Hall 1
Chair: John Isaacs
• The changing use of disease-modifying anti-rheumatic drugs in individuals with RA
from the general practice research database (GPRD). Christopher Edwards
• Duration of response to a single treatment course of rituximab (RTX) in active
rheumatoid arthritis (RA): efficacy and safety data from a 2-year follow-up of a
randomised trial. Thomas Sheeran
• The react trial: efficacy evaluation of adalimumab (Humira ® ) in patients
switching from prior biologic DMARD therapies. Frank McKenna
• Serum MMP-3 levels fall following the initiation of methotrexate in patients with
early rheumatoid arthritis. Steven Young-Min
• 24-week efficacy and safety results form the adalimumab effectiveness in psoriatic
arthritis trial (ADEPT). Philip Mease
• Sustained efficacy and safety following a second treatment course of rituximab in
patients with rheumatoid arthritis. Paul Emery
18:30 – 19:30 Welcome buffet reception Hall 3
19:30 – 20:30 Debate: The majority of rheumatology services can be managed in
primary care Hall 1
Chair: Prof David Isenberg, BSR President, London, UK
• Speaking in favour of the motion: Prof Elaine Hay, Staffordshire, UK and
Dr Graham Davenport, President of PCR Society, UK
• Speaking against the motion: Prof. Gabriel Panayi, London, UK and Prof. David
Blake, Bath, UK
• Discussion panel: Prof. Bryan Williams, Cardiff, UK and Prof. Alan Silman,
Manchester, UK
Wednesday 20 April 2005
07:30 – 08:30 CMF Breakfast Hall 7A
08:30 – 10:00 Poster viewing Hall 3 Balcony
10:00 – 11:00 Poster discussions
Bone/Osteoporosis Hall 4
Chair: John Kanis
• Low vitamin D is associated with low peak bone mass in UK South Asian women.
Dipak Roy
• Influence of inflammatory polyarthritis on bone quality. Stephen Pye
8

• Regional audits of the prevention of corticosteroid-induced osteoporosis in
patients with rheumatic diseases in the West Midlands. Zoe Paskins
• Paternal skeletal size predicts neonatal bone mineral accrual. Nicholas Harvey
• Compliance and effect of bone protective treatment in elderly females: 5 year
follow up study. Sheelagh Doherty
• Persistence with oral bisphosphonate therapy is high amongst patients
followed in a DGH osteoporosis clinic. Alan Hakim
• Are biochemical markers predictive of radiographic progression in early
rheumatoid arthritis and do they perform better than traditional markers?
Steven Young-Min
• Assessment of criteria for lateral morphometry in over 65 year olds attending
for bone densitometry. Anne Dolan
Cellular interactions and immunological mechanisms Hall 10
Chair: Frances Hall
• Interleukin 6 (IL-6) signalling in rheumatoid arthritis. Sara Carty
• IL-6 and the soluble receptor in paired juvenile idiopathic arthritis (JIA) serum
and SF samples. Nicholas Peake
• Improvement of T-cell function in RA patients in clinical remission is
associated with the recovery of IL-7 expression and depends on familial
history of RA. Frederique Ponchel
• The signalling signature downstream of the notch receptor in
CD4+CD25 high regulatory T-cells in RA defines anergic cells: Insight into
resistance to anti-TNF therapies. Frederique Ponchel
• BiP stimulation induces an anti-inflammatory gene activation profile in
monocytes. Valerie Corrigall
• Tissue-specificity of adult human mesenchymal stem cells. Cosimo De Bari
• Non-DRB1 MHC genes associated with Rheumatoid Arthritis are also
differentially expressed. Sinead Harney
• Tumour Necrosis Factor Alpha (TNFα) Single Nucleotide Polymorphisms
(SNPs) in the Idiopathic Inflammatory Myopathies (IIMs). Hector Chinoy
Health services Hall 9
Chair: Deborah Symmons
• Can rheumatologists increase the uptake of influenza vaccination?
Jennifer Hamilton
• When serum creatine kinase is persistently elevated screen for the presence
of macro CK. Michael Fahie-Wilson
• Rheumatology and orthopaedic audit of carpal tunnel syndrome
management. Preeti Shah
• Missing out the middle man… direct access GP referrals for carpal tunnel
tests. David Coady
• Provision of foot health services in rheumatology in the UK.
Anthony Redmond
• Reducing work disability in ankylosing spondylitis: the AS work instability
scale (AS-WIS). Gill Gilworth
• Use of intention-to-treat analysis in rheumatology trials. Allan Clark
RA Treatment Hall 1
Chair: Alister Taggart
• Screening for lung disease prior to methotrexate in rheumatoid arthritis.
Asmita Dixit
• Biologics in early RA – who gets them and who doesn’t? Gisela Westhoff
9

• Do the proposed recommendations for assessing tuberculosis risk in patients
due to start anti-TNFα therapy alter resource use? Clare Wilkinson
• Biologics in rheumatoid arthritis (RA) – switching is effective? Ramesh Jois
• Change in the use of DMARDS and steroids after commencement of
anti-TNF therapy. George Kitas
• Long-term survival after lymphocytotoxic monoclonal antibody therapy for
rheumatoid arthritis. John Isaacs
• Is respiratory infection in patients with rheumatoid arthritis caused by
disease modifying drugs? Clive Kelly
• Comparison of treatment and outcome of rheumatological and non
rheumatological care in patients with rheumatoid arthritis. Ania Strangfeld
10:00 – 11:00 BHPR: Droitwich Lecture Hall 5
Lecturer: Mike Hurley
Chair: Candy McCabe
The Droitwich Trust has supported research into the cause and treatment of rheumatic
diseases, and has very generously offered to support a regular, prestigious lectureship
as part of the BHPR Spring Meeting. We are delighted that the inaugural Droitwich
Lecture will be given by Dr Mike Hurley, and he will begin by briefly describing the
research carried out in the Rehabilitation Research Unit, King’s College London.
Dr Hurley will go on to discuss the use of this research and the difficulties encountered
when conducting clinical trials of complex healthcare interventions, but points out
why these are essential. Finally, Dr Hurley will question why basic science research
gets a disproportionately large allocation of research resources compared to clinical
research, when basic research produces very little in the way of useful research
product, whereas clinical research produces what patients, healthcare professionals,
research-funders, the tax-payer and government want – high quality, clinically relevant
research that deliver better quality health care.
11:00 – 11:30 Coffee Hall 3
11:30 – 13:00 Performing arts medicine Hall 1
Chair: John Mathews
• Introduction; including a description and discussion of the place for Musicians'
Clinics within the field of Rheumatology and Performing Arts Medicine
John Mathews
• Upper limb disorders in musicians Prof Eckart Altenmüller, Hanover, Germany
Based on data of more than 2000 professional musicians, epidemiology, causes
and treatment of upper limb disorders in musicians will be reviewed. Myofascial
pain syndromes and focal dystonia with loss of voluntary control of skilled
movement patterns were seen most frequently. Novel therapeutic strategies will
be discussed.
• Sound in body and in mind, including demonstrations performed on his own violin
Prof. Paul Robertson, Leader of the Internationally renowned Medici Quartet and
explorer of the science of music
11:30 – 13:00 Imaging arthritis… from the fine detail to the big picture Hall 9
Chairs: Paul Bowness and Elisabeth Märker-Hermann
• Nanotopography as a novel strategy for therapeutic developments
Dr Matthew Dalby, Glasgow, Scotland
The use of a number of cell types cultured on nanoscale surface features has
allowed us to gain understanding into mechanotranductive events that could
influence differentiation. This study looks at these events and relates them to
osteoprogenitor differentiation.
10

• Cytometric analysis of immune responses Prof. Andreas Radbuch, Berlin,
Germany
Antigen-specific activation of the immune system, although involving only
few specific cells, can result in systemic changes in gene expression of
effector cell types. These changes are reflected on the mRNA and protein
levels, indicate the type of the underlying immune reaction, and allow to
classify rheumatic inflammation.
• The potential of molecular imaging for analysis and monitoring of
arthritis Dr. Ulf Müller-Ladner, Regensburg, Germany
In this talk, the current and future approaches of molecular imaging in
arthritis will be presented. A specific focus will address the visualization of
molecular processes operative in different in vitro and in vivo settings.
• Imaging beyond conventional radiography: mini arthroscopy, duplex
ultrasonography and positron emission tomography Dr. B. Ostendorf,
Düsseldorf, Germany
Modern imaging procedures, such as mini-arthroscopy, duplex
ultrasonography and positron emission tomography complete the set of
diagnostic tools for rheumatologists, when other diagnostics reach their
limits. These techniques open a widespread goal in terms of
aetiopathogenesis, early diagnosis and monitoring of inflammatory
rheumatic diseases.
11:30 – 13:00 Teaching old Drugs new tricks Hall 4
Chairs: Adrian Jones and Ekkehard Geth
• Rituximab - from cancer to chronic disease David Isenberg
Although introduced for the treatment of lymphoma, B cell depletion has
now been claimed to have major benefits for patients with rheumatoid
arthritis and systemic lupus erythematosus. This talk reviews the evidence for
this claim.
• Combination therapy – who gets it and when? Ernest Choy
Combination therapy is commonly used in treating patients with established
rheumatoid arthritis who have inadequate response to a single DMARD. A
number of recent studies have examined the role of combination therapy in
early RA. This lecture will review the use of combination therapy in
rheumatoid arthritis especially in patients with early disease.
• Systemic glucocorticoids - what should be their current role in
rheumatic disease? Prof. Dr. Frank Buttgereit, Berlin, Germany
Our understanding of the actions of glucocorticoids has greatly increased in
the last few years. In general, glucocorticoids mediate their effects by genomic
and non-genomic mechanisms. These various mechanisms of action provide
(a) the background for further improving the therapy using conventional
glucocorticoids and (b) interesting and sometimes very advanced starting
points for the development of optimised glucocorticoids and glucocorticoid
receptor ligands (such as SEGRAs, nitro-steroids or long-circulating liposomal
glucocorticoids).
11:30 – 13:00 BHPR: Utilising patients experiences Hall 5
Chairs: Sarah Ryan and Alison Hammond
• Patients experiences of anti-TNF. Lesley Kay
We have conducted qualitative research looking at patients' experience of
treatment with anti-TNF drugs for Rheumatoid Arthritis and Ankylosing
Spondylitis. Patients' expectations of treatment are very high and they describe
benefits (and problems) in dimensions not captured by data collected in
randomised controlled trials.
11

13:00 – 14:30 Lunch Hall 3
• Using patients experiences to develop a work instability tool. Gill Gilworth
This presentation will illustrate how data derived from qualitative interviews was
used as the basis for development of the RA-Work Instability Scale. The RA-WIS is a
simple, self-complete questionnaire which meets the stringent requirements of
modern measurement but also demonstrates excellent face validity because the
items on the scale emerged directly from real patients experiences.
• Patients, health professionals and managers views of services for
osteoarthritis. Jiri Chard
This study used qualitative and quantitative methods to investigate the views
of patients, health professionals and managers towards the provision of
services for OA. It further investigated the differences that exist between
these groups, and the potential impact this had on service provision.
BHPR & ARMA Meeting – are YOU able to offer the right standards of care?
Hall 10
(Lunch will be available at the meeting.)
Share ideas on how you can use the ARMA Standards of Care to help develop services
in your area. Hear about the forthcoming Dept of Health Musculoskeletal Services
Framework and how it could help you.
Chair: Krysia Dziedzic
• Learning from good practice. Maureen Cox, Clinical Nurse Specialist in
Rheumatology, Oxford
• Latest policy developments and how they might affect you. Sophie Edwards,
ARMA Chief Executive
BSRBR Open Meeting Hall 4
(Lunch will be available at the meeting.)
Chair: Ian Griffiths
• Welcome and introduction Ian Griffiths
• Update on the register Deborah Symmons
• Findings of the consultant survey 2005 Lesley Kay
• Data capture, transmission and retrieval Susan Oliver
• Questions and answers
RATs Meeting Hall 8B
(Lunch will be available at the meeting.)
14:30 – 16:30 BSR & BHPR Plenary oral presentations of abstracts Hall 1
Chairs: David Isenberg and Candy McCabe
• Serious infection rates in patents receiving biologic therapy in the United Kingdom:
results from the BSR Biologics Register (BSRBR). Will Dixon
• One-year outcomes of the “lifestyle management for arthritis” programme for
people with inflammatory arthritis. Alison Hammond
• Association of soluble tumour necrosis factor receptor II levels with mortality in
rheumatoid arthritis. Derek Mattey
• Perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable,
ignored. Sarah Hewlett
• Young Investigator Award Winner: Environmental risk factors for the
development of psoriatic arthritis: a case-control study. Emily Pattison
• Michael Mason Prize Winner: “Not only… but also:” factors that contribute to
accelerated atherosclerosis and premature coronary heart disease in systemic lupus
erythematosus. Ian Bruce
12

16:30 – 17:00 Tea Hall 3
17:00 – 18:00 Heberden Oration Hall 1
Orator: Prof. Marc Feldmann, London, UK
Chair: David Isenberg, BSR President, London, UK
As a mark of distinction every year the BSR President appoints a Heberden Orator
to give an hour keynote lecture at the BSR Annual Meeting. This tradition dates
back to 1938 and the distinguished Orator is awarded a medal.
18:00 – 19:45 Special Interest Groups
Cardiovascular co-morbidity in RA Executive Room 1
Convenor: George Kitas
• Epidemiology of cardiovascular comorbidity and death in RA.
Deborah Symmons
• Mechanisms for increased CVD in RA – potential therapeutics role of statins.
Jill Belch
• Trial of atorvastatin for the primary prevention of cardiovascular events in
rheumatoid arthritis (TRACE RA): design and practical considerations.
George Kitas
• General discussion and way forward
Clinical trials Hall 6B
Convenor: Ernest Choy
Aims and objectives: the main objective of the clinical trials SIG is to foster
and promote high quality clinical trials in musculoskeletal diseases. The
programme below should be of interest to anyone who is conducting or
planning to conduct clinical trials.
• A risk based approach to trial monitoring. Sarah Meredith
• Conducting successful clinical trials in primary care. Gareth Jones
• Large pragmatic trials. Richard Gray
Heritable disorders of connective tissue: New research into the Joint
Hypermobility Syndrome (JSH) – short papers and discussion
Executive Room 2
Co-chairs: Rodney Grahame and Howard Bird
Target audience: adult and paediatric rheumatologists and allied health
professionals in rheumatology.
Aims and objectives: to update BSR and BHPR members and guests on current
research trends in this most common of all rheumatological disorders, one that is
poorly understood, frequently overlooked, misdiagnosed and neglected.
• Musculoskeletal reflex function in JHS. William Ferrell
• The influence of JHS on outcome amongst attendees at a back pain
rehabilitation programme. Simon Ashton and Alan Hakim
• Experience of JHS in paediatric rheumatology practice;
• In a district general hospital. Nathan Hasson
• In a tertiary referral centre. Navid Adib
• Physiotherapy management. Susan Maillard
• Impact of joint hypermobility on the pattern of musculoskeletal morbidity
in young and older female dancers. Rodney Grahame
13

Lupus Hall 9
Co-convenors: Ian Bruce and Bridget Griffiths
Aims and objectives: The purpose of the group is to inform and update BSR
members who have an interest in Lupus about current research taking place.
In particular there are multi centre collaborative studies that are taking place which
they could take part in.
• Current multicentre studies in SLE. Ian Bruce, Bridget Griffiths
• The new BILAG 2004 index; current update. Chee-Seng Yee
• Subclinical atherosclerosis in a SLE cohort. Yasmeen Ahmad
• Future therapies for SLE. Bevra Hahn
PMR/Giant cell arteritis Hall 7B
Convenor: Bhaskar Dasgupta
Aims and Objectives: Attendees to this session will learn about the exciting
scientific programme of the Third International Conference on GCA and PMR to be
held at St John’s College, Cambridge on 24 th – 27 th July, 2005. The BSR also wishes to
develop guidelines for the management of PMR and GCA. We will discuss the
formation of a multi-disciplinary guidelines group for PMR and GCA. A very
preliminary review of the literature on PMR will be presented along with draft
guidelines for discussion.
• Third international conference on GCA/PMR, St John’s College,
24 – 27 July 2005. Brian Hazleman
• Scientific programme for GCA/PMR meeting. Paul Bacon
• BSR committee on quality, guidelines and audit standards. Tom Kennedy
• A preliminary review of literature on PMR. Nada Hassan
• Draft guidelines for management of GCA and PMR. Way Main Wong
RA Outcomes Hall 8B
Convenor: Adam Young
• The national database for German arthritis centres. Angela Zink
• Databases and audit tools for RA. BSR Working Party
• Health care commission perspective. Jonathan Boyce
• Cachexia and functional disability in RA. Kathryn Chester, Sam Marcora and
Peter Maddison
Soft tissue and sports medicine Hall 6A
Convenor: Cathy Speed
• Sports & exercise medicine in rheumatology. Roger Wolman
• Tendinopathies: scientific update. Graham Riley
• Tendinopathies: therapies old and new. Cathy Speed
Spondyloarthritis: Recent advances in genetics and treatment of ankylosing
spondylitis Hall 8A
Convenor: Paul Bowness
Target Audience: practicing clinicians with an interest in spondyloarthritis and/or
anti-TNF therapy, and individuals with scientific interest in the pathogenesis and
genetics of spondyloarthritis. All welcome.
Aims & Objectives: to increase the audience’s knowledge of the genetic basis of,
and current research in SpA, and to give participants an up to date knowledge of the
indications for, assessment of, and pitfalls involved in treatment of Spa with TNF
blockers.
• Recent advances in genetics of AS. Paul Wordsworth
• Anti-TNF treatment for AS, update from clinical trials and practical considerations.
Paul Emery
• Open discussion
14

Ultrasound: How to train in musculoskeletal ultrasound Hall 10
Convenor: David Kane
• Musculoskeletal ultrasound training in rheumatology – where are we in
developing guidelines and a curriculum? Andrew Brown
• How to assess musculoskeletal ultrasound competency – a practical experience
of a competency examination. Alister Taggart
• Discussion
• How can we implement MSUS in rheumatology training and practice?
• What is the research agenda for MSUS in rheumatology?
Vasculitis Hall 7A
Convenor: David Carruthers
• Clinical: Management of subglottic stenosis in Wegeners;
• Case presentation
• Management discussion
• Research: study update
• BSR/arc clinical trial. David Carruthers
• BVAS 2003. Raashid Luqmani
• Genetics. Richard Watts
• Research: new areas
• Diagnostic criteria for vasculitis. Raashid Luqmani
• Vasculitis treatment guidelines. David Scott
20:00 – 21:30 Satellite symposia
Abbott: Broadening Horizons in Anti-TNF Therapy – express your views
and join the interactive debate. Hall 4
• Introduction from chairman and interactive warm-up questions. Paul Emery
• Efficacy update on anti-TNF therapy. Paul Wordsworth
• Safety update anti-TNF therapy. David Isenberg
• What is the future for anti-TNF therapy? Duncan Porter
• Are funding issues and guidelines influencing prescribing habits?
Gabriel Panayi
• Questions and answers from the audience. Facilitated by Paul Emery
• Interactive evaluation questions. Facilitated by Paul Emery
MSD: Controversies and Challenges in Rheumatology 2005.
Off-site, Hyatt Hotel
Co-chairs: David Blake and Bryan Williams
The panel will be presented with a series of educational yet provocative questions,
case histories, and conundrums. This will be preceded by a look at what evidence
we can trust about efficacy and harm for analgesics, including a short COX-2
selective inhibitor clinical data update by Dr Andrew Moore, pain expert and
editor of the evidence based newsletter Bandolier.
Panel members: Henry Averns, Paul Bacon, Andrew Bamji, Mike Doherty, Brian
Hazleman, Peter Hollingworth, Rob Moots, Gabriel Panayi, Paul Reilly, Michael
Snaith, Usha Srinivasan, Robert Thompson, Douglas Veale, David Walker
Schering Plough: “Beneath the Skin”: treatment goals for underlying
disease in IMIDs Hall 5
• Welcome. David GI Scott, Chair
• Changing goals in the treatment of early rheumatoid arthritis. Peter Taylor
• Biologics in Ankylosing Spondylitis and Psoriatic Arthritis: new hope for our
patients? Bruce Kirkham
• Biologics in clinical practice. David GI Scott
15

Thursday 21 April 2005
07:30 – 08:30 Meet the Expert Workshops
• Dermatology Executive Room 1
Experts: Chris Lovell and Neil McHugh
• Fibromyalgia Executive Room 2
Expert: Jeremy Jones
• Pregnancy and joint disease Executive Room 8
Experts: Robert Moots and Steve Walkinshaw
• Renal lupus Executive Room 10
Experts: Jo Adu and Caroline Gordon
• Scleroderma Executive Room 9
Expert: Ariane Herrick
• Vasculitis Executive Room 7
Expert: Wolfgang Gross
Please note that there is an additional fee of £20 to attend one of these workshops,
and a continental breakfast is included in this fee. Places are limited and will be
allocated on a first come, first served basis. If you wish to attend one of these
sessions please check availability at the registration desks.
08:30 – 10:00 Poster viewing Hall 3 Balcony
08:30 – 09:30 BHPR Special Interest Groups
Connective tissue disease Hall 7A
• Multi-system lupus – a case study. Sue Brown
• Treatment of the skin in lupus Chris Lovell, Consultant Dermatologist, RUH, Bath
• CTD panel Q&A session
Osteoporosis Hall 7B
Chair: Alison Marchbank
• Welcome from chair
• Fracture liaison service and audit. Mayrine Fraser
• Wirral exercise class audit. Linda Cooper
• Questions/discussion
• 2006 SIG meeting speakers/topics
Rheumatoid arthritis Hall 5
Chair: Janet Cushnaghan
• Anti-TNF in children – clinical registry issues for the uninitiated Kate Cotter and
Nicky Freeman, Birmingham Children’s Hospital
• Remission in RA – are we achieving it? Lindsey Hawley, Christchurch Hospital
09:30 – 10:00 BHPR AGM Hall 5
10:00 – 10:30 Coffee Hall 3
16

10:30 – 12:30 Sytemic Sjögren’s Syndrome Hall 8
Chairs: Simon Bowman and Thomas Dörner
• Why do Sjögren’s syndrome patients get lymphoma?
Prof. Costantino Pitzalis, London, UK
Sjögren’s syndrome (SS) is an autoimmune exocrinopathy affecting lachrymal
and salivary glands characterised by focal periductal lymphocytic infiltration,
autoanti body production and glandular dysfunction. Within the salivary
glands, ectopic lymphoid neogenesis can occur with the formation of highly
organized periductal foci with the acquisition of germinal centre-like structures
involved in the production of specific autoantibodies. The progression from
polyclonal to monoclonal lymphoproliferation and the development of
lymphoma in approximately 5% of cases is regarded as a multi-step process.
The cellular and molecular mechanisms involved in this process will be
discussed.
• Anti-Ro/La antibodies and the neonatal lupus syndrome
Prof. Thomas Dörner, Berlin, Germany
Clinical manifestations of neonatal autoimmune syndromes, including
cutaneous lupus and congenital heart block will be reviewed with emphasis on
maternal and foetal risk factors as well as current therapeutic approaches in
these entities.
• Management of systemic Sjögren’s syndrome
Prof. Patrick Venables, London, UK
Although Sjögren's syndrome was first described in detail in 1933, for
rheumatologists it is a relatively novel disease. In this review I will describe how
management, which has historically been regarded as conservative and
symptomatic, has recently evolved into the use of disease modifying drugs,
including preliminary trials with biological therapies
• Sjögren’s syndrome - a look into the future?
Dr. Philip C Fox, Maryland, USA
A number of new therapeutic approaches, including salivary gland gene
transfer and B cell suppression, show promise in the future management of
Sjögren's syndrome. These also shed light on possible aetiopathogenic
mechanisms of the disorder.
10:30 – 12:30 Paediatric rheumatology Hall 1
Chair: Alison Leak
I. Unusual diagnoses of arthritis in childhood
• Paediatric episodic fever syndromes Dr Joost Frenkel, Utrecht, Holland
Mevalonate kinase deficiency is an inborn error of metabolism. It causes
autoinflammatory disease. Interleukin-1 plays a central role in the pathogenesis
of this inflammation.
• Paediatric lyme disease Prof. Hans-Iko Huppertz, Wurzberg, Germany
Lyme arthritis is the most frequent bacterial infection-associated arthritis in
children and adolescents and amenable to antibiotic treatment. Therefore
correct and early diagnosis is important.
II. JIA treatment registries – international experience
• Introduction Prof. Tauny Southwood, (for BSPAR) Birmingham, UK
In my talk, the philosophy underpinning the BSPAR Biologics Registry for
juvenile idiopathic arthritis will be discussed in relationship to other national
biologics registries in the USA, Germany and Italy. Future approaches to
detecting rare adverse events by pooling standardised international data will
be discussed.
17

• Experience with the German registry detailing 380 patients with JIA
Dr. Gerd Horneff, Halle, Germany
The German etanercept registry for treatment of Juvenile Idiopathic Arthritis
(JIA) has been founded in 2001, shortly after Enbrel became available. Since
then 451 JIA-Patients and 12 patients with different diagnoses have been
registered. Surveillance of adverse events and reasons for discontinuations are
major aims despite the analysis of clinical efficacy.
III. Growing up and moving on
• Transitional care in rheumatology Dr. Janet McDonagh, Birmingham, UK
Presentation of the evolving evidence base for transitional care for young people
with chronic rheumatic disease - including why, how and when to do it!
10:30 – 12:30 Should musculoskeletal ultrasound be available in your
rheumatology clinic? Hall 4
Chairs: Roger Sturrock and Wolfgang Schmidt
• Ultrasound in the diagnosis and management of soft tissue and tendon
disease Dr. Marina Backhaus, Erlangen, Germany
The ‘real-time’ capability of musculoskeletal ultrasound allows dynamic assessment
of joint and tendon movements, to visualize the structural abnormalities. The early
detection of inflammatory joint changes is crucial for initiating therapy influencing
the further course of the disease. A number of studies have described improved
sensitivity for detection of joint effusion, synovitis, and bone erosions in RA joints
with the use of ultrasound as compared with conventional clinical and radiological
methods
• Ultrasound in the diagnosis and management of bone erosion and cartilage
disease Dr. Richard Wakefield, Leeds, UK
This talk will discuss the value of ultrasound in the detection of bone erosions and
cartilage pathology in patients with rheumatic diseases
• The effect of ultrasound on clinical management Dr. David Kane, Newcastle, UK
This lecture will review the practical applications of musculoskeletal ultrasound in
everyday clinical rheumatology and the evidence that ultrasound improves clinical
outcomes.
• Beyond the joint: applications of ultrasound in diagnosing vasculitis, arteritis
and connective tissue disease Prof. Wolfgang Schmidt, Berlin, Germany
In temporal arteritis and Takaysu arteritis ultrasound delineates characteristic wall
swelling, stenoses, and occlusions. In Sjogren’s syndrome salivary glands are dark
and inhomogenous
10:30 – 12:30 BHPR oral presentations of abstracts Hall 5
Chairs: Krysia Dziedzic and Sarah Ryan
• Classifying hand OA in a population of older people: a reliability study.
Helen Myers
• Effects of combined exercise and self-management regimens on pain and function
in patients with osteoarthritis of the hip and kness: a systematic review with
meta-analysis. Nicola Walsh
• Patient expectations of anti-TNF therapy. Elizabeth McIvor
• “Pull yourself together”: a qualitative study of self-consciousness and selfdiscrepancy
in people with rheumatic disease. Elizabeth Hale
• Young Investigator Award Winner: Life satisfaction and depression across 1
year with rheumatoid arthritis: testing interactive effects of coping resources and
perceived stress. Gareth Treharne
• How much does pain, depression and anxiety affect the health assessment
questionnaire (HAQ) in the assessment of rheumatoid arthritis (RA) over time.
Sam Norton
18

12:30 – 14:30 Lunch Hall 3
12:45 – 14:00 BSR AGM Hall 9
14:30 – 16:30 Concurrent oral presentations of abstracts
Cellular interactions and immunological mechanisms Hall 9
Chair: Rob Moots
• Garrod Prize Winner: The role of cell surface HLA-B27 heavy chain
homodimer interactions with NK receptors in the pathogenesis of
spondyloarthropathies. Simon Kollnberger
• The association of different B27 alleles with the peptide loading complex.
Jane Goodall
• Young Investigator Award Winner: CD8+ regulatory T cells in patients
with ankylosing spondylitis (AS). Lorna Jarvis
• Sodium salicylate promotes neutrophil apoptosis. Andrew Cross
• Young Investigator Award Winner: A novel multicellular model of
leukocyte recruitment into the rheumatoid synovium reveals a critical role for
interleukin-6 (IL-6). Emily Smith
• The transcription T-BET is required for optimal pro-inflammatory trafficking of
CD + T-cells. Ravi Rao
• A role for IL-7 in regulating CD4 + CD25 high regulatory T cells. Frederique Ponchel
• The MYD88-independent lipopolysaccharide signalling pathway is regulated by
tissue specificity in TRAM expression. Olivier Harari
CTD Hall 4
Chair: Peter Maddison
• Synergy between monocyte chemoattractant protein-3 (MCP- 3) and TGFß1 in
promoting fibrosis. Voon Ong
• Transforming growth factor beta(1) induces endothelin expression by lung
fibrpoblasts: possible role of endothelin in pulmonary fibrosis in scleroderma.
Xu Shiwen
• Diffuse systemic sclerosis: role of SMAD3 polymorphisms. Sudeep Pushpakom
• CXCL13 and CCL21 expression is associated with the progressive organisation
of lymphoid-like structures in Sjögren’s syndrome. Francesca Barone
• The immunomodulatory effects of atorvastatin may be mediated by disruption
of membrane microdomains. Elizabeth Jury
• Translocation of CD45 to lipid raft signalling domains and abnormal relocation
during B-lymphocyte activation in SLE. Fabian Flores-Boria
• Infection in infancy and the presence of ANA in adults. Christopher Edwards
• The prevalence and incidence of biopsy proven lupus nephritis – influence of
ethnicity. Mumtaz Patel
Therapeutics 2 Hall 1
Chair: Bryan Williams
• Mortality among RA patients receiving anti-TNFα therapy in the United
Kingdom: results from the BSR Biologics Register. Kath Watson
• Efficacy and safety of adalimumab (Humira ® ) in European clinical practice:
the REACT trial. Gerd Burmester
• Aglycosyle anti-CD3 monoclonal antibody therapy in rheumatoid arthritis –
results of a pilot safety study. Catherine Lawson
• Predicting response to anti-TNFα therapy among patients with rheumatoid
arthritis. Kimme Hyrich
19

• Characterisation of regulatory T cells in rheumatoid arthritis before and after
treatment with anti-TNFα therapy. Catherine Mathews
• Major clinical response and sustained remission over 4 years in patients with
rheumatoid arthritis treated with adalimumab (humira r® ) plus methotrexate.
Paul Emery
• Follow up study of B-lmphocyte depletion in the treatment. Maria Leandro
• Efficacy and safety of adalimumab in children with juvenile idiopathic arthritis
(JIA). Daniel Lovell
Vascular injury and vasculitis Hall 8
Chair: Raashid Luqmani
• Self-reported arthritis and cardiovascular disease share common risk factors.
Alexandra Clarke
• Rheumatoid factor is an independent risk factor for ischaemic heart disease in men.
Christopher Edwards
• Association between inflammatory markers and atherosclerotic disturbance of
common carotid artery in patients with rheumatoid arthritis. Olena Galyutina
• A role for protease-activated receptor-2 in thrombin-mediated cytoprotection of
vascular endothelium. Justin Mason
• Anomalous NKG2D expression on CD4+CD28- T-cells in Wegner’s granulomatosis.
Peter Lamprecht
• European medicines agency (EMEA) consensus on the classification of the primary
systemic vasculitides (PSV) for epidemiological studies. Suzanne Lane
• Primary systemic vasculitis – unchanged incidence over 15 years. Richard Watts
• Interferon – alpha treatment in refractory Churg-strauss syndrome: first results of a
phase II prospective open label study. Claudia Metzler
14:30 – 16:30 BHPR: Communication Hall 5
Chairs: Paul Creamer and Jackie Hill
• Patient initiated review clinics. Sarah Hewlett
Traditionally, patients with rheumatoid arthritis have been given lifelong regular
reviews, initiated by the hospital team. Reports of a randomized controlled trial
into patient-initiated reviews will be presented, and consideration of their practical
implications.
• The role of DIPEx. Jane Carter
The launch of the rheumatoid arthritis module, as part of the DIPEx website, is a
valuable educational resource for both patients and healthcare professionals alike.
This collection of individual patient experiences about 'what it is like to live with
RA', together with information and resources, will be discussed.
• Comparing professional and patient narratives – issues of concordance and
discor dance. BN Ong
This presentation will explore the concept of concordance in examining the
relationships between clinicians and back pain patients, using the Back Pain in
North Staffordshire study. The relevance of this concept for managing chronic
musculoskeletal problems will be discussed.
• The experiences of running telephone help-lines. Cath Thwaites.
Following a national survey of rheumatology departments, a qualitative study was
conducted to explore Rheumatology Nurse Specialists experiences of providing tele
phone helpline advice.
16:30 – 17:00 Tea Hall 3
20

17:00 – 18:00 Heberden Round “Looking to the Future in the Treatment of Systemic
Lupus Erythematosus and Its Complications” Hall 1
Roundsperson: Dr. Bevra Hahn, California, USA
Chair: David Isenberg, BSR President
The Heberden Round was initiated in 1948 to acknowledge the work of an
individuals’ outstanding contribution to clinical rheumatology. The award
traditionally took the form of a ward round in the appointee’s own hospital.
In 1999 it was decided that the Round would be incorporated into the BSR’s
Annual Meeting to ensure greater exposure to the membership. This has proved
to be a huge success and the one hour annual Heberden Round presentation
remains a highlight within the rheumatology calendar.
Friday 22 April 2005
08:30 – 10:00 Poster viewing (BSR & BHPR) Hall 3 Balcony
10:00 – 11:00 Poster Discussions
CTD Hall 4
Chair: Anisur Rahman
• The pathogenesis of systemic sclerosis – insights from the innate immune
system. Marina Anderson
• Lower and upper limb macrovascular disease is uncommon in scleroderma
but is amenable to angioplasty. Neeraj Garg
• The distribution of the endogenous retrovirus HERV-K113 and –K115 in
health and disease: HERV-K113 as a novel risk factor for Sjögren’s syndrome.
David Moyes
• Effect of Sjögren’s syndrome on senses of smell and taste: impact on quality
of life. Usama Kamel
• The Y-linked autoimmune accelerator YAA gene is sufficient to break
immunological tolerance. Michelle Hayward
• Could B cells have the potential to control lupus-like syndrome in MRL/lpr?
Karina Chavez
• Soluble L-selectin levels correlate with genotype and a clinical subset of
systemic lupus erythematosus (SLE). Andrew Russell
• Seronegative antiphospholipid (Hughes) syndrome. Shirish Sangle
Education research Hall 9
Chair: Jane Dacre
• Doctors’ confidence in teaching musculoskeletal examination skills to
medical students. Ann Marie Smith
• Comparing the feedback from final year medical students in rheumatology:
is a consultant better than a clinical nurse educator? Kate Gadsby
• What influences undergraduate medical students to utilise the computer
assisted learning package “virtual rheumatology”? Pirashanthie
Vivekananda-Schmidt
• Use of the internet in rheumatology outpatients – trends and barriers.
Wendy Holden
• Primary care rheumatology – what do general practitioners want to know?
Inam Haq
21

• Validation of modular training in diagnostic and interventional
musculoskeletal ultrasound in patients with hip osteoarthritis. Ismael Atchia
• Audit of locomotor system assessment of patients admitted for acute
medical conditions to general medical wards. Ahmed Bawendi
RA Clinical Hall 1
Chair: Peter Dawes
• Prevalence, treatment and assessment of foot involvement in rheumatoid
arthritis: a neglected area. Sarah Farrow
• Longitudinal measurement of traditional observer and laboratory based
markers enhances prediction of radiographic progression in early rheumatoid
arthritis. Patient based responses were of limited use. Steven Young-Min
• Anaemia of chronic disease in rheumatoid arthritis: relationships with disease
activity. Olena Ostapchuk
• Socioeconomic differences in rheumatoid arthritis in Gujerati Asian and Caucasian
communities in Leicester: a profound effect on the patient? Catherine Neville
• Rheumatoid factor and HLA-DRB1*0401, but not cigarette smoking, are
independently associated with antibodies to cyclic citrullinated peptides in
rheumatoid arthritis. Derek Mattey
• Body composition and disease severity in patients with rheumatoid arthritis.
Mykola Stanislavchuk
• Hypertension (HT) prevalence is high and target blood pressure (BP) is under
achieved in a rheumatoid arthritis (RA) out-patient population. Neil McKay
• Longitudinal study of lung function in rheumatoid arthritis treated with
methotrexate. Vaivelis Saravanan
Spondyloarthropathies Hall 8
Chair: Elisabeth Märker-Hermann
• Extended haplotypes of MICA, TNF-alpha and lyphotoxin in psoriatic arthritis.
Eleanor Korendowych
• Nail and distal interphalangeal joint in psoriatic patients, Raffaele Scarpa
• Radiological progression in established psoriatic arthritis. Jaya Ravindran
• Adalimumab efficacy and safety results in patients with moderate to severe chronic
plaque psoriasis: subanalysis of patients with and without PsA. M Alan Menter
• Phenotypic and functional characterisation of natural killer (NK) receptor expressing
T lymphocytes in spondyloarthritis. Antoni Chan
• A longitudinal study of clinical and psychosocial status in ankylosing spondylitis.
Jane Martindale
• Low-dose infliximab for ankylosing spondylitis in clinical practice - ? more cost
effective. Ramesh Jois
• The cost effectiveness and efficacy of IV pamidronate in ankylosing spondylitis.
Alison Leak
10:30 – 11:30 BHPR oral & prize presentations Hall 5
Chairs: Lindsey Hawley and Margaret Somerville
• Audit of an advanced exercise programme for patients with inflammatory
joint disease (IJD). Mohamed Nisar
• Winner of the arc Silver Medal
Complementary therapies in RA Ginny Rose
• Winner of the Special Innovation Prize NRAS Patients in Focus Awards 2005
The innovative collaboration between rheumatological occupational therapy
services and a high street jeweller, to produce finger orthotics as silver jewellery.
Christina Macleod
22

11:00 – 11:30 Coffee Hall 3
11:30 – 12:30 State of the Art Lecture – Infection, inflammation, autoimmunity:
sorting out chronic disease Hall 1
Speaker: Prof. Ave Mitchison, London, UK
Chair: David Isenberg, BSR President
The State of the Art lecture is generally of broader interest, but relevant to
rheumatologists, and is traditionally given by an invited lecturer who is eminent
within their field.
11:30 – 12:30 BHPR: Professional issues. Hall 5
Chairs: Sarah Hewlett and Krysia Dziedzic
• arc education for health professionals update. Karen Mounce
The Arthritis Research Campaign has developed a programme of education for
allied health professionals working in rheumatology in partnership with the
University of Brighton. The flexible programme is the Graduate Certificate in
Rheumatology Practice and is designed to meet the training needs of
extended role practitioners.
• Making a difference, the role of ACUMeN in multi-disciplinary
development. Jackie Hill
The Academic and Clinical Unit of Musculoskeletal Nursing (ACUMeN) was
launched in April 2003 with the aim of generating, disseminating and
applying knowledge for the improvement of nursing practice and patient out
comes. However, nursing does not function in isolation within the
musculoskeletal environment and the development of multidisciplinary
working will be explored in this session.
12:30 – 13:00 Lunch Hall 3
13:00 Close of meeting
23

Additional Meetings
Please note that as a general rule all meetings within this listing are by invitation only, exceptions are the
open/public meetings which are shown in colour.
Date & Time Meeting Name Room
Tuesday 19 April
13:00 – 14:15 BSR Standards, Audit and Guidelines Working
Group Open Mtg Hall 8
13:00 – 14:00 ERAN AGM Hall 10B
13:00 – 14:00 Rheumatology Open Debate/Forum Hall 9
16:45 – 18:00 BSRBR Management Committee Executive Room 7
Wednesday 20 April
07:30 – 08:30 Christian Medical Fellowship Breakfast Hall 7A
07:30 – 08:30 Biologics Register Control Centre Meeting Executive Room 1
10:00 – 11:00 BSR Clinical Affairs Committee Hall 6A
13:00 – 14:30 RATs Meeting Hall 8B
13:00 – 14:30 BSR Biologics Register Open Meeting Hall 4
13:00 – 14:30 BHPR & ARMA Meeting – are YOU able to offer
the right standards of care? Hall 10
13:00 – 14:30 arc/BSR/MRC MIPA Clinical Trial Meeting Executive Room 1
14:30 – 16:30 Ankylosing Spondylitis anti-TNF guideline group Hall 6A
Thursday 21 April
12:45 – 14:00 BSR AGM Hall 9
10:00 – 11:30 CARDERA Trial Meeting Executive Room 1
Friday 22 April
07:15 start Fun Run – sponsored by Wyeth, please visit their
(coach departs ICC 06:30) exhibition stand for more details. Alexander Stadium
07:30 – 08:30 arc/BSR/MRC QUINS Clinical Trial Meeting Artists Lounge
12:00 – 13:00 BSPAR Register Management Committee meeting Artists Lounge
14:30 onwards PRCA meeting Hall 5
As usual all rooms are in high demand throughout the BSR Annual Meeting and the turnaround time
between sessions is very tight, therefore it is essential that all meetings/sessions commence and conclude
in a timely fashion. Any over-run will have a severe impact on the remainder of the scientific programme.
If you are attending any of the above meetings please ensure that you arrive promptly in order
to avoid a late start, and any resultant over-run.
24

Concurrent Oral Sessions
Tuesday 19 April 2005, 16:30 – 18:00
Therapeutics I (OP1 – OP6) Hall 1
OP1 THE CHANGING USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN INDIVIDUALS
WITH RA FROM THE GENERAL PRACTICE RESEARCH DATABASE (GPRD) THE CHANGING USE OF
DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RA FROM THE GENERAL PRACTICE
RESEARCH DATABASE.
C.J. Edwards 1 , N.K. Arden 1,2 , T.P. Van Staa 2 , I. Reading 2 , J.C. Saperia 2 , D. Fisher 2 , C. Cooper 2
1
Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton, United
Kingdom; 2 MRC Epidemiology Resource Centre, University of Southampton, Soputhampton, United
Kingdom
OP2 DURATION OF RESPONSE TO A SINGLE TREATMENT COURSE OF RITUXIMAB (RTX) IN
ACTIVE RHEUMATOID ARTHRITIS (RA): EFFICACY AND SAFETY DATA FROM A 2-YEAR
FOLLOW-UP OF A RANDOMISED TRIAL.
T. Sheeran 1 , P. Emery 2 , P.B. Lehane 3 , N. Saiedabadi 3 , T.M. Shaw 3
1
Cannock Chase Hospital, Cannock, United Kingdom; 2 Leeds General Infirmary, Leeds, United
Kingdom; 3 Roche Products Ltd, Welwyn, United Kingdom
OP3 THE REACT TRIAL: EFFICACY EVALUATION OF ADALIMUMAB (HUMIRA®) IN PATIENTS
SWITCHING FROM PRIOR BIOLOGIC DMARD THERAPIES.
F. McKenna 1 , S. Bombardieri 2 , A.G. Tzioufas 3 , M.G. Malaise 4 , D.G. Webber 5 , H. Kupper 5
1
Trafford General Hospital, Manchester, United Kingdom; 2 Azienda Ospedaliera Pisana P.O.S., Chiara,
Pisa, Italy; 3 National University of Athens, Athens, Greece; 4 CHU University of Liege, Liege, Belgium;
5
Abbott Laboratories, Ludwigshafen, Germany
OP4 SERUM MMP-3 LEVELS FALL FOLLOWING THE INITIATION OF METHOTREXATE IN
PATIENTS WITH EARLY RHEUMATOID ARTHRITITS.
S.A. Young-Min 1 , N. Marshall 2 , E. Ohuchi 3 , I.D. Griffiths 2 , T.E. Cawston 1
1
Musculoskeletal Research Group, University of Newcastle-upon-Tyne, Newcastle upon Tyne, Tyne &
Wear, United Kingdom; 2 Rheumatology, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear,
United Kingdom; 3 Daiichi Fine Chemical Co Ltd, Toyama, Japan
OP5 24-WEEK EFFICACY AND SAFETY RESULTS FROM THE ADALIMUMAB EFFECTIVENESS IN
PSORIATIC ARTHRITIS TRIAL (ADEPT).
P.J. Mease 1 , E.H.S. Choy 2 , D.D. Gladman 3 , C.T. Ritchlin 4 , E.M. Ruderman 5 , S.D. Steinfeld 6 , M.A.
Weinberg 7
1
University of Washington School of Medicine, Seattle, WA, United States; 2 King's College London,
London, United Kingdom; 3 University of Toronto, Toronto, Canada; 4 University of Rochester School
of Medicine and Dentistry, Rochester, NY, United States; 5 Feinberg School of Medicine,
Northwestern University, Chicago, IL, United States; 6 Eraseme University Hospital, Brussels, Belgium;
7
Abbott Laboratories, Abbott Park, IL, United States
OP6 SUSTAINED EFFICACY AND SAFETY FOLLOWING A SECOND TREATMENT COURSE OF
RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS.
P. Emery 1 , T. Sheeran 2 , L. Szczepanski 3 , J. Szechinski 4 , A. Filipowicz-Sosnowska 5 , M. Nahir 6 , K.
Pavelka 7 , N. Saiedabadi 8 , P.B. Lehane 8
1
Leeds General Infirmary, Leeds, United Kingdom; 2 Cannock Chase Hospital, Cannock Chase, United
Kingdom; 3 Medical University, Lublin, Poland; 4 Medical University, Wroclaw, Poland; 5 Rheumatology
Inst, Warsaw, Poland; 6 Rambam Medical Centre, Haifa, Israel; 7 Rheumatology Inst, Prague, Czech
Republic; 8 Roche Products Ltd, Welwyn Garden City, United Kingdom
25

Clinical Genetics (OP7-OP12) Hall 9
OP7 ASSOCIATION OF THE HLA-DRB1 SHARED EPITOPE WITH MORTALITY IN RHEUMATOID
ARTHRITIS.
D.L. Mattey 1 , W. Thomson 2 , W.E.R. Ollier 2 , M. Batley 3 , G. Koduri 3 , A. Young 3
1
Rheumatology Centre, University Hospital North Staffs, Stoke-on-Trent, United Kingdom; 2 Centre for
Integrated Genomic Medical Research, University, Manchester, United Kingdom; 3 On behalf of ERAS, City
Hospital, St Albans, United Kingdom
OP8 ASSOCIATION OF THE TNFα CLEAVAGE ENZYME (TACE) GENE WITH RHEUMATOID ARTHRITIS.
C. Potter 1 , A. Cope 2 , J. Worthington 1 , A. Barton 1
1
ARC-EU, University of Manchester, Manchester, United Kingdom; 2 Kennedy Institute, UCL, London,
United Kingdom
OP9 A ROLE FOR THE PROTEIN TYROSINE PHOSPHATASE N22 (PTPN22) GENE IN AUTOIMMUNE
DISEASE.
A. Hinks 1 , A. Barton 1 , A. Simpson 2 , S. John 3 , S. Eyre 1 , I. Bruce 1 , C. Hawkins 4 , C.E.M. Griffiths 5 , B.S.P.A.R.
Study Group 1 , R. Donn 1 , W. Thomson 1 , A. Silman 1 , J. Worthington 1
1
ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 North West Lung
Centre, Wythenshawe Hospital, Manchester, United Kingdom; 3 Centre for Integrated Genomic Medical
Research, University of Manchester, Manchester, United Kingdom; 4 Keele Multiple Sclerosis Research
Group, Department of Neurology, University Hospital of North Staffordshire, Stoke on Trent,
Staffordshire, United Kingdom; 5 Dermatology Centre, Hope Hospital, University of Manchester,
Manchester, United Kingdom
OP10 PSORIATIC ARTHRITIS IS ASSOCIATED WITH A CROHN'S DISEASE GENE.
P. Ho 1 , I. Bruce 1 , A. Silman 1 , D. Symmons 1 , B. Newman 3 , H. Young 2 , C. Griffiths 2 , J. Worthington 1 ,
A. Barton 1
1
ARC-EU, University of Manchester, Manchester, United Kingdom; 2 Dermatology Centre, University of
Manchester, Manchester, United Kingdom; 3 Academic Department of Medical Genetics, University of
Manchester, Manchester, United Kingdom
OP11 KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) POLYMORPHISM IN PSORIATIC ARTHRITIS.
E. Korendowych 1 , N.J. McHugh 1 , J. Trowsdale 2 , S. Gaudieri 3 , J.A. Traherne 2
1
Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 2 Cambridge Institute for Medical
Research, Cambridge, United Kingdom; 3 Centre for Clinical Immunology and Biomedical Statistics, Royal
Perth Hospital, Perth, WA, Australia
OP12 POLYMORPHISMS IN CTLA4 AND CD28 ARE ASSOCIATED WITH SYSTEMIC LUPUS
ERYTHEMATOSUS.
D.C. Graham, A. Wong, T.J. Vyse
Rheumatology, Imperial College, London, United Kingdom
BSR/BATS Joint Session (OP13 – OP18) Hall 4
OP13 BONE MASS IN CHILDHOOD IS NOT RELATED TO MEASURES OF PARENTAL DEPRIVATION.
E.M. Clark 1 , A. Ness 1 , J. Tobias 2
1
The ALSPAC Study Team, Community Based Medicine, University of Bristol, Bristol, United Kingdom;
2
Clinical Medicine at South Bristol, Bristol Royal Infirmary, Bristol, United Kingdom
OP14 GROWTH IN INFANCY AND CHILDHOOD PREDICTS HIP FRACTURE RISK IN LATE ADULTHOOD.
M.K. Javaid 1 , J.G. Eriksson 2 , T. Forsen 2 , C. Osmand 1 , D.J. Barker 1 , C. Cooper 1
1
Bone and Joint, MRC Epidemiology Resource Centre, Southampton, Hampshire, United Kingdom;
2
Diabetes and Genetic Epidemiology, The National Public Health Institute, Helsinki, Finland
26

OP15 LIPID PROFILE IS RELATED TO BONE MINERAL DENSITY IN MIDDLE AGED UK MEN AND
WOMEN: THE HERTFORDSHIRE COHORT STUDY.
E.M. Dennison, H.E. Syddall, A. Aihie Sayer, H.J. Gilbody, C. Cooper
MRC Resource Centre, Southampton General Hospital, Tremona Road, Southampton, Hants, United
Kingdom
OP16 PREVALENT FRACTURES, FALLS AND WALKING AID USE AND THE RISK OF FUTURE
FRACTURE.
Z. Cole 1 , S. Crozier 1 , F. Anderson 2 , H. Smith 3 , H. Raphael 3 , C.J. Edwards 1 , C. Cooper 1 , N.K. Arden 1
1
MRC Epidemiology Resource Centre, Southampton General Hospital, Southampton, Hampshire,
United Kingdom; 2 University of Geriatric Medicine, Southampton General Hospital, Southampton,
United Kingdom; 3 Department of Primary Care, Division of Community-Based Clinical Sciences,
Southampton General Hospital, Southampton, United Kingdom
OP17 INCREASED IκB LEVELS IN PATIENTS WITH PAGET'S DISEASE OF BONE CARRYING THE
P392L SEQUESTOSOME 1 GENE MUTATION.
A. Daroszewska, R.J. van 't Hof, S.H. Ralston
Medicine and Therapeutics, University of Aberdeen, Aberdeen, Aberdeenshire, United Kingdom
OP18 COMPARISON OF LONGITUDINAL CHANGES IN BMD IN ADVANCED PROSTATE CANCER
PATIENTS TREATED WITH ANDROGEN ABLATION OR ANTI- ANDROGEN HORMONAL THERAPY.
A. Hussain, V. Wadhwa, R. Weston, N. Parr, E. George
Rheumatology, Wirral Hospital, Wirral, Merseyside, United Kingdom
Imaging (OP19 – OP24) Hall 8
OP19 DISTRIBUTION OF EROSIONS IN EARLY RHEUMATOID ARTHRITIS USING
MACRORADIOGRAPHS.
N.G. Shenker 1 , E. Messent 3 , C. Stevens 2 , C. Buckland-Wright 3 , D.R. Blake 1
1
Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United
Kingdom; 2 School for Health, University of Bath, Bath, United Kingdom; 3 School of Biomedical
Sciences, King's College, London, United Kingdom
OP20 ULTRASOUND ASSESSMENT OF CHRONIC DEFORMING HAND ARTHRITIS IN SLE.
S.A. Wright 1 , E. Filippucci 3 , W. Grassi 3 , A. Grey 2 , A.L. Bell 1
1
Queens University Lupus Research Group, Musgrave Park Hospital, Belfast, United Kingdom;
2
Deparment of Radiology, Musgrave Park Hospital, Belfast, United Kingdom; 3 Cattedra di
Reumatologia., Università Politecnica delle Marche., Ancona, Italy
OP21 A COMPARISON OF CLINICAL VERSUS ULTRASOUND DETERMINED SYNOVITIS IN
RHEUMATOID ARTHRITIS UTILIZING POWER DOPPLER AND INTRAVENOUS SONOVUE®
MICROBUBBLE ENHANCMENT.
J.D. Rees 1 , J. Pilcher 2 , C. Heron 2 , P.D.W. Kiely 1
1
Rheumatology, St Georges Healthcare NHS Trust, London, United Kingdom; 2 Radiology, St Georges
Healthcare NHS Trust, London, United Kingdom
OP22 AN AUDIT ON THE USE OF MAGNETIC RESONANCE IMAGING (MRI) TO DIAGNOSE AXIAL
SPONDYLOARTHROPATHY (SpA).
A. Gibbs, O. FitzGerald, B. Bresnihan, D.J. Veale
St. Vincents University Hospital, Dublin 4, Ireland
27

OP23 HEBERDEN'S NODES: WHAT HEBERDEN DIDN'T SEE - A HIGH-RESOLUTION POSITRON
EMISSION TOMOGRAPHY WITH 18F-FLUORIDE STUDY OF OSTEOARTHRITIC AND NORMAL HANDS.
A.L. Tan 1 , M.L. Waller 2 , A.P. Jeavons 3 , R.F. Bury 4 , E.M.A. Hensor 1 , S.F. Tanner 3 , P. Emery 1 , D. McGonagle 1
1
Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 2 Department of
Medical Physics and Engineering, Leeds General Infirmary, Leeds, United Kingdom; 3 Academic Unit of
Medical Physics, University of Leeds, Leeds, United Kingdom; 4 Department of Nuclear Medicine, Leeds
General Infirmary, Leeds, United Kingdom
OP24 CORTICAL PROCESSING OF CHRONIC ARTHRITIC PAIN VERSUS ACUTE EXPERIMENTAL PAIN
USING 18 FLURODEOXYGLUCOSE (18FDG) POSITRON EMISSION TOMOGRAPHY (PET).
B. Kulkarni 1 , E. Boger 1 , A. Watson 1 , P. Julyan 2 , R. Elliott 3 , D. Hastings 2 , A.K.P. Jones 1
1
Human Pain Research Group, University of Manchester Rheumatic Diseases Centre, Hope Hospital,
Salford, United Kingdom; 2 North Western Medical Physics, Christie Hospital NHS Trust, Withington,
Manchester, United Kingdom; 3 Neuroscience and Psychiatry Unit, Stopford Building, University of
Manchester, Manchester, United Kingdom
BSR & BHPR Plenary Session
Wednesday 20 April 2005, 14:30 – 16:30 (OP25 – OP30) Hall 1
OP25 SERIOUS INFECTION RATES IN PATIENTS RECEIVING BIOLOGIC THERAPY IN THE UNITED
KINGDOM: RESULTS FROM THE BSR BIOLOGICS REGISTER (BSRBR).
W. Dixon, K. Hyrich, K. Watson, D. Symmons, A. Silman
The BSR Biologics Register; ARC Epidemiology Unit, University of Manchester, Manchester, United
Kingdom
OP26 ONE-YEAR OUTCOMES OF THE "LIFESTYLE MANAGEMENT FOR ARTHRITIS" PROGRAMME FOR
PEOPLE WITH INFLAMMATORY ARTHRITIS.
A. Hammond 1 , J. Bryan 2 , A. Hardy 1
1
Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom; 2 Occupational Therapy,
Ripley Community Hospital, Ripley, Derbyshire, United Kingdom
OP27 ASSOCIATION OF SOLUBLE TUMOUR NECROSIS FACTOR RECEPTOR II LEVELS WITH
MORTALITY IN RHEUMATOID ARTHRITIS.
J.R. Glossop 1,2 , P.T. Dawes 2 , A.B. Hassell 2 , D.L. Mattey 1,2
1
Keele University, Stoke-on-Trent, Staffs, United Kingdom; 2 Staffordshire Rheumatology Centre,
Stoke-on-Trent, Staffs, United Kingdom
OP28 PERCEPTIONS OF FATIGUE IN RHEUMATOID ARTHRITIS: OVERWHELMING, UNCONTROLLABLE,
IGNORED.
S. Hewlett 1 , M. Hehir 1 , M. Byron 1 , Z. Cockshott 1 , K. Kitchen 1 , S. Tipler 2 , D. Pope 2
1
Rheumatology Unit, University of Bristol, Bristol, United Kingdom; 2 Rheumatology Centre, Bristol Royal
Infirmary, Bristol, United Kingdom
OP29 ENVIRONMENTAL RISK FACTORS FOR THE DEVELOPMENT OF PSORIATIC ARTHRITIS:
A CASE-CONTROL STUDY.
E.J. Pattison 1 , B.J. Harrison 1 , C.E. Griffiths 2 , A.J. Silman 1 , I.N. Bruce 1
1
ARC Epidemiology Unit, The University of Manchester, Manchester, United Kingdom; 2 Dermatology
Centre, The University of Manchester, Hope Hospital, Salford, United Kingdom
OP30 "NOT ONLY… BUT ALSO:" FACTORS THAT CONTRIBUTE TO ACCELERATED ATHEROSCLEROSIS
AND PREMATURE CORONARY HEART DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS
I.N. Bruce.
The University of Manchester, Rheumatism Research Centre, Central Manchester and Manchester
Children’s University Hospital Trust, Oxford Road, Manchester, M13 9WL, UK
28

BHPR Oral Presentations
Thursday 21 April 2005, 10:30 – 12:30 (OP31 – OP36) Hall 5
OP31 CLASSIFYING HAND OA IN A POPULATION OF OLDER PEOPLE: A RELIABILITY STUDY.
H. Myers 1 , K. Dziedzic 1 , E. Thomas 1 , E. Hay 1,2 , P. Croft 1
1
Primary Care Sciences Research Centre, Keele University, Keele, Staffs, United Kingdom;
2
Staffordshire Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, Staffs, United Kingdom
OP32 EFFECTS OF COMBINED EXERCISE AND SELF-MANAGEMENT REGIMENS ON PAIN AND
FUNCTION IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND KNEE: A SYSTEMATIC REVIEW
WITH META-ANALYSIS.
N.E. Walsh 1 , M.V. Hurley 2 , H.L. Mitchell 2 , B.C. Reeves 3
1
Faculty of Health and Social Care, University of the West of England, Bristol, United Kingdom;
2
Rehabilitation Research Unit, Kings College London, London, United Kingdom; 3 Health Services
Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
OP33 PATIENT EXPECTATIONS OF ANTI TNF THERAPY.
E.M. McIvor
Rheumatology, Stobhill Hospital, Glasgow, Scotland, United Kingdom
OP34 "PULL YOURSELF TOGETHER": A QUALITATIVE STUDY OF SELF-CONSCIOUSNESS AND
SELF-DISCREPANCY IN PEOPLE WITH RHEUMATIC DISEASE.
E.D. Hale 1 , G.J. Treharne 1,2 , D.L. Mitton 1,3 , Y. Norton 4 , C. Gordhan 5 , P.A. Bacon 5 , G.D. Kitas 1,2,5
1
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands,
United Kingdom; 2 School of Psychology, University of Birmingham, Birmingham, United Kingdom;
3
School of Health Sciences, University of Birmingham, Birmingham, United Kingdom; 4 West
Midlands Branch, Lupus UK, Coseley, West Midlands, United Kingdom; 5 Department of
Rheumatology, Division of Immunology and Infection, School of Medicine, University of
Birmingham, Birmingham, United Kingdom
OP35 LIFE SATISFACTION AND DEPRESSION ACROSS 1 YEAR WITH RHEUMATOID ARTHRITIS:
TESTING INTERACTIVE EFFECTS OF COPING RESOURCES AND PERCEIVED STRESS.
G.J. Treharne 1,2 , A.C. Lyons 3 , D.A. Booth 1 , G.D. Kitas 1,2,4
1
School of Psychology, University of Birmingham, Birmingham, United Kingdom; 2 Department of
Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom;
3
School of Psychology, Massey University, Auckland, New Zealand; 4 Department of Rheumatology,
Division of Immunity and Infection, School of Medicine, University of Birmingham, Birmingham,
United Kingdom
OP36 HOW MUCH DOES PAIN, DEPRESSION AND ANXIETY AFFECT THE HEALTH ASSESSMENT
QUESTIONNAIRE (HAQ) IN THE ASSESSMENT OF RHEUMATOID ARTHRITIS (RA) OVER TIME.
S. Norton 1 , D. Wellsted 2 , C. Mayes 1 , N. Cox 1 , P. Prouse 1 , D. James 1
1
On behalf of the Early Rheumatoid Arthritis Study (ERAS), City Hospital, St Albans, United
Kingdom; 2 R&D Support Unit, University of Hertfordshire, Hatfield, United Kingdom
29

Concurrent Oral Presentations
Thursday 21 April 2005, 14:30 – 16:30
CTD (OP37 – OP44) Hall 4
OP37 SYNERGY BETWEEN MONOCYTE CHEMOATTRACTANT PROTEIN-3 (MCP-3) AND TGFß1 IN
PROMOTING FIBROSIS.
V.H. Ong, M.T. Carulli, G. Lindahl, S. Xu, D.J. Abraham, C.M. Black, C.P. Denton
Centre for Rheumatology, Royal Free Hospital, London, United Kingdom
OP38 TRANSFORMING GROWTH FACTOR BETA(1) INDUCES ENDOTHELIN EXPRESSION BY LUNG
FIBROBLASTS: POSSIBLE ROLE OF ENDOTHELIN IN PULMONARY FIBROSIS IN SCLERODERMA.
X. Shiwen 1 , A. Leask 1 , C.P. Denton 1 , E.A. Renzoni 2 , F. Rodriguez-Pascual 3 , S. Lamas 3 , R.M. du Bois 2 , D.J.
Abraham 1 , C.M. Black 1
1
Department of Rheumatology, Royal Free Hospital, London, United Kingdom; 2 Interstitial Lung Disease
Unit, Royal Brompton Hospital, London, United Kingdom; 3 Biological Research Centre, C.S.I.C, Madrid,
Spain
OP39 DIFFUSE SYSTEMIC SCLEROSIS: ROLE OF SMAD3 POLYMORPHISMS.
S.P. Pushpakom 1 , A.L. Herrick 2 , S. Kumar 1 , J.E. Worthington 3
1
Pathology, Medical School, University of Manchester, Manchester, United Kingdom; 2 Rheumatic Diseases
Centre, Hope Hospital, Salford, United Kingdom; 3 Arthritis Research Campaign- Epidemiology Unit,
University of Manchester, Manchester, United Kingdom
OP40 CXCL13 AND CCL21 EXPRESSION IS ASSOCIATED WITH THE PROGRESSIVE ORGANIZATION OF
LYMPHOID-LIKE STRUCTURES IN SJÖGREN'S SYNDROME.
F. Barone 1 , M. Bombardieri 1 , A. Manzo 1 , M. Blades 1 , P.R. Morgan 2 , S.J. Challacombe 2 , G. Valesini 3 ,
C. Pitzalis 1
1
Rheumatology, GKT School of Medicine Kings College, London, United Kingdom; 2 Oral Pathology and
Medicine, GKT School of Medicine Kings College, London, United Kingdom; 3 Reumatologia, Università La
Sapienza, Roma, Italy
OP41 THE IMMUNOMODULATORY EFFECTS OF ATORVASTATIN MAY BE MEDIATED BY DISRUPTION
OF MEMBRANE MICRODOMAINS.
E.C. Jury, C. Mauri, M.R. Ehrenstein
Department of Medicine, University College London, London, United Kingdom
OP42 TRANSLOCATION OF CD45 TO LIPID RAFT SIGNALLING DOMAINS AND ABNORMAL
RELOCATION DURING B-LYMPHOCYTE ACTIVATION IN SLE.
F. Flores-Borja 1 , P.S. Kabouridis 1 , E. Jury 2 , D. Isenberg 2 , R.A. Mageed 1
1
Bone and Joint Research Unit, St Bartholomew's and The Royal London, Queen Mary School of
Medicine, London, United Kingdom; 2 Centre for Rheumatology, University College London, London,
United Kingdom
OP43 INFECTION IN INFANCY AND THE PRESENCE OF ANA IN ADULTS.
C.J. Edwards 1 , S. Westlake 1 , H.S. Sydall 2 , P. Goswami 1 , E.M. Dennison 2 , N.K. Arden 2 , C. Cooper 2
1
Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton, United
Kingdom; 2 MRC Epidemiology Resource Centre, University of Southampton, Southampton, United
Kingdom
OP44 THE PREVALENCE AND INCIDENCE OF BIOPSY PROVEN LUPUS NEPHRITIS - INFLUENCE OF
ETHNICITY.
M. Patel 1 , A. Clarke 2 , I. Bruce 2 , F. Qasim 1 , D. Symmons 2
1
MINT, Manchester Royal Infirmary, Manchester, United Kingdom; 2 ARC Epidemiology Unit, The University
of Manchester, Manchester, United Kingdom
30

Cellular Interactions and Immunological Mechanisms (OP45 – OP52) Hall 9
OP45 THE ROLE OF CELL SURFACE HLA-B27 HEAVY CHAIN HOMODIMER INTERACTIONS WITH
NK RECEPTORS IN THE PATHOGENESIS OF SPONDYLOARTHRITIS
S Kollnberger.
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital,
Headington, Oxford, OX3 9DS, UK
OP46 THE ASSOCIATION OF DIFFERENT B27 ALLELES WITH THE PEPTIDE LOADING COMPLEX.
J.C. Goodall, L. Ellis, H.J.S. Gaston
Medicine, University of Cambridge, Cambridge, Cambs, United Kingdom
OP47 CD8+ REGULATORY T CELLS IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS).
L.B. Jarvis, M.K. Matyszak, J.H. Gaston
Dept. Medicine, University of Cambridge, Cambridge, United Kingdom
OP48 SODIUM SALICYLATE PROMOTES NEUTROPHIL APOPTOSIS.
A. Cross 1 , M. Derouet 1 , L. Thomas 1 , R.J. Moots 2 , S.W. Edwards 1
1
School of Biological Sciences, University of Liverpool, Liverpool, Merseyside, United Kingdom;
2
Academic Rheumatology Group, University of Liverpool, Liverpool, United Kingdom
OP49 A NOVEL, MULTI-CELLULAR MODEL OF LEUKOCYTE RECRUITMENT INTO THE
RHEUMATOID SYNOVIUM REVEALS A CRITICAL ROLE FOR INTERLEUKIN-6 (IL-6).
E. Smith 1 , F. Lally 1 , A. Filer 2 , M.A. Stone 3 , J.S. Shaw 3 , G.B. Nash 1 , C.D. Buckley 2 , G.E. Rainger 1
1
Department of Physiology, University of Birmingham, Birmingham, United Kingdom; 2 Department
of Rheumatology, University of Birmingham, Birmingham, United Kingdom; 3 Respiratory and
Inflammation Research, AstraZeneca, Alderley Edge, United Kingdom
OP50 THE TRANSCRIPTION T-BET IS REQUIRED FOR OPTIMAL PRO-INFLAMMATORY
TRAFFICKING OF CD4 + T-CELLS.
R.M. Rao 1 , G.M. Lord 2 , H. Choe 3 , A.H. Lichtman 1 , F.W. Luscinskas 1 , L.H. Glimcher 2
1
Center of Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital,
Boston, MA, United States; 2 Department of Immunology and Infectious diseases, Harvard School of
Public Health, Boston, MA, United States; 3 Department of Pediatrics, Children's Hospital, Boston,
MA, United States
OP51 A ROLE FOR IL-7 IN REGULATING CD4 + CD25 high REGULATORY T CELLS.
C.A. Lawson 1,2 , A.K. Brown 1 , S.L. Field 2 , C. Burgoyne 2 , P. Emery 1 , J.D. Isaacs 3 , F. Ponchel 1,2
1
Department of Rheumatology, University of Leeds, Leeds, United Kingdom; 2 Molecular Medicine
Unit, University of Leeds, Leeds, United Kingdom; 3 Department of Rheumatology, University of
Newcastle, Newcastle, United Kingdom
OP52 THE MYD88-INDEPENDENT LIPOPOLYSACCHARIDE SIGNALLING PATHWAY IS REGULATED
BY TISSUE SPECIFICITY IN TRAM EXPRESSION.
O.A. Harari 2 , J.K. Liao 1
1
Vascular Medicine Research, Brigham & Womens Hospital, Harvard Medical School, Cambridge,
MA, United States; 2 Eric Bywaters Centre for Arthritis and Vascular Inflammation, Hammersmith
Hospital, Imperial College London, London, United Kingdom
Vascular Damage and Vasculitis (OP53 – OP60) Hall 8
OP53 SELF-REPORTED ARTHRITIS AND CARDIOVASCULAR DISEASE SHARE COMMON RISK
FACTORS.
A. Clarke 1 , R. Harrison 2 , P. Elton 3 , D. Symmons 1
1
ARC Epidemiology Unit, The University of Manchester, Manchester, United Kingdom; 2 Bolton
Primary Care Trust, Bolton, United Kingdom; 3 Bury Primary Care Trust, Bury, United Kingdom
31

OP54 RHEUMATOID FACTOR IS AN INDEPENDENT RISK FACTOR FOR ISCHAEMIC HEART DISEASE
IN MEN.
C.J. Edwards 1,2 , H.E. Syddall 2 , P. Goswami 1 , R. Goswami 1 , E.M. Dennison 2 , N.K. Arden 1,2 , C. Cooper 2
1
Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton, United
Kingdom; 2 Medical Research Council Epidemiology Resource Centre, University of Southampton,
Southampton, United Kingdom
OP55 INCREASED ARTERIAL STIFFNESS IN PATIENTS WITH TAKAYASU'S ARTERITIS.
W.F. Ng 1 , R. Schiff 2 , F. Dockery 2 , K.A. Davies 3 , C. Rajkumar 3 , J.C. Mason 1
1
Rheumatology, Eric Bywaters Centre, Hammersmith Hospital, London, United Kingdom; 2 Elderly Care,
Hammersmith Hospital, London, United Kingdom; 3 Medicine, Brighton and Sussex Medical School,
Brighton, United Kingdom
OP56 A ROLE FOR PROTEASE-ACTIVATED RECEPTOR-2 IN THROMBIN-MEDIATED CYTOPROTECTION
OF VASCULAR ENDOTHELIUM.
E.A. Lidington 1 , R. Steinberg 1 , A. Kinderlerer 1 , C. Landis 1 , M. Ohba 2 , A. Samarel 3 , D.O. Haskard 1 , J.C.
Mason 1
1
Cardiovascular Medicine Unit, Eric Bywaters Centre, Imperial College, London, United Kingdom; 2 Institute
of Molecular Oncology, Showa University, Tokyo, Jordan; 3 The Cardiovascular Institute, Loyola University,
Chicago, United States
OP57 ANOMALOUS NKG2D EXPRESSION ON CD4+CD28- T-CELLS IN WEGENER'S
GRANULOMATOSIS.
A. Mueller 1 , D. Capraru 1 , K. Holl-Ulrich 2 , E. Csernok 1 , J. Voswinkel 1 , W.L. Gross 1 , P. Lamprecht 1
1
Department of Rheumatology, University Hospital of SH, Campus Luebeck, Luebeck, Germany; 2 Institute
of Pathology, University Hospital of SH, Campus Luebeck, Luebeck, Germany
OP58 EUROPEAN MEDICINES AGENCY (EMEA) CONSENSUS ON THE CLASSIFICATION OF THE PRIMA-
RY SYSTEMIC VASCULITIDES (PSV) FOR EPIDEMIOLOGICAL STUDIES.
S.E. Lane 1 , R.A. Watts 1 , D.G.I. Scott 2
On Behalf of EMEA Vasculitis Group; 1 Rheumatology, Ipswich Hospital, Ipswich, Suffolk, United Kingdom;
2
Rheumatology, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom
OP59 PRIMARY SYSTEMIC VASCULITIS - UNCHANGED INCIDENCE OVER 15 YEARS.
R.A. Watts 1 , S.E. Lane 1 , J. Mooney 2 , D.G.I. Scott 2
1
Rheumatology Department, Ipswich Hospital, Ipswich, Suffolk, United Kingdom; 2 Rheumatology
Department, Norfolk & Norwich University Hospital, Norwich, Norfolk, United Kingdom
OP60 INTERFERON-ALPHA TREATMENT IN REFRACTORY CHURG-STRAUSS SYNDROME: FIRST RESULTS
OF A PHASE II PROSPECTIVE OPEN LABEL STUDY.
C. Metzler, W.L. Gross, B. Hellmich
Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
Therapeutics II (OP61 – OP68) Hall 1
OP61 MORTALITY AMONG RA PATIENTS RECEIVING ANTI-TNFα THERAPY IN THE UNITED KINGDOM:
RESULTS FROM THE BSR BIOLOGICS REGISTER.
K. Watson, K. Hyrich, A. Silman, D. Symmons
The BSR Biologics Register; ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom
OP62 EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA®) IN EUROPEAN CLINICAL PRACTICE:
THE REACT TRIAL.
G.R. Burmester 1 , P. Wordsworth 2 , X. Mariette 3 , I. Monteagudo Sáez 4 , J.W.J. Bijlsma 5 , D.G. Webber 6 ,
H. Kupper 6
1
Universitätsklinikum Charité, Berlin, Germany; 2 University of Oxford, Oxford, United Kingdom; 3 Centre
Hospitalier de Bicêtre, Bicêtre, France; 4 H.G.U. Gregorio Marañón, Madrid, Spain; 5 University Medical
Center Utrecht, Utrecht, Netherlands; 6 Abbott GmbH & Co. KG, Ludwigshafen, Germany
32

OP63 AGLYCOSYL ANTI-CD3 MONOCLONAL ANTIBODY THERAPY IN RHEUMATOID
ARTHRITIS – RESULTS OF A PILOT SAFETY STUDY.
C.A. Lawson 1,2 , B. Griffiths 3 , F. Ponchel 1,2 , G. Hale 4 , H. Waldmann 4 , J.D. Isaacs 3
1
Molecular Medicine Unit, University of Leeds, Leeds, United Kingdom; 2 Department of
Rheumatology, University of Leeds, Leeds, United Kingdom; 3 Department of Rheumatology,
University of Newcastle, Newcastle, United Kingdom; 4 Dunn School of Pathology, University of
Oxford, Oxford, United Kingdom
OP64 PREDICTING RESPONSE TO ANTI-TNFα THERAPY AMONG PATIENTS WITH RHEUMATOID
ARTHRITIS.
K. Hyrich, K. Watson, D. Symmons, A. Silman
The BSR Biologics Register; ARC Epidemiology Unit, University of Manchester, Manchester,
United Kingdom
OP65 CHARACTERIZATION OF REGULATORY T CELLS IN RHEUMATOID ARTHRITIS BEFORE AND
AFTER TREATMENT WITH ANTI-TNFα THERAPY.
C.J. Mathews, J. Evans, F. Choudry, M.R. Ehrenstein, C. Mauri
Centre for Rheumatology, University College London, London, United Kingdom
OP66 MAJOR CLINICAL RESPONSE AND SUSTAINED REMISSION OVER 4 YEARS IN
PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ADALIMUMAB (HUMIRA®)
PLUS METHOTREXATE.
P. Emery 1 , M.H. Schiff 2 , J.R. Kalden 3 , G.T. Spencer-Green 4 , O.G. Segurado 5
1
University of Leeds, Leeds, United Kingdom; 2 Denver Arthritis Clinic P.C., Denver, CO, United States;
3
University of Erlangen, Erlangen, Germany; 4 Abbott Laboratories, Parsippany, NJ, United States;
5
Abbott Laboratories, Abbott Park, IL, United States
OP67 FOLLOW UP STUDY OF B-LYMPHOCYTE DEPLETION IN THE TREATMENT OF PATIENTS
WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
M.J. Leandro, J.C.W. Edwards, M.R. Ehrenstein, G. Cambridge, D.A. Isenberg
Centre for Rheumatology, University College London, London, United Kingdom
OP68 EFFICACY AND SAFETY OF ADALIMUMAB IN CHILDREN WITH JUVENILE IDIOPATHIC
ARTHRITIS (JIA).
D.J. Lovell 1 , N. Ruperto 2 , S. Goodman 3 , A. Reiff 4 , A. Martini 2 , E.H. Giannini 1 , R. Carcereri-De-Prati 5 ,
G.T. Spencer-Green 6
1
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; 2 Printo-IRCCS G
Gaslini, Genova, Italy; 3 Arthritis Associates of South Florida, DelRay Beach, FL, United States;
4
Children's Hospital Los Angeles, Los Angeles, CA, United States; 5 Abbott GmbH & Co. KG,
Ludwigshafen, Germany; 6 Abbott Laboratories, Parsippany, NJ, United States
33

BHPR Oral Presentations
Friday 22 April 2005, 10:00 – 11:00 Hall 5
OP69 AUDIT OF AN ADVANCED EXERCISE PROGRAMME FOR PATIENTS WITH INFLAMMATORY
JOINT DISEASE (IJD).
H. Nutland, H. Smith, A. Douglas, M. Nisar
Dept of Rheumatology, Queen's Hospital, Burton on Trent, United Kingdom
To be followed by oral presentations from the winners of the arc and NRAS prizes.
Poster Viewing Session 1
Wednesday 20 April 2005, 08:30 – 10:00
Biology of bone, cartilage and connective tissue disease
1 ARE BIOCHEMICAL MARKERS PREDICTIVE OF RADIOGRAPHIC PROGRESSION IN EARLY
RHEUMATOID ARTHRITIS AND DO THEY PERFORM BETTER THAN TRADITIONAL MARKERS?
S.A. Young-Min 1 , I. Griffiths 1 , N. Marshall 1 , D. Coady 1 , E. Ohuchi 3 , S. Christgau 4 , S. Robins 5 , T. Saxne 6 ,
T. Cawston 1
1
Musculoskeletal Research Group, University of Newcastle & Freeman Hospital, Newcastle upon Tyne,
United Kingdom; 2 Daiichi Fine Chemical Co Ltd, Toyama, Japan; 3 Nordic Bioscience, Herlev, Denmark;
4
Rowett research Institute, Aberdeen, United Kingdom; 5 Lund University Hospital, Lund, Sweden
2 NK CELLS SUPPORT OSTEOCLAST FORMATION IN VITRO.
L. Danks, S. Owen, M. Feldmann, F. Brennan, N.J. Horwood
Kennedy Institute of Rheumatology, Imperial College, Charing Cross Site, Hammersmith, London, United
Kingdom
Osteoporosis and metabolic bone disease
3 PATERNAL SKELETAL SIZE PREDICTS NEONATAL BONE MINERAL ACCRUAL.
N.C.W. Harvey 1 , M.K. Javaid 1 , P. Taylor 2 , S.R. Crozier 1 , E.M. Dennison 1 , H.M. Inskip 1 , K.M. Godfrey 1 ,
C. Cooper 1
1
MRC Epidemiology Resource Centre, Southampton, United Kingdom; 2 Medical Physics and
Bioengineering, Southampton General Hospital, Southampton, United Kingdom
4 BIRTH WEIGHT AND CALCIUM ABSORPTION AS DETERMINANTS OF BONE MINERAL DENSITY IN
ADULT MEN: THE HERTFORDSHIRE COHORT STUDY.
M.B.R. Patel 1 , H.E. Syddall 1 , L.M. Masterson 1 , C. Shanmugasundaram 1 , R.I.G. Holt 2 , R. Swaminathan 3 ,
C. Cooper 1 , N.K. Arden 1
1
Medical Research Council, Epidemiology Resource Centre, University of Southampton, Southampton,
Hampshite, United Kingdom; 2 School of Medicine, University of Southampton, Southampton,
Hampshire, United Kingdom; 3 Department of Chemical Pathology, St Thomas' Hospital, London,
United Kingdom
5 LOW VITAMIN D IS ASSOCIATED WITH LOW PEAK BONE MASS IN UK SOUTH ASIAN WOMEN.
D.K. Roy 1 , J.L. Berry 2 , J.E. Adams 3 , C.M. Swarbrick 1 , Y. King 1 , S.R. Pye 1 , A.J. Silman 1 , T.W. O'Neill 1
1
ARC Epidemiology Unit, University of Manchester, Manchester, Greater Manchester, United Kingdom;
2
Department of Medicine, Manchester Royal Infirmary, Manchester, Greater Manchester, United
Kingdom; 3 Department of Imaging Science and Biomedical Engineering, University of Manchester,
Manchester, Greater Manchester, United Kingdom
34

6 INFLUENCE OF DISEASE AND NON-DISEASE RELATED FACTORS ON BONE MINERAL DENSI-
TY IN WOMEN WITH ESTABLISHED INFLAMMATORY POLYARTHRITIS.
T. Marshall 1 , S.R. Pye 2 , K. Gaffney 1 , D.P.M. Symmons 2 , T.W. O'Neill 2 , A.J. Silman 2
1
Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Trust, Norwich,
United Kingdom; 2 ARC Epidemiology Unit, The University of Manchester, Manchester, United
Kingdom
7 PREDICTORS OF OSTEOPOROSIS IN PATIENTS WITH INFLAMMATORY DISEASE -
A CROSS SECTIONAL STUDY.
S.L. Westlake 1 , A.K. Muddu 1 , S. Crozier 1 , K. Javaid 1 , R. McCrudden 2 , M. Stroud 3 , P. Taylor 4 ,
C. Cooper 1 , D.R. Fine 2 , N.K. Arden 1
1
MRC Enviromental Epidemiology Unit and Department of Rheumatology and Medical Physics,
Southampton General Hospital, Southampton, United Kingdom; 2 Department of Gastroenterology,
Southampton General Hospital, Southampton, United Kingdom; 3 Department of Nutrition,
Southampton General Hospital, Southampton, United Kingdom; 4 Department of Medical Physics,
Southampton General Hospital, Southampton, United Kingdom
8 INFLUENCE OF INFLAMMATORY POLYARTHRITIS ON BONE QUALITY.
S.R. Pye 1 , T. Marshall 2 , K. Gaffney 2 , J. Camus 3 , R.N. Luben 3 , N.E. Day 3 , D.P.M. Symmons 1 , A.J. Silman 1 ,
T.W. O'Neill 1
1
ARC Epidemiology Unit, The University of Manchester, Manchester, United Kingdom; 2 Department
of Rheumatology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom;
3
Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom
9 OSTEOPOROSIS AND LIFESTYLE.
S.Y. Khan 1 , A. Wood 1 , J. Beynon 2 , C. Joyce 3 , K.R. MacKay 1
1
Rheumatology Dept, Portsmouth Hospitals NHS Trust, Portsmouth, Hants, United Kingdom; 2 Elderly
Care Dept, Portsmouth Hospitals NHS Trust, Portsmouth, Hants, United Kingdom; 3 Medical Physics
Dept, Portsmouth Hospitals NHS Trust, Portsmouth, Hants, United Kingdom
10 REGIONAL AUDITS OF THE PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS IN
PATIENTS WITH RHEUMATIC DISEASES IN THE WEST MIDLANDS.
Z. Paskins 1 , T. Potter 2 , K. Obrenovic 3 , N. Erb 4 , I.F. Rowe 2
1
Department of Rheumatology, University Hospitals of Coventry and Warwickshire NHS Trust,
Coventry, Warwickshire, United Kingdom; 2 Highfield Unit, Worcester Centre for Rheumatic Diseases,
Worcestershire Acute Hospitals NHS Trust, Worcester, Worcestshire, United Kingdom; 3 Department
of Clinical Audit, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom;
4
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands,
United Kingdom
11 STEROIDS AND OSTEOPOROSIS - ARE THE 2002 RCP GUIDELINES BEING FOLLOWED?
S. Bawa 1 , E. Wong 2 , A. Bradlow 1 , S. Edmonds 2 , M. Webley 2
1
Department of Rheumatology, Royal Berkshire and Battle Hospital NHS Trust, Reading, United
Kingdom; 2 Department of Rheumatology, Stoke Mandeville Hospital, Aylesbury, United Kingdom
12 ASSESSMENT OF CRITERIA FOR LATERAL MORPHOMETRY IN OVER 65 YEAR OLDS
ATTENDING FOR BONE DENSITOMETRY.
A.L. Dolan, J. Wilkinson, B. Coutinho
Dept. of Rheumatology, Queen Elizabeth Hospital, Woolwich, London, United Kingdom
13 OSTEOPOROTIC VERTEBRAL FRACTURES: ARE THEY RECOGNISED AND REPORTED BY
RADIOLOGISTS?
H.M. Joy 1 , F.M. Witham 1 , K.R. MacKay 2
1
Department of Diagnostic Imaging, Portsmouth Hospitals NHS Trust, Portsmouth, Hants, United
Kingdom; 2 Rheumatology Department, Portsmouth Hospitals NHS Trust, Portsmouth, Hants,
United Kingdom
35

14 HEEL DENSITOMETRY - CLINICAL UTILITY AND RELATIONSHIP TO CENTRAL DEXA.
A.O. Adebajo, N. Peel, R. Eastell, E. Gossage, A. Blumsohn
Rheumatology, Barnsley District General Hospital, Barnsley, United Kingdom; Division of Clinical Sciences
(NGHT), Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, South Yorkshire, United
Kingdom
15 HOW WELL DOES IVA PERFORM AS A TOOL TO DETECT VERTEBRAL FRACTURE:
A PRAGMATIC STUDY.
A.M. Scott-Russell 1 , E.M. Dennison 2 , L. Jones 3 , E.E. Rutherford 4 , C. Cooper 2
1
Rheumatology Department, Christchurch Hospital, Bournemouth, Dorset, United Kingdom; 2 Medical
Research Council Epidemiology Resource Centre, Southampton, Hampshire, United Kingdom;
3
Osteoporosis Centre, Southampton General Hospital, Southampton, Hampshire, United Kingdom;
4
Radiology Department, Southampton General Hospital, Southampton, Hampshire, United Kingdom
16 UNDER ESTIMATION OF SERUM 25 OH VITAMIN D BY THE NICHOLS ADVANTAGE ASSAY IN
PATIENTS RECEIVING VITAMIN D REPLACEMENT THERAPY.
P. Leventis 1 , L. Garrison 2 , M. Sibley 1 , P. Peterson 1 , M. Egerton 3 , G.E. Levin 2 , P.D.W. Kiely 1
1
Rheumatology, St Georges Healthcare NHS Trust, London, United Kingdom; 2 Chemical Pathology,
St Georges Healthcare NHS Trust, London, United Kingdom; 3 Chemical Pathology, West Park Hospital,
Epsom, Surrey, United Kingdom
17 COMPLIANCE AND EFFECT OF BONE PROTECTIVE TREATMENT IN ELDERLY FEMALES:
5 YEAR FOLLOW-UP STUDY.
S.M. Doherty, A. Goodby, S.A. Steel
Centre for Metabolic Bone Disease, Hull and East Yorkshire Hospitals NHS Trust, Hull, E Yorks,
United Kingdom
18 PERSISTENCE WITH ORAL BISPHOSPHONATE THERAPY IS HIGH AMONGST PATIENTS FOLLOWED
IN A DGH OSTEOPOROSIS CLINIC.
E. Prowse, D. McGetrick, V. Thompson, A.J. Hakim, D.V. Doyle
The Academic Rheumatology and Osteoporosis Unit, Whipps Cross University Hospital,
London, United Kingdom
19 EFFICACY OF ANNUAL PAMIDRONATE AT A DOSE OF 90MG: 3-YEAR FOLLOW-UP OF PATIENTS
WITH OSTEOPOROSIS.
S.W. Smale 1 , J.C. Martin 1 , E.W. Thomas 2
1
Rheumatology, Royal Glamorgan Hospital, Llantrisant, United Kingdom; 2 Rheumatology, University
Hospital of Wales, Cardiff, United Kingdom
Cell receptor-ligand interaction, signalling, activation and apoptosis
20 MATURATION OF DENDRITIC CELLS BY WEGENER'S AUTOANTIGEN VIA PROTEASE-ACTIVATED
RECEPTOR-2 PATHWAY.
E. Csernok 1 , M.-X. Ai 1 , P. Jagiello 2 , A. Mueller 1 , J.T. Epplen 2 , W.L. Gross 1
1
Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Schleswig-Holstein,
Germany; 2 Human Genetics, Ruhr University of Bochum, Bochum, Nordrhein-Westfalen, Germany
21 ABD56 IS A POTENT INHIBITOR OF RANKL- AND TNF-STIMULATED NF?B AND ERK
ACTIVATION IN VITRO.
A.I. Idris, I.R. Greig, S.H. Ralston, R.J. van 't Hof
Medicine & Therapeutics, University of Aberdeen, Aberdeen, Aberdeenshire, United Kingdom
36

22 T-bet EXPRESSION IN RA PATIENTS WITH EARLY, DMARDs NAÏVE DISEASE IS LOW AND
CORRELATES WITH LOW LEVELS OF IL-7 AND T-CELL DYSFUNCTIONS.
F. Ponchel 1 , A. Brown 2 , S. Field 1 , J. Isaacs 3 , P. Emery 2
1
Molecular Medicine, University of Leeds, Leeds, United Kingdom; 2 Rheumatology, University of
Leeds, Leeds, United Kingdom; 3 Rheumatology, University of Newcastle, Newcastle, United
Kingdom
23 THE SIGNALING SIGNATURE DOWNSTREAM OF THE NOTCH RECEPTOR IN CD4+CD25 HIGH
REGULATORY T-CELLS IN RA DEFINES ANERGIC CELLS: INSIGHT INTO RESISTANCE TO ANTI-TNF
THERAPIES.
K. Snow 1 , S. Field 1 , P. Emery 2 , J. Isaacs 3 , F. Ponchel 1
1
Moleculae Medicine, University of Leeds, Leeds, United Kingdom; 2 Rheumatology, University of
Leeds, Leeds, United Kingdom; 3 Rheumatology, University of Newcastle, Newcastle, United
Kingdom
Cytokines and inflammatory mediators
24 EVIDENCE OF REGULATORY EFFECTS OF PERIPHERAL T-CELLS ON IFN? AND IL-10
PRODUCTION OF SYNOVIAL TISSUE CELLS IN RHEUMATOID ARTHRITIS.
F. Behrens 1 , B. Beutel 1 , J.P. Kaltwasser 1 , B. Moller 2 , H.H. Radeke 3
1
Rheumatology/ZAFES, J.W.Goethe University, Frankfurt, Germany; 2 Rheumatology, Insel-Spital,
University, Berne, Switzerland; 3 Immune Pharmacology/ZAFES, J.W.Goethe University, Frankfurt,
Germany
25 ONCOSTATIN M IN RHEUMATOID ARTHRITIS: A KEY CYTOKINE ACTS SYNERGISTICALLY
WITH OTHER PRO-INFLAMMATORY CYTOKINES.
U. Fearon 1 , R. Mullan 1 , R.A. Poole 2 , T. Markham 1 , O. FitzGerald 1 , B. Bresnihan 1 , D.J. Veale 1
1
Rheumatology, St. Vincents University Hospital and The Conway Institute, Dublin, Ireland; 2 Joint
Diseases Laboratory, Shriners Hospital ad McGill University, Montreal, QC, Canada
26 EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID 1, TRPV1, BY SYNOVIAL
MACROPHAGES.
H.C. Seegers, P.S. Avery, D.F. Williams, S. Suri, D.A. Walsh
Academic Rheumatology, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom
27 IMPROVEMENT OF T-CELL FUNCTION IN RA PATIENTS IN CLINICAL REMISSION IS ASSOCI-
ATED WITH THE RECOVERY OF IL-7 EXPRESSION AND DEPENDS ON A FAMILIAL HISTORY OF
RA.
F. Ponchel 1 , A. Brown 2 , S. Field 1 , J. Isaacs 3 , P. Emery 2
1
Molecular Medicine, University of Leeds, Leeds, United Kingdom; 2 Rheumatology, University of
Leeds, Leeds, United Kingdom; 3 Rheumatology, University of Newcastle, Newcastle, United
Kingdom
28 INTERLEUKIN 6 (IL-6) SIGNALLING IN RHEUMATOID ARTHRITIS.
S.M. Carty 1 , M.A. Nowell 2 , R.M. Goodfellow 1 , N. Topley 3 , S.A. Jones 2 , B.D. Williams 1 , A.S. Williams 1
1
Rheumatology, Cardiff University, Cardiff, United Kingdom; 2 Biosciences, Cardiff University, Cardiff,
United Kingdom; 3 Nephrology, Cardiff University, Cardiff, United Kingdom
29 DEFICIENCY OF BiP MAY BE A CHRONICITY FACTOR IN THE PERPETUATION OF RHEMATOID
ARTHRITIS (RA).
H. Cornell, V.M. Corrigall, G.S. Panayi
Academic Rheumatology, GKT School of Medicine, KCL, London, United Kingdom
37

30 BiP STIMULATION INDUCES AN ANTI-INFLAMMATORY GENE ACTIVATION PROFILE IN
MONOCYTES.
V.M. Corrigall, C. Shah, M.D. Bodman-Smith, G.S. Panayi
Academic Rheumatology, GKT School of Medicine, KCL, London, United Kingdom
31 IL-6 AND THE SOLUBLE RECEPTOR IN PAIRED JUVENILE IDIOPATHIC ARTHRITIS (JIA) SERUM AND
SF SAMPLES.
N. Peake 1 , K. Khawaja 2 , A. Myers 2 , M. Nowell 3 , S. Jones 3 , D. Rowan 1 , T. Cawston 1 , H. Foster 1
1
Musculoskeletal Research Group, University of Newcastle-upon-Tyne, Newcastle upon Tyne, Tyne &
Wear, United Kingdom; 2 Rheumatology, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear, United
Kingdom; 3 Molecular Cell Biology Research Group, Cardiff School of Biosciences, Cardiff, Wales, United
Kingdom
32 ELEVATED SERUM G-CSF IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS COMPARED
WITH RHEUMATOID ARTHRITIS (RA) PATIENTS AND HEALTHY CONTROL SUBJECTS.
D.J. Armstrong 1 , E.M. Whitehead 1 , A.D. Crockard 2 , A.L. Bell 3
1
Department of Rheumatology, United Hospitals Trust, Antrim, Co Antrim, United Kingdom; 2 Regional
Immunology Laboratory, Royal Victoria Hospital, Belfast, United Kingdom; 3 Department of Rheumatology,
Musgrave Park Hospital and Queen's University Belfast, Belfast, United Kingdom
Matrix metalloproteinases and its inhibitors
33 EXPRESSION PROFILING OF METALLOPROTEINASES AND TISSUE INHIBITORS OF
METALLOPROTEINASES IN NORMAL, PAINFUL AND RUPTURED ACHILLES TENDON.
G.C. Jones 1 , A.N. Corps 1 , C.J. Pennington 2 , I.M. Clark 2 , D.R. Edwards 2 , B.L. Hazleman 1 , G.P. Riley 1
1
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom;
2
School of Biological Sciences, University of East Anglia, Norwich, Norfolk, United Kingdom
34 MMP'S AS MARKERS OF DISEASE ACTIVITY AND OUTCOME IN JUVENILE IDIOPATHIC
ARTHRITIS (JIA).
N. Peake 1 , K. Khawaja 2 , A. Myers 2 , D. Rowan 1 , C. Tim1, F. Helen 1
1
Musculoskeletal Research Group, University of Newcastle-upon-Tyne, Newcastle upon Tyne, Tyne & wear,
United Kingdom; 2 Rheumatology, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear, United
Kingdom
34 USE OF QUANTITATIVE ENZYME ZYMOGRAPHY TO ANALYSE PROTEINASE ACTIVITY IN
JUVENILE IDIOPATHIC ARTHRITIS (JIA) SERUM AND SF SAMPLES.
N. Peake 1 , K. Khawaja 2 , D. Rowan 1 , T. Cawston 1 , H. Foster 1
1
Musculoskeletal Research Group, University of Newcastle-upon-Tyne, Newcastle upon Tyne, Tyne &
Wear, United Kingdom; 2 Rheumatology, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear,
United Kingdom
35 THE BIALLELIC 1G/2G SINGLE NUCLEOTIDE POLYMORPHISM AT POSITION -1607BP OF THE
MMP-1 PROMOTER IS NOT ASSOCIATED WITH RHEUMATOID ARTHRITIS, DOES NOT SIGNIFICANTLY
AFFECT MEASURED LEVELS OF SERUM MMP-1 AND IS NOT ASSOCIATED WITH INCREASED
RADIOGRAPHIC DESTRUCTION.
S.A. Young-Min 1 , A. Rowan 1 , N. Marshall 2 , S. Charlton 1 , D. Coady 2 , I.D. Griffiths 2 , T.E. Cawston 1
1
Musculoskeletal Research Group, University of Newcastle-upon-Tyne, Newcastle upon Tyne, United
Kingdom; 2 Rheumatology, Freeman Hospital, Newcastle upon Tyne, United Kingdom
36 THE DOMINANT ROLE OF SERUM MMP-3 COMPARED TO SERUM MMP-1 AND MMP-13 IN
THE GENERATION OF BREAKDOWN PRODUCTS FROM JOINT TISSUES IN PATIENTS WITH EARLY
RHEUMATOID ARTHRITIS.
S.A. Young-Min 1 , I.D. Griffiths 1 , N. Marshall 1 , E. Ohuchi 2 , S. Christgau 3 , S. Robins 4 , T. Saxne 5 , T. Cawston 1
1
Musculoskeletal Research Group, University of Newcastle & Freeman Hospital, Newcastle upon Tyne,
United Kingdom; 2 Daiichi Fine Chemical Co Ltd, Toyama, Japan; 3 Nordic Bioscience, Herlev, Denmark;
4
Rowett Research Institute, Aberdeen, United Kingdom; 5 Lund University Hospital, Lund, Sweden
38

Stem cells and tissue engineering
37 TISSUE-SPECIFICITY OF ADULT HUMAN MESENCHYMAL STEM CELLS.
C. De Bari 1 , F. Dell'Accio 1 , J. Vanlauwe 2 , C. Pitzalis 1 , F.P. Luyten 2
1
Rheumatology, King's College London, London, United Kingdom; 2 Rheumatology, University
Hospitals KU Leuven, Leuven, Belgium
38 TRANSCRIPTION FACTOR EXPRESSION IN FRESHLY PURIFIED VERSUS EXPANDED BONE
MARROW MESENCHYMAL STEM CELLS.
F. Ponchel 1 , E. Jones 1 , S. Field 1 , S. Kinsey 2 , P. Emery 3 , D. McGonagle 3
1
Molecular Medicine, University of Leeds, Leeds, United Kingdom; 2 Pediatric Haematology, University
of Leeds, Leeds, United Kingdom; 3 Rheumatology, University of Leeds, Leeds, United Kingdom
39 THE VALUE OF CELL SURFACE AND MOLECULAR MARKERS TO DEFINE MULTIPOTENTIAL
MESENCHYMAL STEM CELLS FROM THE BONE MARROW OR THE SYNOVIAL FLUID.
E. Jones 1 , F. Ponchel 1 , S. Field 1 , P. Emery 2 , D. McGonagle 2
1
Molecular Medicine, University of Leeds, Leeds, United Kingdom; 2 Rheumatology, University of
Leeds, Leeds, United Kingdom
Functional genomics
40 NON-DRB1 MHC GENES ASSOCIATED WITH RHEUMATOID ARTHRITIS ARE ALSO
DIFFERENTIALLY EXPRESSED.
S.M.J. Harney, C. Vilarino-Guell, C. Meisel, B.P. Wordsworth, M.A. Brown
Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom
41 ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TELOMERIC MHC WITH
LEVELS OF EXPRESSION OF CANDIDATE GENES FOR RA SUSCEPTIBILITY.
D. Mewar, M. Ioanna, J.M. Timms, R. Kilding, A.G. Wilson
Division of Genomic Medicine, University of Sheffield, Sheffield, United Kingdom
42 SYNOVIAL FIBROBLAST TRANSCRIPTIONAL RESPONSE TO RHEUMATOID ARTHRITIS
SYNOVIAL FLUID STIMULATION.
A. Julia 1 , A. Bassols 1 , M. Serra 3 , L. Azorin 4 , P. Barcelo 1 , S. Marsal 1
1
Unitat de Recerca de Reumatologia, Institut de Recerca Vall Hebron, Barcelona, Spain;
2
Departament de Bioquímica i Biologia Molecular, Facultat de Veterinària, Barcelona, Spain; 3 Servei
de COT, Hospital Universitari Vall d'Hebron, Barcelona, Spain
43 ANALYSIS OF THE SYNOVIAL PROTEOME IN JUVENILE IDIOPATHIC ARTHRITIS.
D.S. Gibson, S. Blelock, M.E. Rooney
Arthritis Research Group, Queen's University Belfast, Musculoskeletal Education and Research Unit,
Musgrave Park Hospital, Belfast, County Antrim, United Kingdom
44 TUMOUR NECROSIS FACTOR ALPHA (TNFα) SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs)
IN THE IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMs).
H. Chinoy 1 , F. Salway 2 , S. John 2 , W.E. Ollier 2 , R.G. Cooper 1
1
Rheumatic Diseases centre, Hope Hospital, Salford, United Kingdom; 2 Centre for Integrated
Genomic Medical Research, Manchester University, Manchester, United Kingdom
45 INTERLEUKIN-4 (IL4), MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP1) AND
INTERFERON-GAMMA (IFNG) SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN THE
IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMs).
H. Chinoy 1 , F. Salway 2 , S. John2, W.E. Ollier 2 , R.G. Cooper 1
1
Rheumatic Diseases Centre, Hope Hospital, Salford, United Kingdom; 2 Centre for Integrated
Genomic Medical Research, University of Manchester, Manchester, United Kingdom
39

Gene therapy
46 DEVELOPMENT OF HUMAN ANTIBODY FRAGMENTS AGAINST COLLAGEN TYPE II
AUTOANTIGENS IN RHEUMATOID ARTHRITIS, USING PHAGE DISPLAY LIBRARIES.
A. Nissim 1 , P. Winyard 2 , C. Davis 1 , G. Cohen 1 , Y. Chernajovsky 1
1
Bone and Joint Research Unit, Barts and The London, Queen Mary School of Medicine and Dentistry,
University of London, London, United Kingdom; 2 Peninsula Medical School, Universities of Exeter and
Plymouth, Exeter, United Kingdom
Metabolic and crystal arthropathies
47 SONOGRAPHIC FEATURES OF GOUT: A PICTORIAL ESSAY.
S.A. Wright 1 , E. Filippucci 2 , C. McVeigh 1 , M. McCarron 1 , A. Grey 3 , W. Grassi 2 , G.D. Wright 1 , A.J. Taggart 1
1
Department of Rheumatology, Musgrave Park Hospital, Belfast, United Kingdom; 2 Cattedra di
Reumatologia., Università Politecnica delle Marche., Ancona, Italy; 3 Department of Radiology, Musgrave
Park Hospital, Belfast, United Kingdom
Orthopaedics and rehabilitation
48 A THERMOGRAPHIC INVESTIGATION OF SKIN TEMPERATURE CHANGES IN RESPONSE TO A
THERMAL WASHOUT OF THE KNEE IN HEALTHY YOUNG ADULTS.
N.J. Hardaker 1 , A. Karki 2 , P. Karppi 2 , J. Ekberg 2 , J. Selfe 1
1
Allied Health Professions Unit, University of Central Lancashire, Preston, Lancashire, United Kingdom;
2
Physiotherapy, Satakunta Polytechnic, Pori, Finland
Osteoarthritis
49 OSTEOCHONDRAL ANGIOGENESIS AND SYNOVIAL INFLAMMATION ARE FEATURES OF
OSTEOARTHRITIS AND MAY CONTRIBUTE TO THE SEVERITY OF CARTILAGE CHANGES.
C.S. Bonnet, E.L. Turner, D.F. McWilliams, D.A. Walsh
Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
50 THE OSTEOARTHRITIS BIOMARKER COMP: SERUM LEVELS ARE GENETICALLY DETERMINED.
F.M.K. Williams 1 , D. Heinegard 3 , T. Saxne 3 , A.J. MacGregor 1,2 , T.D. Spector 1
1
Twin Research and Genetic Epidemiology Unit, St Thomas' Hospital, London, United Kingdom;
2
Department of Medicine, University of East Anglia, Norwich, United Kingdom; 3 Departments of
Rheumatology & Cell and Molecular Biology, Plan C12 BMC, Lund, Sweden
51 GENE REGULATION INDUCED BY CARTILAGE INJURY.
F. Dell'Accio, C. De Bari, C. Pitzalis
Rheumatology, King's College London, London, United Kingdom
52 FACTOR ANALYSIS OF SIX BIOMARKERS IN A LONGITUDINAL STUDY OF KNEE OSTEOARTHRITIS
SUGGESTS THAT PATHOLOGICAL PROCESS OCCUR IN DIFFERENT JOINT TISSUES.
R. Granell 1,2 , J.R. Kirwan 2 , M. Sharif 3 , C. Elson 4
1
Department of Mathematics, University of Bristol, Bristol, Avon, United Kingdom; 2 Academic
Rheumatology Unit, University of Bristol, Bristol, Avon, United Kingdom; 3 Department of Anatomy,
University of Bristol, Bristol, Avon, United Kingdom; 4 Department of Pathology and Microbiology,
University of Bristol, Bristol, Avon, United Kingdom
53 FURTHER EVIDENCE THAT CARTILAGE PANNUS JUNCTION SYNOVITIS PREDILICATION IS NOT A
SPECIFIC FEATURE OF RHEUMATOID ARTHRITIS.
L.A. Rhodes 1 , P.G. Conaghan 2 , A. Radjenovic 1 , A.J. Grainger 3 , P. Emery 2 , D. McGonagle 2
1
Academic Unit of Medical Physics, University of Leeds, Leeds, Yorkshire, United Kingdom; 2 Academic
Unit of Musculoskeletal Disease, Leeds General Infirmary, Leeds, Yorkshire, United Kingdom;
3
Department of Radiology, Leeds General Infirmary, Leeds, Yorkshire, United Kingdom
40

54 EVIDENCE FOR INTRAUTERINE PROGRAMMING IN SYMPTOMATIC KNEE OSTEOARTHRITIS.
K.M. Jordan, H.E. Syddall, A. Aihie Sayer, E. Dennison, C. Cooper, N.K. Arden
MRC Epidemiology Resource Centre, Bone and Joint Division, Southampton University Hospital,
Southampton, Hampshire, United Kingdom
55 HIGH RESOLUTION MAGNETIC RESONANCE IMAGING (MRI) OF KNEE CARTILAGE IN
HEALTHY VOLUNTEERS DEMONSTRATES DETECTABLE AM-PM DIFFERENCES IN VOLUME.
S.J. Gandy 1 , S.C. Curtis 2 , R. Hartley-Davies 2 , D. Jeffrey 3 , C.M. Walker 4 , I. Watt 3
1
Medical Physics, Ninewells Hospital (NHS Tayside), Dundee, Angus, United Kingdom; 2 Medical
Physics, Bristol General Hospital (UBHT), Bristol, United Kingdom; 3 Clinical Radiology, Bristol Royal
Infirmary (UBHT), Bristol, United Kingdom; 4 Clinical Radiology, Ninewells Hospital (NHS Tayside),
Dundee, Angus, United Kingdom
56 THE ASSOCIATION OF KNEE OA PROGRESSION AND PROGRESSION OF OA OF THE HAND,
HIP AND LUMBAR SPINE: THE CHINGFORD STUDY
G. Hassett 1 , D.J. Hart 2 , D.V. Doyle 3 , L. March 1 , T.D. Spector 2
1
Professorial Department of Rheumatology, Royal North Shore Hospital, Sydney, NSW, Australia;
2
Twin Research & Genetic Epidemiology Unit, St Thomas' Hospital, London, United Kingdom;
3
Department of Rheumatology, Whipps Cross Hospital, London, United Kingdom
57 PREVALENCE AND RISK FACTORS FOR RADIOGRAPHIC METATARSOPHALANGEAL
OSTEOARTHRITIS IN MIDDLE AGED WOMEN:THE CHINGFORD STUDY.
D.J. Hart 1 , L. Aslam 1 , D.V. Doyle 2 , T.D. Spector 1
1
Twin Research & Genetic Epidemiology, St Thomas' Hospital, London, United Kingdom;
2
Department of Rheumatology, Whipps Cross Hospital, London, United Kingdom
58 RADIOGRAPHIC KNEE OSTEOARTHRITIS PRESENCE AND SEVERITY IS ASSOCIATED WITH
THE URINARY BIOCHEMICAL MARKERS CTX-II AND GLUCOSYL-GALACTOSYL-PYRIDINOLINE.
K.M. Jordan 1 , H.E. Syddall 1 , A. Aihie Sayer 1 , E.M. Dennison 1 , P. Garnero 2,3 , P.D. Delmas 2 , C. Cooper 1 ,
N.K. Arden 1
1
MRC ERC, Bone and Joint Division, Southampton University Hospital, Southampton, Hampshire,
United Kingdom; 2 E Herriot Hospital, Rheumatology, Lyon, Cedex 03, France; 3 Molecular Markers,
Synarc, Lyon, Cedex 03, France
59 ANXIETY AND DEPRESSION ARE COMMON IN LOWER LIMB OSTEOARTHRITIS.
A. Butt, B. Jim, A. John, B. M
Psychiatry, St George's Hospital Medical School, London, United Kingdom; Mental Health, SGHMS,
London, United Kingdom; Rheumatology, SGHMS, London, United Kingdom; Community Health
Sciences, University of York, York, United Kingdom
60 LAY ATTRIBUTIONS OF THE CAUSE OF OSTEOARTHRITIS.
A.P. Turner 1 , J.H. Barlow 1 , M. Buszewicz 2 , G. Rait 2 , A. Atkinson 2
1
Interdisciplinary Research Centre in Health, Coventry University, Coventry, United Kingdom;
2
Department of Primary Care & Population Sciences, Royal Free & University College Medical School,
London, United Kingdom
61 BIOMECHANICAL CHANGES IN THE CONSERVATIVE TREATMENT OF MEDIAL
COMPARTMENT OSTEOARTHRITIS OF THE KNEE.
J.D. Richards 1 , R.K. Jones 2 , W.Y. Kim 3
1
Faculty of Health, University of Central Lancashire, Preston, United Kingdom; 2 Centre for
Rehabilitation and Human Performance Research, University of Salford, Salford, United Kingdom;
3
NorthWest Orthopeadic Higher Surgical Rotaion, Hope Hospital, Salford, United Kingdom
41

62 AN OPEN LABEL STUDY OF PAMIDRONATE FOR SPINAL OSTEOARTHRITIS ASSOCIATED WITH
MRI DETERMINED BONE OEDEMA.
A.L. Tan 1,2 , J. Madden 1 , L. Sutton 3 , K. Muralikuttan 4 , P. Emery 2 , P.G. Conaghan 2 , D. McGonagle 1,2
1
Department of Rheumatology, Calderdale Royal Infirmary, Halifax, United Kingdom; 2 Academic Unit of
Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 3 Department of Radiology,
Calderdale Royal Hospital, Halifax, United Kingdom; 4 Department of Orthopaedics, Calderdale Royal
Infirmary, Halifax, United Kingdom
63 LUMIRACOXIB 100 MG ONCE DAILY IS AN EFFECTIVE AND WELL-TOLERATED TREATMENT FOR
OSTEOARTHRITIS: A POOLED ANALYSIS.
R. Alten 1 , K. Pavelka 2 , D. Dutta 3 , S. Litschig 4 , A. Moore 4 , V. Sloan 3
1
Schlosspark-Klinik, Berlin, Germany; 2 Institute of Rheumatology, Charles University, Prague, Czech
Republic; 3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; 4 Novartis Pharma AG,
Basel, Switzerland
64 LONG TERM OUTCOME FOLLOWING KNEE ARTHROPLASTY: A CONTROLLED
LONGITUDINAL STUDY.
J. Cushnaghan 1 , I. Reading 1 , P. Dieppe 2 , P. Croft 3 , D. Coggon 1 , P. Byng 1 , K. Cox 1 , C. Cooper 1
1
MRC Epidemiology Resource Centre, University of Southampton, Southampton, Hampshire, United
Kingdom; 2 MRC Health Services Research Collaboration, Bristol University, Bristol, South Glos, United
Kingdom; 3 Primary Care Sciences Research Centre, Keele University, Keele, Staffordshire, United Kingdom
65 A RANDOMISED CONTROLLED TRIAL OF TIDAL IRRIGATION AND CORTICOSTEROID INJECTION
IN KNEE OSTEOARTHRITIS: THE KIVIS STUDY.
N.K. Arden 1 , I.R. Reading 1 , K.M. Jordan 1 , L. Thomas 1 , H. Platten 1 , A. Hassan 1 , C. Cooper 1 , J. Ledingham 2
1
MRC Resource Centre, Southampton University Hospitals NHS Trust, Southampton, Hampshire, United
Kingdom; 2 Department of Rheumatology, Queen Alexander Hospital, Portsmouth, Hampshire,
United Kingdom
Health services research, economics and outcomes research
66 A PATIENT-BASED DISEASE ACTIVITY SCORE (PDAS) THAT CAN REPLACE DISEASE ACTIVITY
SCORE IN RHEUMATOID ARTHRITIS (RA) RESEARCH AND CLINICAL PRACTICE.
B. Khoshaba 1 , D. Cooper 1 , A. MacGregor 2 , D.L. Scott 1 , E.H. Choy 1
1
Rheumatology, 1 King's College London, London, United Kingdom; 2 Rheumatology, University of East
Anglia, Norwich, East Anglia, United Kingdom
67 QUALITY OF CARE FOR NSAID USERS: DEVELOPMENT OF AN ASSESSMENT TOOL.
P. Jobanputra 1 , V. Arthur 1 , M. Pugh 2 , F. Spannuth 3 , P. Griffiths 4 , E. Thomas 1 , T. Sheeran 5
1
Rheumatology & Pharmacy, Selly Oak Hospital, University Hospital Birmingham Foundation Trust,
Birmingham, United Kingdom; 2 Rheumatology, St Mary's Hospital, Newport, Isle of Wight, United
Kingdom; 3 Kingsfield Medical Centre, South Birmingham PCT, Birmingham, United Kingdom; 4 Harborne
Medical Practice, South Birmingham PCT, Birmingham, United Kingdom; 5 Rheumatology, Cannock Chase
Hospital NHS Trust, Cannock, United Kingdom
68 SOCIAL DEPRIVATION: AN IMPORTANT PREDICTOR OF RESPONSE TO TREATMENT IN A CLINICAL
TRIAL SITUATION.
M. Harrison 1 , K. Tricker 2 , L. Davies 2 , P. Dawes 3 , D. Scott 4 , D. Mulherin 6 , M. Davis 5 , D. Symmons 1
1
ARC Epidemiology Unit, The University of Manchester, Manchester, United Kingdom; 2 HER@M, The
University of Manchester, Manchester, United Kingdom; 3 Staffordshire Rheumatology Centre, Stoke,
United Kingdom; 4 King's College, London, United Kingdom; 5 Royal Cornwall Hospital, Truro, United
Kingdom; 6 Cannock Chase Hospital, Cannock, United Kingdom
69 USE OF INTENTION-TO-TREAT ANALYSIS IN RHEUMATOLOGY TRIALS.
A.B. Clark, L. Shepstone
School of Medicine, University of East Anglia, Norwich, United Kingdom
42

70 NEW ESTIMATES OF PREVALENCE RATES OF MAJOR MUSCULOSKELETAL CONDITIONS IN
THE UK BASED ON CONSULTATION IN GENERAL PRACTICE.
A.M. Clarke 1 , P.R. Croft 2 , K. Jordan 2 , D.P.M. Symmons 1
1
Arthritis Research Campaign Epidemiology Unit, The University of Manchester, Manchester, United
Kingdom; 2 Primary Care Sciences Research Centre, Keele University, Keele, United Kingdom
71 AN AUDIT OF REFERRAL LETTERS TO A RHEUMATOLOGY DEPARTMENT.
E. Wise 1,2 , D.J. Walker 2 , A. Myers 2 , L.J. Kay 2
1
Belmont Surgery, Durham, United Kingdom; 2 Department of Rheumatology, Freeman Hospital,
Newcastle upon Tyne, United Kingdom
72 PATIENT CHOICES - SITING OF RHEUMATOLOGY SERVICES IN NORFOLK.
C. Ellis, A.R. Brooksby, D.G.I. Scott
Rheumatology, Norfolk & Norwich University Hospital NHS Trust, Norwich, Norfolk, United
Kingdom; Quality & Clinical Audit, Norfolk & Norwich University Hospital NHS Trust, Norwich,
Norfolk, United Kingdom; Rheumatology, Norfolk & Norwich University Hospital NHS Trust,
Norwich, Norfolk, United Kingdom
73 INTERFACE AUDIT OF REFERRALS TO RHEUMATOLOGY FROM PRIMARY CARE.
G.A. Swallow, J.B. Francis, A. Samanta
Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, East Midlands, United
Kingdom
74 DEVELOPING AN INTEGRATED MUSCULOSKELETAL SERVICE IN ESSEX: RESULTS OF A
BASELINE ASSESSMENT AUDIT.
A.M. Rae 1 , B. Fashanu 2 , S. Sarkar 3 , J. China 4 , R. Sharp 5 , G. Malinowski 6 , A. Rainforth 3 , B. Dasgupta 1
1
Rheumatology, Southend Hospital NHS Trust, Westcliff, Essex, United Kingdom; 2 Rehabilitation,
Southend Hospital NHS Trust, Westcliff, Essex, United Kingdom; 3 Orthopaedics, Southend Hospital
NHS Trust, Westcliff, Essex, United Kingdom; 4 Facilities, Southend Hospital NHS Trust, Westcliff,
Essex, United Kingdom; 5 Podiatry, Southend Hospital NHS Trust, Westcliff, Essex, United Kingdom;
6
Acute Commissioning, Southend PCT, Southend, Essex, United Kingdom
75 AUDIT OF THE CLINICAL CODING OF RHEUMATOLOGY INPATIENT EPISODES.
R.W. Marshall, R.G. Hull, J.M. Ledingham, F.C. McCrae, R. Shaban, A.L. Thomas, K.R. MacKay
Rheumatology, Queen Alexandra Hospital, Cosham, Portsmouth, United Kingdom
76 INNOVATIVE ARTHRITIS RESOURCE CENTRES IN MANCHESTER & GREATER MANCHESTER.
B. Pal
Rheumatology, Withington Hospital, Manchester, United Kingdom
77 PROVISION OF FOOT HEALTH SERVICES IN RHEUMATOLOGY IN THE UK.
A.C. Redmond, R. Waxman, P.S. Helliwell
Academic unit of Musculoskeletal Disease, University of Leeds, Leeds, W. Yorks, United Kingdom
78 HEALTH CARE UTILIZATION AND DIRECT MEDICAL COSTS IN PATIENTS WITH
RHEUMATOID ARTHRITIS IN AN DEVELOPING COUNTRY.
E.R. Soriano 1,2 , C. Castel del Cid 1 , F. Devoto 3 , L. Narvaez Ponce 1 , P.M. Imamura 1,2 , L.J. Catoggio 1,2
1
Rheumatology Unit, Servicio de Clinica Medica, Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina; 2 Fundacion Pedro M. Catoggio, Buenos Aires, Argentina; 3 Pfizer Argentina SRL, Buenos
Aires, Argentina
79 MANAGEMENT OF CHRONIC KNEE PAIN: PATIENTS RARELY GET WHAT THEY
NEED-OR WANT.
H.L. Mitchell, M.V. Hurley
Rehabilitation Research Unit, GKT School of Biomedical Sciences, London, United Kingdom
43

80 PAIN MANAGEMENT AND SERVICE PROVISION FOR ADULTS WITH OSTEOARTHRITIS.
G.A. McHugh 1 , K.A. Luker 1 , A.J. Silman 2 , P.R. Kay 3
1
School of Nursing, Midwifery & Social Work, University of Manchester, Manchester, United Kingdom;
2
Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United Kingdom;
3
Department of Orthopaedics, Wrightington Centre for Hip Surgery, Wigan, United Kingdom
81 PHYSIOTHERAPY REDUCES THE CONSIDERABLE HEALTH SERVICE UTILISATION AND INDIRECT
COSTS ASSOCIATED WITH CHRONIC LOW BACK PAIN.
D.J. Critchley, M.V. Hurley
Physiotherapy, King's College London, London, United Kingdom
82 PATIENT'S NEGATIVE PERCEPTIONS OF CHRONIC KNEE PAIN ARE IMPROVED BY PARTICIPATION
ON AN INTEGRATED REHABILITATION PROGRAMME.
V. Bhavnani 1 , M. Hurley 2 , F. Stevenson 3 , N. Britten 4
1
General Practice & Primary Care, KCL, London, United Kingdom; 2 Rehabilitation Research Unit, KCL,
London, United Kingdom; 3 Primary Care & Pop Sci, UCL, London, United Kingdom; 4 Inst of Clin
Education, University of Exeter and Plymouth, Exeter, United Kingdom
83 REDUCING WORK DISABILITY IN ANKYLOSING SPONDYLITIS: THE AS WORK INSTABILITY
SCALE (AS-WIS).
G. Gilworth 1 , P. Emery 1 , N. Barkam 1 , M.G. Smyth 2 , P. Helliwell 1 , A. Tennant 1
1
Academic Unit of Musculoskeletal Medicine and Rehabilitation, University of Leeds, Leeds, West
Yorkshire, United Kingdom; 2 Work Fit, Occupational Physiotherapy and Ergonomics Services, Leeds,
West Yorkshire, United Kingdom
84 IMPACT OF ANTI-TNF THERAPY ON RESOURCE UTILIZATION IN A HOSPITAL RHEUMATOLOGY
DEPARTMENT.
R.S. Sandhu, G.J. Treharne, K. Cassim, K. Douglas, K. Obrenovic, A. Saratzis, N. Erb, G.D. Kitas
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United
Kingdom
85 POST OPERATIVE COMPLICATIONS IN PATIENTS ON ANTI TNF THERAPIES: RESULTS FROM THE
MERSEYSIDE ANTI TNF AUDIT.
T.C. Barnes 1 , J. Novak 1 , E. Mulvey 2 , K. Over 2 , S. Hennell 3 , V.E. Abernethy 1
1
Rheumatology Practice Development Unit, St Helens Hospital, St Helens, Merseyside, United Kingdom;
2
Rheumatology Department, Countess of Chester Foundation Trust, Chester, Cheshire, United Kingdom;
3
Rheumatology Department, Wirral Hospital NHS Trust Arrowe Park Hospital, Wirral, Merseyside, United
Kingdom
86 A COMPARISON OF THE STANDARD OF DMARD MONITORING, COMPARING GENERAL
PRACTICE WITH A RHEUMATOLOGY DEPARTMENT.
M.T. Pugh, M. Abdin-Mohamed, J.R. Kriel, E.D. Healey
Rheumatology, St Mary's Hospital, Newport, Isle of Wight, United Kingdom
87 EVIDENCE BASED PRACTICE: DMARD SIDE EFFECTS AND THEIR OCCURRENCE OVER TIME.
E. Roussou, C. Iacovou, J. Leahy, G.M. Dabrera, C. Tranmer
Rheumatology and Rehabilitation, King George Hospital at BHR, Ilford, Essex, United Kingdom
88 APPROPRIATENESS OF COX-2 PRESCRIBING IN THE GENERAL RHEUMATOLOGY CLINIC.
L.C. Pollard
Department of Rheumatology, King's College Hospital, London, United Kingdom
89 THE USE OF COMPLEMENTARY MEDICINE AMONG PATIENTS WITH RHEUMATOLOGICAL
CONDITIONS.
A.M. Salih
Rheumatology Department, Warrington Hospital, Warrington, Cheshire, United Kingdom
44

90 A SURVEY OF JOINT ASPIRATION, INJECTION, AND OTHER PROCEDURES BY DIFFERENT
CLINICIANS: GUIDELINES DEVELOPMENT FOR PATIENTS ON ANTI-COAGULANTS AND
ANTI- PLATELET THERAPY.
W. Koualty, B. Pal, M. B, S. S
Rheumatology, Withington Hospital, Manchester, United Kingdom
91 JOINT AND SOFT TISSUE INJECTIONS: WHAT DO GENERAL PRACTITIONERS DO?
W.G. Liddell, C.R. Carmichael, N.J. McHugh
Research & Clinical Effectiveness Unit, Royal National Hospital for Rheumatic Diseases, Bath,
Somerset, United Kingdom
92 MUSCULOSKELETAL ULTRASOUND (MSUS) BY RHEUMATOLOGISTS IS PREDOMINANTLY
PERFORMED FOR JOINT AND SOFT TISSUE INFLAMMATION AND INJECTION GUIDANCE.
G. Raftery, D. Kane
Dept. of Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
93 RHEUMATOLOGY AND ORTHOPAEDIC AUDIT OF CARPAL TUNNEL SYNDROME
MANAGEMENT.
P. Shah, M. Bukhari, M. O'Donnell, W. Dodds, J. Halsey
Rheumatology Department, Royal Lancaster Infirmary, Lancaster, United Kingdom
94 MISSING OUT THE MIDDLE MAN ... DIRECT ACCESS GP REFERRALS FOR CARPAL
TUNNEL TESTS.
D.A. Coady, S. Abdullah, P. Mangion, A. Chuck
Rheumatology, University Hospital of North Durham, Durham, United Kingdom
95 WHEN SERUM CREATINE KINASE IS PERSISTENTLY ELEVATED SCREEN FOR THE PRESENCE
OF MACRO CK.
M. Fahie-Wilson 1 , S. Burrows 1 , T. Gordon 2 , W. Wong 2 , B. Dasgupta 2
1
Clinical Biochemistry, Southend Hospital, Westcliff-on-Sea, Essex, United Kingdom; 2 Rheumatology,
Southend Hospital, Westcliff-on-Sea, Essex, United Kingdom
96 THE PREVALENCE OF OSTEOPOROSIS IN HOSPITALIZED SENIORS SUSTAINING A FRACTURE.
J.A. Rankin 1 , C.J. Banack 2
1
Faculty of Nursing, University of Calgary, Calgary, Alberta, Canada; 2 Seniors Health, Calgary Health
Region, Calgary, Alberta, Canada
97 AN ASSESSMENT OF THE USEFULNESS OF PICTURE ARCHIVING AND COMMUNICATION
SYSTEMS (PACS) IN RHEUMATOLOGY.
Z. Paskins 1 , A. Kinder 2 , W. Hassan 2 , J. Dixey 3 , D.G.I. Scott 4 , A. Rai 1
1
Highfield Unit, Worcester Centre for Rheumatic Diseases, Worcestershire Royal Hospital, Worcester,
Worcestershire, United Kingdom; 2 Department of Rheumatology, Leicester Royal Infirmary, Leicester,
Leicestershire, United Kingdom; 3 Department of Rheumatology, Robert Jones and Agnes Hunt
Orthopaedic Hospital, Oswestry, Shropshire, United Kingdom; 4 Department of Rheumatology,
Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom
98 CAN RHEUMATOLOGISTS INCREASE THE UPTAKE OF INFLUENZA VACCINATION?
S. Doe, C.A. Kelly, C.R. Heycock, J. Binding, J.D. Hamilton
Rheumatology Department, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom
99 CURRENT CONSENT PRACTICES OF WELSH RHEUMATOLOGISTS.
S.E. Green, S.M. Linton
Department of Rheumatology, Nevill Hall Hospital, Abergavenny, Monmouthshire, United Kingdom
100 LONDON'S LONGEST RUNNING MUSICIANS' CLINIC?
J.A. Mathews, S.P. Oakley, F.M.K. Williams
Department of Rheumatology, St. Thomas' Hospital, London, United Kingdom
45

Rheumatoid arthritis – aetiopathogenesis and animal models
101 AUTOANTIBODIES TO FERRITIN IN RHEUMATOID ARTHRITIS.
D. Mewar 1 , D.J. Moore 2 , P.F. Watson 3 , A.G. Wilson 1
1
Genomic Medicine, University of Sheffield, Sheffield, United Kingdom; 2 Department of Radiology, Royal
Hallamshire Hospital, Sheffield, United Kingdom; 3 Clinical Sciences, University of Sheffield, Sheffield,
United Kingdom
102 CITRULLINATED ALPHA-ENOLASE, A NOVEL CITRULLINATED AUTOANTIGEN IN RA.
A. Kinloch, V. Tatzer, R. Wait, D. Moyes, P. Venables
Infection & Inflammation, Kennedy Institute of Rheumatology, London, United Kingdom
103 THE INTERFERONγ/INTERLEUKIN-26 GENE CLUSTER IN RHEUMATOID ARTHRITIS:
HIGH-RESOLUTION SNP ANALYSIS INDICATES SEX-SPECIFIC ASSOCIATION.
K. Vandenbroeck, S. Heggarty, I. Alloza, M. Rooney
Pharmacy, The Queen's University of Belfast, Belfast, N. Ireland, United Kingdom; Musculoskeletal
Education and Research Centre, The Queen's University of Belfast, Belfast, N. Ireland, United Kingdom
104 EARLY RHEUMATOID ARTHRITIS PATIENTS WITH DR4 SHARED EPITOPE ALLELES PROGRESS
RADIOLOGICALLY AND HAVE ELEVATED LEVELS OF SERUM MMP-3, SERUM COMP, URINARY
GLC-GAL-PYD AND URINARY COLLAGEN CROSSLINKS.
S.A. Young-Min 1 , I.D. Griffiths 1 , N. Marshall 1 , D. Coady 1 , E. Ohuchi 3 , T. Saxne 4 , S. Robins 5 , S. Christgau 6 ,
S. Charlton 1 , A. Rowan 1 , A. Dunn 7 , T.E. Cawston 1
1
Musculoskeletal Research Group, University of Newcastle-upon-Tyne & Freeman Hospital, Newcastle
upon Tyne, United Kingdom; 2 Daiichi Fine Chemical Co Ltd, Toyama, Japan; 3 Rheumatology, Lund
University Hospital, Lund, Sweden; 4 Rowett Research Institute, Aberdeen, United Kingdom; 5 Nordic
Biosciences, Herlev, Denmark; 6 Blood Transfusion Service, Newcastle upon Tyne, United Kingdom
105 THE TYPE 1 DIABETES SUSCEPTIBILITY GENE SUMO-4 AT IDDM5 IS NOT ASSOCIATED WITH
SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS (RA) OR JUVENILE IDIOPATHIC ARTHRITIS (JIA).
L.J. Gibbons 1 , W. Thomson 1 , E. Zeggini 2 , J. Worthington 1 , A. Barton 1 , S. Eyre 1 , R. Donn 1 , B.S.P.A.R. Study
Group 1 , A. Hinks 1
1
ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Wellcome Trust Centre
for Human Genetics, University of Oxford, Oxford, United Kingdom
106 INFLUENCE OF HLA-DRB1*04 AND HLA-Cw*07 ALLELES ON THE SUSCEPTIBILITY OF RHEUMA-
TOID ARTHRITIS IN SAUDI PATIENTS.
K. Al Hussein 1 , N.R. Rama 1 , A. Al Shaikh 2 , S. Al Saleh 2 , A. Al Dalaan 2
1
Biological and Medical Research, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia;
2
Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
107 DIFFERENTIAL SURVIVAL OF LEUCOCYTE SUBSETS BY SYNOVIAL, BONE MARROW AND SKIN
FIBROBLASTS: SITE-SPECIFIC RESCUE OF CD4 T CELLS VERSUS ACTIVATION-INDUCED RESCUE OF
NEUTROPHILS.
A. Filer 1 , G. Parsonage 1 , A. Thomas 2 , J. Curnow 1 , A. Akbar 3 , M. Salmon 1 , C. Buckley 1
1
Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom; 2 Royal
Orthopaedic Hospital, Birmingham, United Kingdom; 3 Dept Immunology, UCL, London, United Kingdom
108 FRAGMENTS OF CHAPERONIN 60.1 (CPN60.1) WITH THERAPEUTIC POTENTIAL.
V.R. Winrow 1,4 , P. Tormay 2 , B. Henderson 3 , A.R.M. Coates 2 , D.R. Blake 1,4 , C.J. Morris 1,4
1
School for Health, University of Bath, Bath, United Kingdom; 2 Department of Medical Microbiology,
St George's Hospital Medical School, London, United Kingdom; 3 Cellular Microbiology Reseach Group,
Eastman Dental Hospital, London, United Kingdom; 4 Royal National Hospital for Rheumatic Diseases,
Bath, United Kingdom
46

109 REGULATORY ROLE OF CCL21 IN THE RECRUITMENT AND EXIT OF IMMUNE CELLS IN
RHEUMATOID SYNOVIUM.
A. Manzo 1 , S. Bugatti 2 , C. Buckley 3 , D. Jackson 4 , R. Caporali 2 , C. Montecucco 2 , C. Pitzalis 1
1
Rheumatology Unit, GKT School of Medicine, London, United Kingdom; 2 Cattedra di Reumatologia,
IRCCS Policlinico S.Matteo, Pavia, Italy; 3 Department of Rheumatology, Birmingham University,
Birmingham, United Kingdom; 4 Institute for Molecular Medicine, John Radcliffe Hospital, Oxford,
United Kingdom
110 INCREASED CD161 mRNA EXPRESSION IN PERIPHERAL BLOOD CD4 + T LYMPHOCYTES
IDENTIFIES RHEUMATOID ARTHRITIS PATIENTS UNLIKELY TO DEVELOP EROSIONS.
H. Kamrova 1 , R.J. Moots 1,2 , J. Dawson 3 , R.N. Thompson 2 , E. Williams 2 , L. Pazmany 1
1
Department of Medicine, University of Liverpool, Liverpool, Merseyside, United Kingdom;
2
Department of Rheumatology, University Hospital Aintree, Liverpool, Merseyside, United Kingdom;
3
Department of Rheumatology, St Helen's and Whiston Hospital, Whiston, Merseyside, United
Kingdom
111 REGULATORY T CELL DEFECT IN THE ARTHRITIS-SUSCEPTIBLE DBA/1 MOUSE.
S.P. Fairchild 1 , M. Schenk 1 , R. Doffinger 2 , F.C. Hall 1
1
Department of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom;
2
Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge,
United Kingdom
Rheumatoid arthritis – treatment
112 METHOTREXATE INDUCED PANCYTOPENIA -SERIOUS AND UNDER RECORDED?
OUR EXPERIENCE OF 25 PATIENTS IN 5 YEARS.
A.Y.N. Lim, K. Gaffney, D.G.I. Scott
Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom
113 SHOULD THE MONITORING OF METHOTREXATE AND LEFLUNOMIDE BE THE SAME?
S. Rajakulendran, D. Allen, C. Deighton
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom
114 A COMPARISON OF THE ADVICE GIVEN FOR ALCOHOL CONSUMPTION IN PATIENTS
TAKING METHOTREXATE AND LEFLUNOMIDE.
S. Rajakulendran, C. Deighton
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom
115 NO DIFFERENCE IN OUTCOME BETWEEN SULFASALAZINE OR METHOTREXATE AS THE
FIRST DMARD IN PATIENTS WITH INFLAMMATORY POLYARTHRITIS.
S.L. Hider, M. Lunt, S. Manning, D. Bunn, A. Silman, D. Symmons
ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom; Norfolk Arthritis
Register, Norwich, United Kingdom
116 SCREENING FOR LUNG DISEASE PRIOR TO METHOTREXATE IN RHEUMATOID ARTHRITIS.
A. Dixit, V. Saravanan, C.A. Kelly
Department of Rheumatology and Medicine, Queen Elizabeth Hospital, Gateshead, Tyne & Wear,
United Kingdom
117 CLINICAL AUDIT: DOES THE MONITORING OF METHOTREXATE THERAPY MEET THE
DEPARTMENTAL GUIDELINES?
R.W. Marshall, A. Wood, R.G. Hull, J.M. Ledingham, F.C. McCrae, R. Shaban, A.L. Thomas,
K.R. MacKay
Rheumatology, Queen Alexandra Hospital, Cosham, Portsmouth, United Kingdom
47

118 ANTI-TNF THERAPY - CAN WE REDUCE THE COST?
V.E. Abernethy, J. Novak, J.K. Dawson, M.P. Lynch
Rheumatology Practice Development Unit, St Helens and Knowsely NHS Hospitals, St Helens, Merseyside,
United Kingdom
119 BIOLOGICS IN EARLY RA – WHO GETS THEM AND WHO DOESN'T?
G. Westhoff 1 , R. Rau 2 , A. Zink 1
1
Epidemiology unit, German Rheumatism Research Centre, Berlin, Germany; 2 Ev. Fachkrankenhaus
Ratingen, Ratingen, Germany
120 FACTORS TO CONSIDER WHEN ASSESSING EFFICACY OF SUBCUTANEOUS ANTI-TNF THERAPY.
J. Leggett, D. Tilley, M. Nisar
Dept of Rheumatology, Queen's Hospital Trust, Burton on Trent, United Kingdom
121 THE SCOTTISH PROSPECTIVE EVALUATION OF CLINICAL EFFECTIVENESS OF ANTI-TNF THERAPY
(SPECTRA): REVIEW OF NORTH GLASGOW PATIENTS OVER THREE YEARS.
B.L. Bound 1 , M.A. Laura 1 , S. Ann 2 , F. Max 1
1
University Medical Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom; 2 Centre for Rheumatic
Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom
122 DO THE PROPOSED RECOMMENDATIONS FOR ASSESSING TUBERCULOSIS RISK IN PATIENTS
DUE TO START ANTI-TNF-α THERAPY ALTER RESOURCE USE?
C.E. Wilkinson, C. Deighton
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom
123 BIOLOGICS IN RHEUMATOID ARTHRITIS(RA)- 'SWITCHING IS EFFECTIVE'?
L. Turner, R.N. Jois, M. Somerville, A. Brooksby, D.G.I. Scott
Rheumatology, Norfolk & Norwich University Hospital, Norwich, Norfolk, United Kingdom
124 ANTI TNFα THERAPY MORTALITY - DISEASE OR DRUG?
V.A. Quincey, R.G. Hull, A.L. Thomas, F.C. McCrae, K.R. Mackay, J.M. Ledingham, R. Shaban
Rheumatology Department, Queen Alexandra Hospital, Portsmouth, Hants, United Kingdom
125 CHANGE IN THE USE OF DMARDS AND STEROIDS AFTER COMMENCEMENT OF ANTI-TNF
THERAPY.
R.S. Sandhu, G.J. Treharne, K. Cassim, K. Douglas, K. Obrenovic, A. Saratzis, N. Erb, G.D. Kitas
Department of Rhematology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands,
United Kingdom
126 COMPARISON OF ANTI-TNF THERAPY IN DAILY PRACTICE.
H. Tahir, S. Moore, M.R. Ehrenstein
Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
127 HOW MANY RHEUMATOID PATIENTS IN THE ROYAL SURREY COUNTY HOSPITAL FULFIL THE
BRITISH SOCIETY FOR RHEUMATOLOGY CRITERIA FOR ANTI-TNFα THERAPY?
J. Evans, A. Behn, R. Gray
Rheumatology Department, Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
128 COMPARING THE EARLY EFFICACY OF ANTI-TNF DRUGS.
K. Gadsby, C. Deighton, S. O'Reilly, M. Regan
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom
129 BIOLOGIC THERAPY IN RA – HOW GOOD ARE WE IN ADHERING TO THE NICE GUIDELINES? – A
DGH EXPERIENCE.
V.V. Kaushik 1 , R. Fahey 2 , K. Binymin 1 , H.R. Sykes 1
1
Department of Rheumatology, Southport District General Hospital, Southport, Merseyside, United
Kingdom; 2 Nurse Resource Service, Ashfield Healthcare, Ashby, Leicestershire, United Kingdom
48

130 PATIENTS AND CARERS EXPERIENCE OF THE BENEFITS OF ANTI-TNF THERAPY FOR
RHEUMATOID ARTHRITIS.
A.J. Kinder 1 , A. Samanta 2 , J. Edwards 3 , A. Clarke 2
1
Rheumatology, Nottingham City Hospital, Nottingham, United Kingdom; 2 Rheumatology, Leicester
Royal Infirmary, Leicester, United Kingdom; 3 Schering Plough, Welwyn Garden City, United Kingdom
131 LONG-TERM SAFETY OF ADALIMUMAB (HUMIRA®) IN WORLDWIDE RHEUMATOID
ARTHRITIS CLINICAL TRIALS.
M.H. Schiff 1 , G.R. Burmester 2 , A. Pangan 3 , H. Kupper 4 , G.T. Spencer-Green 5
1
Denver Arthritis Clinic P.C., Denver, CO, United States; 2 Universitätsklinikum Charité, Berlin,
Germany; 3 Abbott Laboratories, Abbott Park, IL, United States; 4 Abbott GmbH & Co. KG,
Ludwigshafen, Germany; 5 Abbott Laboratories, Parsippany, NJ, United States
132 THREE YEARS OF ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE THERAPY SUSTAINS
RADIOGRAPHIC INHIBITION OF STRUCTURAL DAMAGE IN PATIENTS WITH LONG-STANDING
RHEUMATOID ARTHRITIS.
E.C. Keystone 1 , A.F. Kavanaugh 2 , J.T. Sharp 3 , G.T. Spencer-Green 4 , J.L. Perez 4 , E.H. Sasso 4
1
Mt. Sinai Hospital, Toronto, ON, Canada; 2 UCSD Center for Innovative Therapy, LaJolla, CA, United
States; 3 University of Washington School of Medicine, Seattle, WA, United States; 4 Abbott
Laboratories, Abbott Park, IL, United States
133 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY LEVELS DECREASE FOLLOWING
INFLIXIMAB AND ETANERCEPT THERAPY IN RHEUMATOID ARTHRITIS.
M.T. Chan 1,2 , P. Owen 2 , N. Shenker 1 , E. Michell 1 , C. Carmichael 1,2 , J. Dunphy 2 , N.J. McHugh 1,2
1
Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, Avon, United Kingdom; 2 Bath
Istitute for Rheumatic Diseases, Bath, Avon, United Kingdom
134 INFLIXIMAB INFUSION REACTIONS - LESS COMMON THAN EXPECTED.
N.D. Kerrigan, M. Somerville, D.G.I. Scott
Rheumatology Department, Norfolk and Norwich University Hospital, Norwich, Norfolk,
United Kingdom
135 REDUCING THE FREQUENCY OF INFLIXIMAB INFUSIONS IN RHEUMATOID ARTHRITIS- IS IT
EFFECTIVE?
H. Siraj, R.N. Jois, M. Somerville, A. Brooksby, D.G.I. Scott
Rheumatology, Norfolk & Norwich University Hospital, Norwich, Norfolk, United Kingdom
136 THE CONVERSION OF INFLIXIMAB TO ADALIMUMAB IN STABLE RA PATIENTS.
D. Hutchinson, J. Tier, S. Soper, G. Wilson, M. Davis
Rheumatology Unit, Royal Cornwall Hospital Trusts, Truro, Cornwall, United Kingdom
137 IS THE EFFICACY OF ETANERCEPT IMPROVED WITH THE CONCURRENT USE OF
METHOTREXATE IN ROUTINE CLINICAL PRACTICE? - MERSEYSIDE EXPERIENCE.
V.E. Abernethy 1 , K. Nelson 2 , P. Chapman 3 , J. Novak 1 , E. Mulvey 4 , K. Over 4
1
Rheumatology Practice Development Unit, St Helens Hospital, St Helens, Merseyside, United
Kingdom; 2 Rheumatology Department, Royal Liverpool University Hospital, Liverpool, Merseyside,
United Kingdom; 3 Rheumatology Department, Arrowe Park Hospital, Wirral, Merseyside, United
Kingdom; 4 Rheumatology Department, Countess of Chester Foundation Trust, Chester, Cheshire,
United Kingdom
138 ABILITY TO DECREASE PREDNISOLONE FOR RHEUMATOID ARTHRITIS PATIENTS ON
ANTI-TNF, AND THE EFFECT ON DAS SCORES.
K. Gadsby, C. Deighton, S. O'Reilly, M. Regan
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom
49

139 RELATIONSHIP BETWEEN CIRCULATING ANTIBODIES AND BLyS FOLLOWING B CELL DEPLETION
THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
G. Cambridge 1 , M.J. Leandro 1 , W. Stohl 2 , M.R. Ehrenstein 1 , T.S. Migone 2 , D.M. Hilbert 4 , M. Teodoresou 3 ,
J.C.W. Edwards 1
1
Centre for Rheumatology, University College London, London, United Kingdom; 2 University of Southern
California, Los Angeles, CA, United States; 3 TheraTest Labs Inc, Lombard, IL, United States; 4 Human
Genome Sciences, Rockville, Oxford, United States
140 LONG-TERM SURVIVAL AFTER LYMPHOCYTOTOXIC MONOCLONAL ANTIBODY THERAPY FOR
RHEUMATOID ARTHRITIS.
J.D. Isaacs 1 , A.M. Clarke 2 , B.L. Hazleman 3 , G. Hale 4 , H. Waldmann 4 , D.P.M. Symmons 2
1
School of Clinical Medical Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, Tyne &
Wear, United Kingdom; 2 ARC Epidemiology Unit, University of Manchester, Manchester, Lancashire,
United Kingdom; 3 Department of Rheumatology, Addenbrooke's Hospital NHS Trust, Cambridge,
Cambridgeshire, United Kingdom; 4 Dunn School of Pathology, University of Oxford, Oxford, Oxfordshire,
United Kingdom
141 SERUM BIOCHEMICAL MARKERS CORRELATE WITH RESPONSE TO TREATMENT OF
RHEUMATOID ARTHRITIS WITH RITUXIMAB.
F. Magrini 1 , V. Mitchell 1 , J. Karl 2
1
Roche Products Ltd, Welwyn, United Kingdom; 2 Roche Diagnostics GmbH, Penzberg, Germany
142 IS RESPIRATORY INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS CAUSED BY DISEASE
MODIFYING DRUGS?
P. Coyne, S. Doe, V. Saravanan, J. Hamilton, C. Heycock, C. Kelly
Rheumatology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom
143 COMPARISON OF TREATMENT AND OUTCOME OF RHEUMATOLOGICAL AND
NON-RHEUMATOLOGICAL CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS.
A. Strangfeld, A. Zink
Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
144 ARE CLINICAL TRIALS IN RHEUMATOID ARTHRITIS GENERALISABLE TO ROUTINE PRACTICE?
A RE-EVALUATION OF TRIAL ENTRY CRITERIA.
G.H. Kingsley 1,2 , B. Khoshaba 1 , C.M. Smith 1 , E.H. Choy 1,3 , D.L. Scott 1,3
1
Rheumatology, GKT School of Medicine, Kings College London, London, United Kingdom;
2
Rheumatology, University Hospital Lewisham, London, United Kingdom; 3 Rheumatology, Kings College
Hospital, London, United Kingdom
145 SAFETY AND EFFICACY OF INTRARTICULAR AND SOFT TISSUE CORTICOSTEROID INJECTIONS.
S. Maddula, K.D. Morley, B. Galarraga
Rheumatic Diseases Unit, Ninewells Hospital and Medical School, Dundee, Tayside, United Kingdom
146 NEGATIVE NITROGEN BALANCE ACCOMPANYING METHYL PREDNISOLONE PULSE THERAPY FOR
ACTIVE RHEUMATOID ARTHRITIS CAN BE PREVENTED BY NUTRITIONAL SUPPLEMENTS.
G. Mittal 1,2 , G. Slade 1 , A. Wayte 1 , N. Hasso 1,2 , A. Breslin 1 , S. Marcora 2 , A. Lemmey 2 , P. Maddison 1,2
1
Rheumatology, Ysbyty Gwynedd, Bangor, Gwynedd, United Kingdom; 2 School of Sport, Health and
Exercise Science, Bangor, Gwynedd, United Kingdom
147 POLYPHARMACY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
K.M. Douglas, J. Iwaszko, G.J. Treharne, R. Sandhu, N. Erb, G.D. Kitas
Rheumatology, Dudley Group of Hospitals, Dudley, West Midlands, United Kingdom
148 ALKALINE MINERAL SUPPLEMENTATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS.
R.M. Cseuz 1 , T. Bender 2 , J. Vormann 3
1
Rheumatology, Revita Clinic, Budapest, Hungary; 2 Rheumatology, Hospitaller Brothers of St.John of God,
Budapest, Hungary; 3 Nutrition, Institute for Prevention and Nutrition, Ismaning/Munich, Germany
50

Poster Viewing Session 2
Thursday 21 April 2005, 08:30 – 10:00
Education research
149 PATIENT-CENTRED? HOW WELL DO MEDICAL STUDENTS APPRECIATE PATIENT
PRIORITIES?
L. Palmer 1 , M. Calnan 2 , P.A. Dieppe 2 , D.J. Sharp 3 , S. Clarke 1
1
Department of Rheumatology, Weston Area Health Trust, Weston Super Mare, Somerset, United
Kingdom; 2 MRC Health Services Collaboration, University of Bristol, Bristol, United Kingdom;
3
Division of Primary Health Care, University of Bristol, Bristol, United Kingdom
150 DOCTORS' CONFIDENCE IN TEACHING MUSCULOSKELETAL EXAMINATION SKILLS TO
MEDICAL STUDENTS.
A.M.M. Smith, L.J. Kay, D.J. Walker
Department of Rheumatology, Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Trust,
Newcastle upon Tyne, Tyne and Wear, United Kingdom
151 DO MEDICAL STUDENTS FEEL MORE COMPETENT IN MUSCULOSKELETAL SKILLS
FOLLOWING A MID-COURSE DEMONSTRATION?
K. Gadsby, C. Deighton
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom
152 COMPARING THE FEEDBACK FROM FINAL YEAR MEDICAL STUDENTS IN
RHEUMATOLOGY: IS A CONSULTANT BETTER THAN A CLINICAL NURSE EDUCATOR?
K. Gadsby, C. Deighton
Department of Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, United Kingdom
153 WHAT INFLUENCES UNDERGRADUATE MEDICAL STUDENTS TO UTILISE THE COMPUTER
ASSISTED LEARNING PACKAGE "VIRTUAL RHEUMATOLOGY"?
P. Vivekananda-Schmidt 1 , M. Lewis 1 , A.B. Hassell 2 , D. Coady 3,4 , L. Kay 3,4 , D. Walker 3,4 , I. Haq 3,5 ,
A. Rahman 3,5 , J. Dacre 3,5 , M.J. Mclean 3
1
Primary Care Sciences Research Centre, Keele University, Newcastle under Lyme, United Kingdom;
2
School of Medicine, Keele University, Newcastle under Lyme, United Kingdom; 3 The arc Virtual
Rheumatology, CAL Research Group, University of Newcastle upon tyne; 4 Royal Free & University
College Medical School, United Kingdom
154 IMPACT OF INTRODUCTION OF "REMS" TO MEDICAL STUDENT CLINICAL SKILLS
TEACHING.
A.M.M. Smith, D.J. Walker, D.A. Coady, L.J. Kay
Department of Rheumatology, Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne,
United Kingdom
155 CAN MEDICAL STUDENTS ASSESS LEG LENGTH DISCREPANCY: A COMPARRISON OF
TWO METHODS.
J. Adnitt, D. Coady, L. Kay, D. Walker
Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear,
United Kingdom
156 VALIDATION OF A PERCEIVED CONFIDENCE LOG IN THE EXAMINATION OF THE
SHOULDER AND KNEE JOINTS.
M. Lewis 1 , P. Vivekananda-Schmidt 1 , A.B. Hassell 2 , D. Coady 3,4 , L. Kay 3,4 , D. Walker 3,4 , I. Haq 3,5 ,
A. Rahman 3,5 , J. Dacre 3,5 , M.J. McLean 3
1
Primary Care Sciences Research Centreq, Keele University, Keele, Newcastle under Lyme, Staffs,
United Kingdom; 2 School of Medicine, Keele University, Keele, Newcastle under Lyme, Staffs, United
Kingdom; 3 The arc Virtual Rheumatology, CAL Research Group. 4 University of Newcastle upon tyne;
5
Royal Free and University College Medical School), Oxford, United Kingdom
51

157 THE COMPUTER ASSISTED LEARNING PACKAGE, VIRTUAL RHEUMATOLOGY, HAS A
MEASURABLE IMPACT ON THE LEARNING OF MUSCULOSKELETAL EXAMINATION SKILLS BY
UNDERGRADUATE MEDICAL STUDENTS.
P. Vivekananda-Schmidt 1 , M. Lewis 1 , A.B. Hassell 2 , D. Coady 3,4 , L. Kay 3,4 , D. Walker 3,4 , I. Haq 3,5 ,
A. Rahman 3,5 , J. Dacre 3,5 , M.J. McLean 3
1
Primary Care Sciences Research Centre, Keele University, Newcastle under Lyme, Staffordshire, United
Kingdom; 2 School of Medicine, Keele University, Newcastle under Lyme, Staffordshire, United Kingdom;
3
The arc Virtual Rheumatology, CAL Research Group; 4 University of Newcastle upon tyne, 5 Royal Free and
University College Medical School United Kingdom
158 STUDENT TO TUTOR RATIO ... DOES SIZE MATTER?
D.A. Coady, N. McKay, I. Atchia, E. Kidd, D. Wright, T. Daymond, C. Holland
Rheumatology, Sunderland Royal Hospital, Sunderland, United Kingdom
159 OBJECTIVE STRUCTURED CLINICAL EXAMINATIONS (OSCEs) OF THE MUSCULOSKELETAL
SYSTEM WHO SHOULD BE SCORING THEM?
D.A. Coady, S. Young-Min, L. Kay, D. Walker
Rheumatology, Freeman Hospital, Newcastle upon Tyne, United Kingdom
160 USE OF THE INTERNET IN RHEUMATOLOGY OUTPATIENTS - TRENDS AND BARRIERS.
W. Holden 1 , J. Joseph 2 , L. Williamson 3
1
Rheumatology, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, United Kingdom;
2
Rheumatology, Nicosia Polyclinic, Nicosia, Cyprus; 3 Rheumatology, Great Western Hospital, Swindon,
Wilts, United Kingdom
161 THE ROLE OF THE GP IN MUSCULOSKELETAL MEDICINE - VIEWS OF RHEUMATOLOGY
TRAINEES.
E. Wise, A. Myers, D.J. Walker
Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, United Kingdom
162 PRIMARY CARE RHEUMATOLOGY - WHAT DO GENERAL PRACTITIONERS WANT TO KNOW?
I. Haq, J. Dacre
Academic Centre for Medical Education, Royal Free and University College Medical School, London,
United Kingdom
163 IS THE REGIONAL EXAMINATION OF THE MUSCULOSKELETAL SYSTEM (REMS) VIDEO
USEFUL AS A TEACHING AID FOR SENIOR HOUSE OFFICER (SHO) EDUCATION IN GENERAL
MEDICAL TRAINING?
N.D. McKay 1 , G. B 2 , J.R. Adnitt 3 , D.A. Coady 2
1
Rheumatology, Wansbeck General Hospital, Ashington, Northumberland, United Kingdom;
2
Rheumatology, Sunderland Royal Hospital, Sunderland, Wearside, United Kingdom; 3 Rheumatology,
Freeman Hospital, Newcastle, Tyneside, United Kingdom
164 ALIDATION OF MODULAR TRAINING IN DIAGNOSTIC AND INTERVENTIONAL
MUSCULOSKELETAL ULTRASOUND IN PATIENTS WITH HIP OSTEOARTHRITIS.
I. Atchia 1 , F. Birrell 1 , D. Kane 2
1
Northumbria NHS Trust and University of Newcastle upon Tyne, Newcastle, United Kingdom; 2 University
of Newcastle, Newcastle, United Kingdom
165 AUDIT OF LOCOMOTOR SYSTEM ASSESSMENT OF PATIENTS ADMITTED FOR ACUTE
MEDICAL CONDITIONS TO GENERAL MEDICAL WARDS.
A.A. Bawendi 1 , P. Prouse 2
1
Rheumatology Department, Southampton General Hospital, Southampton, United Kingdom;
2
Rheumatology Department, North Hampshire Hospital, Basingstoke, United Kingdom
52

166 RHEUMATOLOGY EDUCATION IN GENERAL PRACTICE - AN EVALUATION OF CURRENT
TRAINING.
E. Wise 1 , T. van Zwanenberg 2 , D.J. Walker 1 , D. Coady 1
1
Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, United Kingdom;
2
Department of General Practice, Postgraduate Institute for Medicine and Dentistry, Newcastle upon
Tyne, United Kingdom
167 THE EXPERIENCES OF NHS EMPLOYEES WITH ARTHRITIS ATTENDING A WORKPLACE
INTERVENTION.
D.R. Ellard, J.H. Barlow
Interdisciplinary Research Centre in Health, Coventry University, Coventry, United Kingdom
168 MODULAR TRAINING IN MUSCULOSKELETAL ULTRASOUND IS EFFECTIVE AND IMPROVES
MUSCULOSKELETAL CLINICAL SKILLS.
J. Adnitt 1 , P. Platt 2 , D. Kane 1
1
Dept. of Rheumatology, University of Newcastle upon Tyne, Newcastle, United Kingdom; 2 Freeman
Hospital, Newcastle upon Tyne, United Kingdom
169 A PROCESS EVALUATION OF A PILOT EDUCATION DAY FOR RHEUMATOID ARTHRITIS (RA)
PATIENTS AND THEIR PARTNERS.
D.R. Ellard 1 , Z. Paskins 2 , R. Squire 2 , J.H. Barlow 1 , I.F. Rowe 2
1
IRCH, Coventry University, Coventry, United Kingdom; 2 Rheumatology Department, Worcestershire
Royal Hospital, Worcester, United Kingdom
170 EXPERIENCES OF TWO INNOVATIVE MUSCULOSKELETAL MULTIDISCIPLINARY LEARNING
EVENTS.
K. Stevenson 1,2 , J.C. Packham 1 , P.T. Dawes 1
1
Physiotherapy Department, University Hospital of North Staffordshire, Stoke on Trent, Staffordshire,
United Kingdom; 2 Department of Health and Rehabilitation, Keele University, Keele, Staffordshire,
United Kingdom
Epidemiology
171 NO OVERALL INCREASE IN CANCER INCIDENCE OBSERVED IN A 10 YEAR PROSPECTIVE
STUDY OF A LARGE PRIMARY-CARE BASED INCEPTION COHORT OF PATIENTS WITH
INFLAMMATORY POLYARTHRITIS.
J.P. Franklin 1 , M. Lunt 1 , D. Bunn 2 , D.P.M. Symmons 1 , A.J. Silman 1
1
ARC Epidemiology Unit, The University of Manchester, Manchester, United Kingdom; 2 Norfolk
Arthritis Register, Norfolk and Norwich University Hospital, Norwich, United Kingdom
172 BRAIN NATRIURETIC PEPTIDE (BNP) IS A POTENTIALLY USEFUL SCREENING TOOL FOR THE
DETECTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA).
S.M.J. Harney 1 , J. Timperley 2 , C. Daly 3 , A. Harin 1 , T. James 4 , M.A. Brown 1 , K. Fox 3 , A. Banning 2 , S.O.
Donnelly 5 , B.P. Wordsworth 1
1
University of Oxford Institute of Musculoskeletal Sciences, Oxford, United Kingdom; 2 Cardiology
Dept, John Radcliffe Hospital, Oxford, United Kingdom; 3 Kim Fox Research Dept, Royal Brompton
Hospital, London, United Kingdom; 4 Biochemistry Dept, John Radcliffe Hospital, Oxford, United
Kingdom; 5 Rheumatology Dept, St George's Hospital, London, United Kingdom
173 AWARENESS OF CO-TWIN HEALTH STATUS IS UNLIKELY TO BE A SIGNIFICANT
CONFOUNDER IN HERITABILITY STUDIES OF RHEUMATIC DISORDERS.
A.J. Hakim 1,2 , A.J. MacGregor 1,3 , T.D. Spector 1
1
The Twin Research and Genetic Epidemiology Unit, St Thomas' Hospital, London, United Kingdom;
2
The Academic Rheumatology and Osteoporosis Unit, Whipps Cross University Hospital, London,
United Kingdom; 3 The Department of Medicine, University of East Anglia, Norwich, United Kingdom
53

174 RETROSPECTIVE ANALYSIS OF RECORDED CAUSE OF DEATH IN PATIENTS ON DMARDS.
A. Dixit, C.A. Kelly, V. Saravanan, J.D. Hamilton
Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom
175 STARTBACK – DEVELOPMENT OF A LOW BACK PAIN SCREENING TOOL.
K.M. Dunn, M. Lewis, R. Mullis, J. Hill, C.J. Main, E.M. Hay
Primary Care Sciences Research Centre, Keele Univeristy, Keele, Staffordshire, United Kingdom
176 CHANGES IN KNEE PAIN IN OLDER ADULTS: THREE YEAR FOLLOW UP OF THE KNEST
POPULATION COHORT.
C. Jinks, K. Jordan, P. Croft
Primary Care Sciences Research Centre, Keele University, Keele, Staffordshire, United Kingdom
177 THE INFLUENCE OF PSYCHOSOCIAL FACTORS OF THE WORK ENVIRONMENT ON THE
RELATIONSHIP OF PIECEWORK WITH MUSCULOSKELETAL PAIN AND GENERAL HEALTH IN A
GENERAL POPULATION.
R.J. Lacey, M. Lewis, J. Sim
Primary Care Sciences Research Centre, Keele University, Keele, Staffordshire, United Kingdom
178 THE IMPACT OF MULTIPLE UPPER AND LOWER LIMB JOINT PROBLEMS IN THE OVER 55S:
RESULTS FROM A LARGE COMMUNITY-BASED STUDY.
A.-M. Keenan 1 , A. Tennant 1 , J. Fear 2 , P. Emery 1 , P.G. Conaghan 1
1
Academic Unit of Musculoskeletal Disease and Rehabilitation, University of Leeds, Leeds, West Yorkshire,
United Kingdom; 2 Director of Public Health, Leeds West PCT, Leeds, West Yorkshire, United Kingdom
179 CHRONIC WIDESPREAD PAIN AND OTHER CHRONIC SYMPTOMS THAT ARE FREQUENTLY
UNEXPLAINED: DO THEY HAVE A COMMON EPIDEMIOLOGY?
V.R. Aggarwal 1 , J. McBeth 1,2 , M. Lunt 2 , J. Zakrzewska 3 , G.J. Macfarlane 1,2
1
Unit of Chronic Disease Epidemiology, University of Manchester, Manchester, United Kingdom; 2 Arthritis
Research Campaign, University of Manchester, Manchester, United Kingdom; 3 Oral Medicine, Barts and
the London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom
180 FOOT PAIN AND DISABILITY IN MARFAN'S SYNDROME.
W. Holden 1 , J. Joseph 2 , P. Wordsworth 1
1
Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom; 2 Rheumatology, Nicosia
Polyclinic, Nicosia, Cyprus
181 PREDICTING THE ONSET OF CHRONIC WIDESPREAD PAIN: IMPROVING OUR ABILITY TO
IDENTIFY THOSE AT HIGH RISK.
A. Gupta 1 , J. McBeth 1 , Y.H. Chiu 1 , G.J. MacFarlane 2 , D. Ray 3 , C. Dickens 3 , R. Morris 4 , A.J. Silman 1
1
ARC, Manchester, United Kingdom; 2 UCDE, ARC, Manchester, United Kingdom; 3 MRI, Manchester,
United Kingdom; 4 Psychiatry, RLUH, Liverpool, United Kingdom
182 DOES REDUCED PAIN THRESHOLD AT BASELINE IN PSYCHOLOGICALLY DISTRESSED SUBJECTS
PREDICT THE FUTURE DEVELOPMENT OF CHRONIC WIDESPREAD PAIN?
A. Gupta 1 , J. McBeth 1 , A.J. Silman 1 , Y. Chiu 1 , D. Ray 2 , C. Dickens 3 , R. Morris 4 , G.J. Macfarlane 5
1
ARC, Manchester, United Kingdom; 2 Endocrine Sciences, Manchester, United Kingdom; 3 Psychiatry, MRI,
Manchester, United Kingdom; 4 Psychiatry, RLUH, Liverpool, United Kingdom; 5 UCDE, ARC, Manchester,
United Kingdom
Miscellaneous rheumatic disease
183 DOES ETANERCEPT OFFER A BETTER PROSPECT FOR PATIENTS WITH AA AMYLOIDOSIS
COMPLICATING INFLAMMATORY ARTHRITIS?
M.E. Perry 1 , L. McKenzie 1 , A. Stirling 1 , R. Gallimore 2 , J. Hunter 1
1
Rheumatology, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom; 2 National Amyloidosis
Centre, Royal Free Hospital, London, United Kingdom
54

184 AN AUDIT OF IN PATIENT CONDITIONS REFERRED TO AN 'ON CALL'
RHEUMATOLOGY TEAM.
J. Hamilton, C. Heycock, C. Kelly
Rheumatology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom
185 TUBERCULOUS ARTHRITIS - A 10 - YEAR CASE SERIES AND COMPARISON WITH BACTERIAL
ARTHRITIS.
M.N. Gupta, M. Field
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom
186 A SURVEY OF SEPTIC ARTHRITIS CAUSING ORGANISMS AND THEIR SUSCEPTIBILITIES IN A
UK DISTRICT GENERAL HOSPITAL 1999-2003.
D. Makkuni 1 , R.J. Kent 1 , G.P.R. Clunie 1
Rheumatology, The Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom; Microbiology,
The Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom
187 SIGNIFICANT ASSOCIATIONS OF HLA-B*51 AND HLA-Cw*06 ALLELES, AND LACK OF
ASSOCIATION OF CLASS II ALLELES WITH BEHCETS DISEASE IN SAUDI PATIENTS.
A. Al Dalaan 1 , K. Al Hussein 2 , A. Al Shaikh 1 , S. Al Saleh 1 , N.R. Rama 2
1
Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia; 2 Biological and
Medical Research, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
188 VOLUNTARY ACTIVATION FAILURE DETECTED IN MYOSITIS PATIENTS WITH CHRONIC
QUADRICEPS FEMORIS (QF) WEAKNESS.
C. Molloy, A. Al-Omar, K. Edge, R.G. Cooper
Rheumatic Diseases Centre, Hope Hospital, Salford, United Kingdom
189 IN IDIOPATHIC INFLAMMATORY MYOSITIS, MR IMAGING CAN QUANTITATIVELY
DIFFERENTIATE BETWEEN INFLAMMATION, ATROPHY AND FAT.
C.E. Hutchinson 1 , J.E. Kilgallon 2 , A.P. Jones 2 , R.G. Cooper 1
1
Rheumatic Disease Centre, Hope Hospital, Salford, United Kingdom; 2 Diagnostic Radiology, Christie
Hospital, Manchester, United Kingdom
190 PERIPHERAL NEUROPATHY DURING TREATMENT WITH LEFLUNOMIDE IN PATIENTS WITH
SYSTEMIC RHEUMATIC DISEASES.
C. Metzler 1 , A.C. Arlt 2 , W.L. Gross 1 , J. Brandt 1
1
Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck,
Schleswig-Holstein, Germany; 2 Neurology, Rheumaklinik Bad Bramstedt, Bad Bramstedt,
Schleswig-Holstein, Germany
191 A RANDOMISED TRIAL OF INTRA-ARTICULAR CORTICOSTEROIDS VERSUS CONSERVATIVE
TREATMENT IN EARLY OLIGOARTHRITIS OVER 12 MONTHS.
H. Marzo-Ortega 1 , M. Green 1 , A.-M. Keenan 1 , R. Wakefield 1 , S. Proudman 2 , P. Emery 1
1
Academic Unit of Musculoskeletal Disease and Rehabilitation, University of Leeds, Leeds, West
Yorkshire, United Kingdom; 2 Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia,
Australia
192 EXERCISE-HOW TO MOTIVATE RHEUMATOLOGY OUTPATIENTS?
H. Timlin
Department of Rheumatology, Great Western Hospital, Swindon, Wiltshire, United Kingdom
55

Paediatric and adolescent rheumatology
193 POSITIVE ASSOCAITION OF WNT-1 INDUCIBLE SIGNALLING PATHWAY PROTEIN 3 (WISP3) AND
JUVENILE IDIOPATHIC ARTHRITIS (JIA).
R.M. Lamb 1 , W. Thomson 1 , E. Ogilvie 2 , R. Donn 1,3
BSPAR, 1 ARC/EU, The University of Manchester, Manchester, United Kingdom; 2 UCL, London, United
Kingdom; 3 Centre for Molecular Medicine, The University of Manchester, Manchester, United Kingdom
194 THE RELATIONSHIP BETWEEN PHYSICAL AND PSYCHOLOGICAL FUNCTION IN CHILDREN WITH
JUVENILE POLYARTICULAR ARTHRITIS.
T. Ding 1 , H.A. Doll 2 , A. Hall 1 , K. Jacobs 3 , J. David 1
1
Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom; 2 Public Health, University of
Oxford, Oxford, United Kingdom; 3 Paediatric Psychology, John Radcliffe Hospital, Oxford, United
Kingdom
195 CASE REPORT OF SUCCESSFUL MANAGEMENT OF MACROPHAGE ACTIVATION SYNDROME
(MAS) FOLLOWING AUTOLOGOUS T CELL DEPLETED STEM CELL TRANSPLANTATION (ASCT) FOR
SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS (SOJIA).
M. Wood 1 , A. Myers 2 , T. Flood 3 , M. Friswell 1 , H. Foster 1,4 , M. Abinun 1,3
1
Paediatric Rheumatology, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom;
2
Rheumatology, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom; 3 Paediatric
Immunology, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom; 4 School of Clinical
Medical Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom
196 UNNECESSARY ADVERSE EFFECTS FROM IMMUNO-SUPPRESSANT DRUGS: A CASE OF
MIS-DIAGNOSIS OF JUVENILE IDIOPAHTIC ARTHRITIS.
L.J. McCann, L.R. Wedderburn
Rheumatology Unit, Institute of Child Health, UCL and Great Ormond Street, London, United Kingdom
197 VACCINATION COVERAGE AMONG CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA).
K. Minden 1,2 , M. Niewerth 2 , W. Singendonk 3 , E. Jaeger-Roman 3 , A. Zink 1
1
II. Children's Hospital, Helios Hospitals Berlin-Buch, Berlin, Germany; 2 Epidemiology Unit, German
Rheumatism Research Centre, Berlin, Germany; 3 Paediatric Practice, Berlin, Germany
198 GROWING UP AND MOVING ON. A MULTICENTRE UK AUDIT OF THE TRANSFER OF ADOLES-
CENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA) FROM PAEDIATRIC TO ADULT CENTRED CARE.
L.P. Robertson 1 , K.L. Shaw 2 , T.R. Southwood 2 , J.E. McDonagh 2
On Behalf of the BSPAR; 1 Department of Rheumatology, Bristol Royal Infirmary, Bristol, United Kingdom;
2
Institute of Child Health, University of Birmingham, Birmingham, United Kingdom
199 GROWING UP AND MOVING ON IN RHEUMATOLOGY: TRANSITIONAL CARE AND QUALITY OF
LIFE OF ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA).
J.E. McDonagh, T.R. Southwood, K.L. Shaw
On Behalf of BSPAR; Institute of Child Health, University of Birmingham, Birmingham, West Midlands,
United Kingdom
200 GROWING UP AND MOVING ON: DEVELOPMENT OF A TRANSITIONAL CARE PROGRAMME FOR
A MULTICENTRE COHORT OF ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA).
J.E. McDonagh, T.R. Southwood, K.L. Shaw
On Behalf of BSPAR; Institute of Child Health, University of Birmingham, Birmingham, United Kingdom
201 HISTOLOGICAL FEATURES IN JUVENILE DERMATOMYOSITIS MAY PREDICT CLINICAL
PROGRESSION.
C.K.C. Li 1 , J.L. Holton 2 , H. Varsani 1 , P. Woo 1 , L.R. Wedderburn 1
1
Rheumatology Unit, Institute of Child Health, London, United Kingdom; 2 Institute of Neurology, London,
United Kingdom
56

202 HISTORY OF FRACTURE AND BONE MINERAL DENSITY IN ADOLESCENCE: THE NORTHERN
IRELAND YOUNG HEARTS PROJECT.
C. Mc Gartland 1 , P. Robson 1 , L. Murray 2 , G. Cran 2 , M. Savage 3 , D. Watkins 3 , M. Rooney 4 ,
C. Boreham 1
1
Northern Ireland Centre for food and health, University of Ulster, Coleraine, N. Ireland, United
Kingdom; 2 Dept Epidemiology and Public Health, The Queen's University of Belfast, Belfast, N.
Ireland, United Kingdom; 3 The Dept of Child Health, The Queen's University of Belfast, Belfast, N.
Ireland, United Kingdom; 4 Musculoskeletal Education and Research Unit, The Queen's University of
Belfast, Belfast, N.Ireland, United Kingdom
203 WHO TELLS WHAT! AN AUDIT OF ADVICE REGARDING ALCOHOL IN PAEDIATRIC
RHEUMATOLOGY CLINICS.
G. Jackson 1 , J.E. McDonagh 2
Paediatric Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; Insititute of
Child Health, University of Birmingham, Birmingham, West Midlands, United Kingdom; on behalf of
the Adolescent Subcommittee, British Society of Paediatric and Adolescent, United Kingdom
204 PREVALENCE OF OBESITY IN PAEDIATRIC RHEUMATOLOGY OUT-PATIENTS.
R. Wilshire 1 , B. Johnson 1 , G. Shaikh 2 , J.E. McDonagh 3
1
Rheumatology, Birmingham Children's Hospital, Birmingham, West Midlands, United Kingdom;
2
Endocrinology, Birmingham Children's Hospital, Birmingham, West Midlands, United Kingdom;
3
Institute of Child Health, University of Birmingham, Birmingham, West Midlands, United Kingdom
Psychology, measurement and management of pain
205 OUTCOMES FROM THE ADDENBROOKE'S MULTIDISCIPLINARY BACK PAIN MANAGEMENT
PROGRAMME.
C. Lumley, S. Dahiya, A. Powell, E. Mitchell, J. Jenner
Rheumatology, Addenbrookes University Hospital, Cambridge, Cambridgeshire, United Kingdom
206 CAUDAL EPIDURAL ANALGESIA FOR LOWBACK PAIN/SCIATICA.
S. Saravana 1 , T.J. Gillott 2
1
Rheumatology, Walsgrave Hospital, Coventry, United Kingdom; 2 Rheumatology, DPOW Hospital,
Grimsby, United Kingdom
207 ATTENTIONAL DYSFUNCTION IN FIBROMYALGIA.
B. Kulkarni 1 , E. Boger 1 , A. Watson 1 , R. Elliott 2 , D. Bentley 1 , W. El Deredy 1 , S.W.G. Derbyshire 3 ,
R. Frackowiak 4 , V. Nadeau 1 , Y. Boyle 1 , A.K.P. Jones 1
1
Human Pain research Group, University of Manchester Rheumatic Diseases Centre, Hope Hospital,
Salford, United Kingdom; 2 Neuroscience and Psychiatry Unit, University of Manchester, Stopford
Building, Manchester, United Kingdom; 3 Department of Anesthesiology, University of Pittsburgh,
Pittsburgh, PA, United States; 4 Wellcome Department of Imaging Neuroscience, UCL, London,
United Kingdom
208 SEX DIFFERENCES IN THE EMOTIONAL RESPONSE TO COGNITIVE BEHAVIOURAL GROUP
THERAPY FOR CHRONIC MUSCULOSKELETAL PAIN.
J.H. Raphael 1 , C. Beddall 1 , G.J. Treharne 2 , K. LeMarchand 1 , J. Wiltshire 1
1
Department of Pain Management, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands,
United Kingdom; 2 Dept of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West
Midlands, United Kingdom
209 THE PREVALENCE AND CHARACTERISTICS OF NIGHT PAIN AMONG GENERAL
RHEUMATOLOGY OUTPATIENTS: A PILOT STUDY.
H.E. Cohen, D.R. Blake
Royal National Hospital for Rheumatic Disease, Bath, United Kingdom
57

210 DIAGNOSIS AND THERAPY OF FEAR OF PROGRESSION (FOP) IN RHEUMATIC DISEASES.
U. Engst-Hastreiter 1 , G. Duran 2 , G. Henrich 2 , S. Waadt 2 , P. Berg 2 , P. Herschbach 2
1
Rheumatology Rehabilitation Centre, Federal Insurance Institute for Salaried Employees, BfA, Bad
Aibling, Germany; 2 Institute for Psychosomatic Medicine, Psychotherapy and Medical Psychology,
Technical University, Muenchen, Germany
211 THE INFLUENCE OF MEDICATION BELIEFS AND OTHER PSYCHOSOCIAL FACTORS ON EARLY
DISCONTINUATION OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS.
M.M. Wong 1 , D. Mulherin 2
1
Physical Health Psychology and Rehabilitation, South Staffordshire Healthcare NHS Trust, Cannock,
Staffordshire, United Kingdom; 2 Department of Rheumatology, Cannock Chase Hospital, Cannock,
Staffordshire, United Kingdom
212 PERCEIVED SOCIAL SUPPORT IN RHEUMATOID ARTHRITIS PATIENTS: EXTENSION OF A GENERAL
MEASURE TO COVER SUPPORT FROM HEALTHCARE PROFESSIONALS AND ITS LONGITUDINAL
IMPACT ON ANXIETY AND DEPRESSION.
G.J. Treharne 1,2 , A.C. Lyons 3 , D.A. Booth 1 , G.D. Kitas 1,2,4
1
School of Psychology, University of Birmingham, Birmingham, United Kingdom; 2 Department of
Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom; 3 School
of Psychology, Massey University, Auckland, New Zealand; 4 Department of Rheumatology, Division of
Immunity and Infection, School of Medicine, University of Birmingham, Birmingham, United Kingdom
Rheumatoid arthritis – clinical aspects
213 MANY PATIENTS WITH RHEUMATOID ARTHRITIS HAVE FUNCTIONAL IMPAIRMENT FROM
DISEASES OTHER THAN RA.
G. Westhoff
Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
214 INCREASING AGE PREDICTS EROSIONS AT FIRST VISIT IN PATIENTS PRESENTING EARLY WITH
INFLAMMATORY POLYARTHRITIS: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER.
M. Bukhari, M. Lunt, D.G.I. Scott, D. Symmons, A. Silman
ARC Epidemiology Unit, The University of Manchester, Manchester, United Kingdom
215 A SIMPLE PROGNOSTIC INDEX IN EARLY RHEUMATOID ARTHRITIS FOR PREDICTING
FUNCTIONAL OUTCOME AT 5 YEARS FOLLOW UP.
N. Bansback 1 , A. Young 2 , J. Dixey 2 , A. Brennan 1
1
School of Health and Related Research, Sheffield, United Kingdom; 2 On behalf of the Early Rheumatoid
Arthritis Study Group (ERAS), St Albans City Hospital, Hertfordshire, United Kingdom
216 A STUDY OF THE DIFFERENCES IN SYNOVIAL VOLUMES IN EARLY AND LATE INFLAMMATORY
ARTHRITIS USING DYNAMIC ENHANCED MRI.
L.A. Rhodes 1 , A.-L. Tan 2 , S.F. Tanner 1 , A. Radjenovic 1 , H. Marzo-Ortega 2 , P. O'Connor 3 , P. Emery 2 ,
D. McGonagle 2
1
Academic Unit of Medical Physics, University of Leeds, Leeds, Yorkshire, United Kingdom; 2 Academic
Unit of Musculoskeletal Disease, Leeds General Infirmary, Leeds, Yorkshire, United Kingdom;
3
Department of Radiology, Leeds General Infirmary, Leeds, Yorkshire, United Kingdom
217 A STUDY OF THE DEVELOPMENT OF EXTRA ARTICULAR FEATURES OF RHEUMATOID ARTHRITIS
AND WHICH FEATURES AT ONSET HAVE PREDICTIVE VALUE FOR OUTCOME MEASURES OF DISEASE
SEVERITY.
G. Koduri, A. Young, M. Batley, S. Norton
On behalf of the Early Rheumatoid Arthritis Study (ERAS), City Hospital, St Albans, Hertfordshire, United
Kingdom
58

218 IS THE RELATIONSHIP BETWEEN DIGITAL X-RAY RADIOGRAMMETRY (DXR) INDICES
AND EROSION COUNTS THE SAME IN MEN AND WOMEN?
W.B. Jawaid 1 , A. Stewart 1 , D. Crosbie 2 , D.M. Reid 1
1
Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom;
2
Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom
219 LONGITUDINAL MEASUREMENT OF TRADITIONAL OBSERVER AND LABORATORY BASED
MARKERS ENHANCES PREDICTION OF RADIOGRAPHIC PROGRESSION IN EARLY RHEUMATOID
ARTHRITIS. PATIENT BASED RESPONSES WERE OF LIMITED USE.
S.A. Young-Min 1 , I. Griffiths 2 , N. Marshall 2 , D. Coady 2 , T. Cawston 1
1
Musculoskeletal Research Group, University of Newcastle-upon-Tyne, Newcastle upon Tyne, Tyne &
Wear, United Kingdom; 2 Rheumatology, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear,
United Kingdom
220 SOCIOECONOMIC DIFFERENCES IN RHEUMATOID ARTHRITIS IN GUJERATI ASIAN AND
CAUCASIAN COMMUNITIES IN LEICESTER: A PROFOUND EFFECT ON THE PATIENT?
C.E. Neville 1 , W. Hassan 2
1
Rheumatology, Wexham Park Hospital, Slough, Berkshire, United Kingdom; 2 Rheumatology,
University Hospitals of Leicester, Leicester, Leicestershire, United Kingdom
221 EVALUATION OF ACUTE PHASE REACTANT LIPOPOLYSACCHARID BINDING PROTEIN IN
RHEUMATOID ARTHRITIS, CORRELATION WITH C-REACTIVE PROTEIN, LARSEN- AND RATINGEN
SCORE.
M. Thun 1 , B. Moeller 2 , J.P. Kaltwasser 1 , R. Wigand 1
1
Rheumatology, J.W. Goethe University Clinic, Frankfurt, Germany; 2 Rheumatology, Inselspital, Bern,
Switzerland
222 ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS: IMPLEMENTING THE BSR GUIDELINES.
S. Silburn, E. McIvor, A. McEntagart
Department of Rheumatology, Stobhill Hospital, Glasgow, Lanarkshire, United Kingdom
223 COMPARISON BETWEEN DAS28 4 SCORE & 3 SCORE - WOULD IT INFLUENCE PATIENT ELI-
GIBILITY FOR, OR EVALUATION OF RESPONSE TO ANTI-TNFα?
S. Bawa, L. Fowler, A. Bradlow
Department of Rheumatology, Royal Berkshire and Battle Hospital NHS Trust, Reading, United
Kingdom
224 AIMING FOR REMISSION: AN AUDIT OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS
PATIENTS.
A.A. Zain 1 , A.N. Bennett 1 , M. Wong 1 , G.S. Panayi 2 , B.W. Kirkham 1
1
Rheumatology, Guy's and St Thomas' Foundation Trust, London, United Kingdom; 2 Academic
Rheumatology, GKT School of Medicine, London, United Kingdom
225 RAPID SERUM SUGAR BIOMARKER ASSAY OF RHEUMATOID ARTHRITIS.
A. Alavi 1 , J.S. Axford 1 , E. Tarelli 2
1
Department of Cellular Molecular Medicine, St George's Hospital Medical School, London, United
Kingdom; 2 Medical Biomics Centre, St George's Hospital Medical School, London, United Kingdom
226 RHEUMATOID FACTOR AND HLA-DRB1*0401, BUT NOT CIGARETTE SMOKING, ARE
INDEPENDENTLY ASSOCIATED WITH ANTIBODIES TO CYCLIC CITRULLINATED PEPTIDES IN
RHEUMATOID ARTHRITIS.
D.L. Mattey 1 , N.B. Nixon 1 , D.G. Hutchinson 2
1
Rheumatology, University Hospital of North Staffordshire, Stoke-on-Trent, Staffordshire, United
Kingdom; 2 Rheumatology, Royal Cornwall Hospital, Truro, Cornwall, United Kingdom
59

227 CORRELATION OF A NEW FLUOROENZYMIMMUNOASSAY FOR MEASUREMENT OF ANTI-CYCLIC
CITRULLINATED PEPTIDE (ANTI-CCP) ANTIBODIES WITH AN ANTI-CCP ENZYMLINKEDIMMUNASSAY
AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA).
M. Thun 1 , F. Behrens 1 , I. diGreci 1 , J.P. Kaltwasser 1 , B. Moeller 2
1
Rheumatology, J.W. Goethe University Clinic, Frankfurt, Germany; 2 Rheumatology, Inselspital, Bern,
Switzerland
228 ANEMIA OF CHRONIC DISEASE IN RHEUMATOID ARTHRITIS: RELATIONSHIPS WITH DISEASE
ACTIVITY.
I.P. Gunko 1 , O.I. Ostapchuk 1 , I.I. Andrushko 1 , S.G. Kryvoruchko 2 , L.B. Vedenko 2
1
Rheumatology, Vinnycia National Medical University, Vinnycia, Ukraine; 2 Rheumatology, Vinnycia
Regional Hospital, Vinnycia, Ukraine
229 FATIGUE IN RHEUMATOID ARTHRITIS (RA): ITS CAUSES AND CONSEQUENCES.
L.C. Pollard, E.H. Choy, D.L. Scott, J.G. Gonzalez
Rheumatology, King's College London, London, United Kingdom
230 PREVALENCE, TREATMENT AND ASSESSMENT OF FOOT INVOLVEMENT IN RHEUMATOID
ARTHRITIS: A NEGLECTED AREA.
S.J. Farrow, D.L. Scott, G.H. Kingsley
Department of Rheumatology, GKT School of Medicine, London, United Kingdom
231 INTERVENTIONS FOR FOOT DISEASE IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW.
S.J. Farrow, G.H. Kingsley, D.L. Scott
Rheumatology, GKT School of Medicine, London, United Kingdom
232 SCREENING FOR HYPERTENSION (HT) IN RHEUMATOID ARTHRITIS (RA): A SURVEY OF
RHEUMATOLOGISTS VIEWS AND BLOOD PRESSURE (BP) MEASUREMENT IN PRIMARY CARE.
N.D. McKay, C.E. Kidd
Rheumatology, Sunderland Royal Hospital, Sunderland, Wearside, United Kingdom
233 DOES THE BURDEN OF INFLAMMATION DETERMINED PROSPECTIVELY IN PATIENTS WITH EARLY
INFLAMMATORY ARTHRITIS DETERMINE THE PROGRESSION OF ATHEROSCLEROSIS?
W.Y. Al-Shehhi 1 , S. Skehan 2 , E. Hefferenan 2 , F. Hughes 2 , D.J. Veale 1 , B. Bresinihan 1 , O. Fitzgerald 1
1
Rheumatology, UCD, Dublin, Ireland; 2 Radiology, UCD, Dublin, Ireland
234 VASCULAR RISK IN RHEUMATOID ARTHRITIS: YOUR PROBLEM OR MINE?
L.A. Dunkley, D. Perry
Department of Rheumatology, Barts & The London NHS Trust, London, United Kingdom
235 ASSOCIATION BETWEEN INFLAMMATORY MARKERS AND ATHEROSCLEROTIC DISTURBANCE OF
COMMON CAROTID ARTERY IN PATIENTS WITH RHEUMATOID ARTHRITIS
O.Y. Galyutina 1 , M.A. Stanislavchuk 2 .
1
Rheumatology, Ukrainian State Scientific Research Institute of Invalid Rehabilitation, Vinnycia, Ukraine;
2
Rheumatology, Vinccycia National Medical University, Vinnycia, Ukraine
236 HYPERTENSION (HT) PREVALANCE IS HIGH AND TARGET BLOOD PRESSURE (BP) IS
UNDERACHIEVED IN A RHEUMATOID ARTHRITIS (RA) OUT-PATIENT POPULATION.
N.D. Mckay, E. Kidd
Rheumatology, Sunderland Royal Hospital, Sunderland, Wearside, United Kingdom
237 ASSESSING CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS.
D.J. Armstrong, E.M. McCausland, A. Quinn, G.D. Wright
Rheumatology Department, Royal Victoria Hospital, Belfast, Northern Ireland, United Kingdom
238 AWARENESS OF INCREASED CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID
ARTHRITIS.
A.J. Kinder, P. Courtney
Rheumatology, Nottingham City Hospital, Nottingham, United Kingdom
60

239 LONGITUDINAL STUDY OF LUNG FUNCTION IN RHEUMATOID ARTHRITIS TREATED WITH
METHOTREXATE.
V. Saravanan, C. Kelly
Department of Rheumatology and Medicine, Queen Elizabeth Hospital, Gateshead, Tyne & Wear,
United Kingdom
240 RENAL FUNCTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS.
P. Wiland, M.A. Sokalska-Jurkiewicz, J. Szechinski
Rheumatology, Wroclaw Medical University, Wroclaw, Poland
241 DIASTOLIC FUNCTION ABNORMALITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS:
RELATION WITH DISEASE DURATION.
M.A. Stanislavchuk 1 , Y.K. Otkalenko 1 , O.Y. Galyutina 2 , O.S. Otkalenko 3 , G.A. Plakhotnyuk 1
1
Rheumatology, Vinnycia Medical National University, Vinnycia, Ukraine; 2 Rheumatology, Ukrainian
State Scientific Research Institute of Invalid Rehabilitation, Vinnycia, Ukraine; 3 Ultrasonography,
Vinnycia Regional Hospital, Vinnycia, Ukraine
242 PREDICTORS OF CUMULATIVE RADIATION DOSE IN RHEUMATOID ARTHRITIS PATIENTS.
G.J. Treharne 1,2 , D.G. Kassimos 2 , R.M. Shave 3 , A.N. Saratzis 2 , G.D. Kitas 1,2,4
1
School of Psychology, University of Birmingham, Birmingham, United Kingdom; 2 Department of
Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom;
3
Department of Radiography, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United
Kingdom; 4 Department of Rheumatology, Division of Immunity and Infection, School of Medicine,
University of Birmingham, Birmingham, United Kingdom
243 CARDIOVASCULAR RESPONSES TO COMBINED MENTAL AND POSTURAL STRESS IN
PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS.
J.J.C.S. Veldhuijzen van Zanten 1,2 , C. Ring 1 , D. Carroll 1 , G.D. Kitas 2,3
1
School of Sport and Exercise Sciences, University of Birmingham, Birmingham, United Kingdom;
2
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, West Midlands, United
Kingdom; 3 School of Medicine, University of Birmingham, Birmingham, United Kingdom
244 BODY COMPOSITION AND DISEASE SEVERITY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
N.B. Ursol 1 , M.A. Stanislavchuk 2
1
Rheumatology, Khmelnytsky District Hospital, Khmelnytsky, Ukraine; 2 Rheumatology, National
Medical University, Vinnycia, Ukraine
245 BODY MASS INDEX, TOTAL AND SEGMENTAL BODY FAT IN PATIENTS WITH RHEUMATOID
ARTHRITIS.
G. Metsios, A. Stavropoulos-Kalinoglou, K. Douglas, G. Treharne, A. Saratzis, Y. Koutedakis, G.D.
Kitas
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, The Guest Hospital, Dudley,
West Midlands, United Kingdom
Soft tissue and regional musculoskeletal disease, fibromyalgia
246 CYTOKINES IL-8, IL-10 AND MELATONIN IN PATIENTS WITH FIBROMYALGIA SYNDROME.
S.V. Kolyadenko, M.A. Stanislavchuk
Rheumatology, Vinnycia National Medical University, Vinnycia, Ukraine
247 POTASSIUM CHANNEL ACTIVITY IN LYMPHOCYTES OF PATIENTS WITH FIBROMYALGIA.
J.H. Raphael 1 , E. Shawcross 2 , M. Labib 3 , G.D. Kitas 4 , K. Lawson 2
1
Department of Pain Management, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands,
United Kingdom; 2 Biomedical Research Centre, Sheffield Hallam University, Sheffield, United
Kingdom; 3 Dept of Clinical Biochemistry, Dudley Group of Hospitals NHS Trust, Dudley, West
Midlands, United Kingdom; 4 Dept of Rheumatology, Dudley Group of Hospitals NHS Trust,
Dudley, West Midlands, United Kingdom
61

248 DISTORTING PROPRIOCEPTION IN FIBROMYALGIA EXACERBATES SENSORY
DISTURBANCES-IMPLICATIONS FOR PATHOLOGY.
C.S. McCabe 1,3 , T. Bodamyali 1,2 , D.R. Blake 1,2,3
1
Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 2 Department of Pharmacy and
Pharmacology, University of Bath, Bath, United Kingdom; 3 School for Health, University of Bath, Bath,
United Kingdom
249 THE INFLUENCE OF AGE ON THE SENSORIMOTOR SYSTEM: AN EXPLANATION FOR AGE
RELATED MUSCULOSKELETLA SYMPTOMS?
J. Hall 1 , C.S. McCabe 1,2 , D.R. Blake 1,2,3
1
RACE, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 2 Department of Pharmacy
and Pharmacology, University of Bath, Bath, United Kingdom; 3 School for Health, University of Bath,
Bath, United Kingdom
250 INCREASED EXPRESSION OF AGGRECAN mRNA IN PAINFUL ACHILLES TENDINOPATHY.
A.N. Corps, G.C. Jones, V.A. Curry, B.L. Hazleman, G.P. Riley
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
251 LATERAL RELEASE FOR TENNIS ELBOW.
S.E.J. Medley, G. Coakley
Department of Rheumatology, Princess Royal Hospital, Haywards Heath, West Sussex, United Kingdom;
Department of Rheumatology, Queen Elizabeth Hospital, Woolwich, London, United Kingdom
252 A RANDOMISED CONTROLLED TRIAL OF PULSED LOW INTENSITY ULTRASOUND THERAPY FOR
CHRONIC LATERAL EPICONDYLITIS: A PILOT STUDY.
A.P. D'Vaz 1 , M.M. Bradley 2 , A.T. Prevost 2 , J.E. Jenner 1 , B.L. Hazleman 1 , C.A. Speed 1 , A.J.K. Ostor 1
1
Rheumatology Research Unit, Addenbrooke's Hospital, Camrbidge, United Kingdom; 2 Centre for Applied
Medical Statistics, Department of Public Health, University of Cambridge, Cambridge, United Kingdom
253 PREDICTORS OF MOTOR AND SENSORY DELAY IN CARPAL TUNNEL SYNDROME.
P. Shah, M. O'Donnell, W. Dodds, J. Halsey, M. Bukhari
Rheumatology, Morecambe Bay Hospitals NHS Trust, Royal Lancaster Infirmary, Lancashire, United
Kingdom
254 A COMPARISON OF WRIST SPLINTS VERSUS CORTICOSTEROID INJECTION FOR CARPAL TUNNEL
SYNDROME: A RANDOMISED TRIAL AND 12 MONTH OUTCOME.
S. Hardwick, D. Youll, J.N. Fordham, M.J. Plant
Departments of Occupational Therapy and Rheumatology, The James Cook University Hospital,
Middlesbrough, United Kingdom
255 FACET JOINT INJECTIONS - AN EFFECTIVE TREATMENT?
F. Rahmeh, P. Thompson, P. Cornell
Rheumatology, Poole Hospital NHS Trust, Poole, Dorset, United Kingdom
256 UNDIAGNOSED JOINT HYPERMOBILITY SYNDROME PATIENTS HAVE POORER OUTCOME THAN
PEERS FOLLOWING CHRONIC BACK PAIN REHABILITATION.
S. Ashton, A.J. Hakim
Academic Rheumatology and Osteoporosis Unit, Whipps Cross University Hospital, London, United
Kingdom
257 RETURNING BACK PAIN TO THE COMMUNITY.
H.J. Mumby-Croft, N.J. Sheehan
Department of Rheumatology, Edith Cavell Hospital, Peterborough, Cambridgeshire, United Kingdom
62

258 BACK PAIN AMONG WOMEN AGED 60-70 YEARS IS ASSOCIATED WITH HRT USE BUT NOT
OTHER REPRODUCTIVE FACTORS.
K. Walker-Bone 1 , H. Syddall 2 , C. Cooper 2 , A. Aihie Sayer 2 , E. Dennison 2
1
Rheumatology, Brighton & Sussex Medical School, Brighton, United Kingdom; 2 MRC Epidemiology
Resource Centre, Southampton General Hospital, Southampton, United Kingdom
259 ABDOMINAL MUSCLE ASYMMETRY IN UNILATERAL LOW BACK PAIN.
D.J. Critchley, M.V. Hurley
Physiotherapy, King's College London, London, United Kingdom
260 THE EPIDEMIOLOGY OF BACK PAIN AND SCIATICA AMONG ELDERLY ADULTS IN THE
GENERAL POPULATION.
K. Walker-Bone 1 , E. Dennison 2 , H. Syddall 2 , A. Aihie Sayer 2 , C. Cooper 2
1
Rheumatology Department, Brighton & Sussex Medical School, Brighton, United Kingdom; 2 MRC
Epidemiology Resource Centre, Southampton General Hospital, Southampton, United Kingdom
261 BONE MINERAL DENSITY IS AN INDEPENDENT RISK FACTOR FOR BACK PAIN AND SCIATICA
AMONG MEN AGED 60-70 YEARS.
K. Walker-Bone 1 , C. Cooper 2 , H. Syddall 2 , E. Dennison 2 , A. Aihie Sayer 2
1
Rheumatology, Brighton & Sussex Medical School, Brighton, United Kingdom; 2 MRC Epidemiology
Resource Centre, Southampton General Hospital, Southampton, United Kingdom
262 IS PAMIDRONATE AN EFFECTIVE ANALGESIC IN PATIENTS WITH REFRACTORY SPINAL PAIN?
S.K. Williams, G.R. Clarke
Rheumatology, Barking, Havering and Redbridge Health Authority, Romford, Essex, United Kingdom
263 BODY PERCEPTION DISTURBANCE IN COMPLEX REGIONAL PAIN SYNDROME.
J.S. Lewis 1,2 , C.S. McCabe 1,3 , D.R. Blake 1,3
1
RACE, The Royal National Hospital for Rheumatic Diseases, Bath, Somerset, United Kingdom;
2
School of Health Professions and Rehabilitation Sciences, University of Southampton, Southampton,
Hampshire, United Kingdom; 3 School of Health, University of Bath, Bath, Somerset, United Kingdom
264 WHAT CRITERIA DO GENERAL PRACTITIONERS USE TO MAKE A DIAGNOSIS OF
POLYMYALGIA RHEUMATICA?
K. Barraclough, W. Liddell, F. Christopher, J. du Toit, M. Thomas
Hoyland House General Practice, Painswick, Glos, United Kingdom; RACE, Royal National Hospital
for Rheumatological Diseases, Bath, United Kingdom; RDSU, Gloucestershire Hospital NHS Trust,
Gloucester, United Kingdom; Minchinhampton General Practice, Minchinhampton, Glos, United
Kingdom
265 HOW DO GPs MANAGE POLYMYALGIA RHEUMATICA (PMR) AND CAN OUTCOME
BE PREDICTED AT DIAGNOSIS?
W.G. Liddell 1 , K. Barraclough 2 , J. du Toit 2 , C. Foy 3 , M. Thomas 4
1
RACE, RNHRD, Bath, Avon, United Kingdom; 2 Hoyland House General Practice, Painswick, Glos,
United Kingdom; 3 RDSU, Gloucestershire Hospital NHS Trust, Gloucester, Glos, United Kingdom;
4
Minchinhampton Practice, Minchinhampton, Glos, United Kingdom
Spondylarthropathies, including psoriatic arthritis
266 EXTENDED HAPLOTYPES OF MICA, TNF-ALPHA AND LYMPHOTOXIN IN PSORIATIC
ARTHRITIS.
E. Korendowych 1 , J. Ravindran 1 , P. Owen 1 , K. Welsh 2 , N.J. McHugh 1
1
Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 2 National Heart and Lung
Institute, Imperial College, London, United Kingdom
63

267 NAIL AND DISTAL INTERPHALANGEAL JOINT IN PSORIATIC PATIENTS.
R. Scarpa 1 , R. Peluso 1 , E. Soscia 2 , M. Atteno 1 , F. Manguso 1 , A. Oriente 1 , P. Punzetto 1 , D.N.M. Di Minno 1 ,
S. Iervolino 1 , M. Salvatore 2
1
Clinical and Experimental Medicine, University Federico II, Naples, Italy, Italy; 2 Radiology Unit,
Biostructures and Bioimaging Institute of National Council of Research, Naples, Italy, Italy
268 RADIOLOGICAL PROGRESSION IN ESTABLISHED PSORIATIC ARTHRITIS.
J. Ravindran 1 , C. Carmichael 1 , C. Balakrishnan 2 , S. Jones 3 , E. Korendowych 1 , N. McHugh 1
1
Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 2 Rheumatology,
P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India; 3 Rheumatology, University
of Wales, Cardiff, United Kingdom
269 ADALIMUMAB EFFICACY AND SAFETY RESULTS IN PATIENTS WITH MODERATE TO SEVERE
CHRONIC PLAQUE PSORIASIS: SUBANALYSIS OF PATIENTS WITH AND WITHOUT PsA.
M.A. Menter 1 , K.B. Gordon 2 , C. Leonardi 3 , M.P. Heffernan 4 , D.M. Chen 5
1
Baylor University Medical Center, Dallas, TX, United States; 2 Loyola University Stritch School of Medicine,
Maywood, IL, United States; 3 St. Louis University, St. Louis, MO, United States; 4 Washington University,
St. Louis, MO, United States; 5 Abbott Laboratories, Abbott Park, IL, United States
270 ANAKINRA (KINERET) IN PSORIASIS AND PSORIATIC ARTHRITIS: A SINGLE CENTER,
OPEN-LABEL, PILOT STUDY.
A. Gibbs, C. Walsh, B. Bresnihan, D.J. Veale, O. FitzGerald
St. Vincents University Hospital, Dublin 4, Ireland
271 PSORIATIC ARTHRITIS (PsA) - THE POTENTIAL SIZE OF THE UK PsA POPULATION MERITING ANTI
TNFα TREATMENT.
P.J. Cornell, S. Richards, P. Thompson
Rheumatology, Poole Hospital NHS Trust, Poole, Dorset, United Kingdom
272 ELIGIBILITY FOR ANTI-TNFα THERAPY IN A PSORIATIC ARTHRITIS OUT PATIENT COHORT.
S.D. Kyle, K. Solanki, C. Carmichael, N.J. McHugh
Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
273 TOLL LIKE RECEPTOR 4 POLYMORPHISMS AND ANKYLOSING SPONDYLITIS.
R. Adam 1 , A. Gracie 2 , R.D. Sturrock 2
1
Glasgow University, Glasgow, United Kingdom; 2 Centre For Rheumatic Diseases, Division of Immunology,
Inflammation and Infection, Glasgow Royal Infirmary, Glasgow, United Kingdom
274 PHENOTYPIC AND FUNCTIONAL CHARACTERISATION OF NATURAL KILLER (NK) RECEPTOR
EXPRESSING T LYMPHOCYTES IN SPONDYLOARTHRITIS.
A.T.Y. Chan, S. Kollnberger, A.J. McMichael, P. Bowness
Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford,
United Kingdom
275 A LONGITUDINAL STUDY OF CLINICAL AND PSYCHOLOGICAL STATUS IN ANKYLOSING
SPONDYLITIS.
J.H. Martindale 1 , J. Smith 3 , C. Sutton 3 , D. Swinson 2 , D. Grennan 2 , J.A. Goodacre 3
1
Department of Physiotherapy, Ashton, Wigan and Leigh Primary Care Trust, Wrightington, Lancashire,
United Kingdom; 2 Department of Rheumatology, Wrightington, Wigan and Leigh NHS Trust,
Wrightington, Lancashire, United Kingdom; 3 Chronic Disease and Rehabilitation Research and Teaching
Group, Faculties of Health and Science, University of Central Lancashire, Preston, Lancashire, United
Kingdom
276 CAN AN INTENSIVE OUTPATIENT PHYSIOTHERAPY COURSE REDUCE THE NEED FOR BIOLOGIC
THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS?
J. Courtney, R. Lewis, P. Creamer
Southmead Hospital, Bristol, United Kingdom
64

277 ANTHROPOMETRIC MEASUREMENT AS A PREDICTOR OF EXERCISE BEHAVIOUR IN PEOPLE
WITH ANKYLOSING SPONDYLITIS.
S.B. Porter 1 , G.A. John 1 , G. Lynne 1 , S. Jane 2 , C. Chandra 1
Lancashire School of Health and Postgraduate Medicine, University of Central Lancashire, Preston,
Lancashire, United Kingdom; Department of Psychology, University of Central Lancashire, Preston,
Lancashire, United Kingdom; Department of Rheumatology, Wrightington Wigan and Leigh NHS
Trust, Wigan, Lancashire, United Kingdom
278 COPING WITH ANKYLOSING SPONDYLITIS: PATIENTS' VIEWS ON EDUCATION AND
EXERCISE.
A.G. Ling, L.J. Kay
Department of Rheumatology, Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, Tyne
and Wear, United Kingdom
279 A SYSTEMATIC REVIEW OF TREATMENT OPTIONS IN ANKYLOSING SPONDYLITIS (AS).
S. Levy 1 , C.M. Smith 1 , E.H. Choy 1
Rheumatology, University Hospital Lewisham, London, United Kingdom; Rheumatology, King's
College London, London, United Kingdom
280 PATIENTS' VIEWS ON THE MANAGEMENT OF ANKYLOSING SPONDYLITIS:
A QUALITATIVE STUDY.
S. Shepherd 1 , L. Kay 2
1
The Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom;
2
Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
281 LOW- DOSE INFLIXIMAB FOR ANKYLOSING SPONDYLITIS IN CLINICAL PRACTICE- ?
MORE COST EFFECTIVE.
R.N. Jois, J. Leeder, A. Gibb, K. Gaffney, P. Merry, D.G.I. Scott
Rheumatology, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom
282 REMISSION OF SPONDYLOARTHROPATHY FLARE WITH LOW DOSE INFLIXIMAB
(2.5 MG/KG) FOR THE 3 LOADING PULSES, FOLLOWED BY 6 MONTHLY AND A "PRN" REGIME.
(THE EXPERIENCE FROM 11 PATIENTS).
E. Roussou, G. laskaris
Rheumatology and Rehabilitation, King George Hospital, Ilford, Essex, United Kingdom; Pharmacy,
Panagia hospital of B' IKA, Thessaloniki, Greece
283 ELIGIBILITY OF ANKYLOSING SPONDYLITIS PATIENTS FOR TNF BLOCKER TREATMENT IN A
DISTRICT GENERAL HOSPITAL (DGH).
A.I. Hassan 1 , J.H. Martindale 2 , W. Naing 1 , D. Temperley 3
1
Rheumatology, Wrightington Hospital, Wigan, Lancashire, United Kingdom; 2 Physiotherapy,
Wrightington Hospital, Wigan, Lancashire, United Kingdom; 3 Radiology, Wrightington Hospital,
Wigan, Lancashire, United Kingdom
284 MEASUREMENT OF PHYSICAL ACTIVITY IN ANKYLOSING SPONDYLITIS PATIENTS RECEIVING
ANTI TNF THERAPY USING THE NUMACT ACTIVITY MONITOR.
S. Abdullah, N.J. Marshall, P. Heslop, K. Nichol, D.J. Walker, L.J. Kay
Musculoskeletal Department, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United
Kingdom
285 ANTI-TNFα THERAPY IN ANKYLOSING SPONDYLITIS – A NORTH WEST SIDE STORY.
V.V. Kaushik, K. Pillai, B. Shaw, H. Sykes, K. Binymin
Department of Rheumatology, Southport District General Hospital, Southport, Merseyside, United
Kingdom
2 8 6 THE COST EFFECTIVENESS AND EFFICACY OF IV PA M I D R O N ATE IN ANKY LOSING SPONDYLITIS.
A. Leak, K. Walton, H. Ewad
Dept of Rheumatology, Queen Elizabeth Queen Mother Hospital, Margate, Kent, United Kingdom
65

Poster Viewing Session 3
Friday 22 April 2005, 08:30 – 10:00
Case reports
287 A NOVEL THERAPY FOR THE TREATMENT OF RHEUMATOID PLEURAL EFFUSIONS.
G. McKellar 1 , M.M. Chee 1 , S. Banham 2 , R.D. Sturrock 1
1
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom; 2 Department of
Respiratory Medicine, Glasgow Royal Infirmary, Glasgow, United Kingdom
288 MULTIPLE HAEMATOLOGICAL MALIGNANCIES IN A PATIENT WITH RHEUMATOID ARTHRITIS
WITHOUT EXPOSURE TO DISEASE MODIFYING DRUGS.
H. Piper 1 , N. Hardwick 2 , D. Mulherin 1
1
Department of Rheumatology, Cannock Chase Hospital, Cannock, Staffordshire, United Kingdom;
2
Department of Dermatology, Cannock Chase Hospital, Cannock, Staffordshire, United Kingdom
289 REFRACTORY SCLERITIS IN PRIMARY SJÖGREN SYNDROME: SUCCESSFUL TREATMENT
WITH RITUXIMAB.
K. Ahmadi-Simab, P. Lamprecht, B. Noelle, P. Aries, W.-L. Gross
Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck,
Germany
290 SJOGREN'S MYELOPATHY.
C. Mukhtyar 1 , P. Wordsworth 1 , J. Palace 2
1
Rheumatology Department, Nuffield Orthopaedic Centre, Oxford, United Kingdom; 2 Neurology
Department, Radcliffe Infirmary, Oxford, United Kingdom
291 FAMILIAL JUVENILE SYSTEMIC GRANULOMATOSIS (BLAU'S SYNDROME).
L. Thomas 1 , J. Cook 2 , A. Thomas 1
1
Rheumatology Department, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom;
2
Dermatology Department, St Mary's Hospital, Portsmouth, Hampshire, United Kingdom
292 DELAYED DIAGNOSIS: JIA IN CHILDREN WITH LEARNING DIFFICULTIES.
M.W. Beresford, G. Cleary, J.A. Sills, J.E. Davidson
Rheumatology, Royal Liverpool Children's NHS Trust, Liverpool, United Kingdom
293 CLAUDICANT LIMB PAIN FROM LUMBAR SPINAL CANAL STENOSIS TREATED BY SPINAL
CORD STIMULATION.
J.H. Raphael 1 , L. Tisdall 1 , G.D. Kitas 2
1
Pain Management, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom;
2
Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom
294 NECK PAIN MISDIAGNOSED AS POLYMYALGIA RHEUMATICA.
R. Callaghan, A. Faizal
Rheumatology Department, Solihull Hospital, Solihull, United Kingdom; Rheumatology Department,
Solihull Hospital, Solihull, United Kingdom
295 CALF SWELLING AND SCIATICA - AN UNUSUAL PRESENTATION.
S.Y. Khan, S.P. Rigby
Rheumatology Department, Warwick Hospital, Warwick, United Kingdom
296 UNILATERAL SACRO-ILIITIS/OSTEITIS RELATED TO SPORTS INJURY AND RESPONSE TO
PAMIDRONATE.
P. Subrahmanyam 1 , R.A. Khazim 2 , B.D. Shah 3 , B. Dasgupta 1
1
Rheumatology, Southend Hospital NHS Trust, Westcliff-on-sea, Essex, United Kingdom; 2 Orthopaedics,
Southend Hospital NHS Trust, Westcliff-on-sea, Essex, United Kingdom; 3 Radiology, Southend Hospital
NHS Trust, Westcliff-on-sea, Essex, United Kingdom
66

297 RITUXIMAB USE IN REFRACTORY RAYNAUD'S DISEASE.
M. Haroon, D. O'Gradaigh, F.N. Darragh
Department of Rheumatology, Waterford Regional Hospital, Waterford, Ireland; Department of
Rheumatology, Waterford Regional Hospital, Waterford, Ireland; Department of Rheumatology,
Waterford Regional Hospital, Waterford, Ireland
298 TREATMENT OF REFRACTORY AUTOIMMUNE DISEASES WITH RITUXIMAB.
R.D. Moco, A.C.S. Grilo, R. Wedgewood, G.R.V. Hughes, D.P. D'Cruz
The Lupus Research Institute, St. Thomas Hospital, London, United Kingdom
299 THE ASSOCIATION OF COELIAC DISEASE WITH AUTOIMMUNE CONNECTIVE TISSUE
DISEASES.
A.C.S. Grilo, R.D. Moco, G.R.V. Hughes, D.P. D'Cruz
The Lupus Research Institute, St. Thomas Hospital, London, United Kingdom
300 REFRACTORY WEGENER'S GRANULOMATOSIS: REPORT ABOUT AN OPEN LABLE STUDY
WITH RITUXIMAB.
P.M. Aries, J. Voswinkel, P. Lamprecht, W.L. Gross
Poliklinik für Rheumatologie, Universitätsklinikium Schleswig-Holstein, Luebeck, Schleswig-Holstein,
Germany
301 ERDHEIM-CHESTER DISEASE: YET ANOTHER MIMIC OF POLYMYALGIA RHEUMATICA AND
GIANT CELL ARTERITIS?
E.C. Derrett-Smith 1 , B. Dasgupta 2
1
Department of Rheumatology, Southend General Hospital, Southend-on-Sea, Essex, United Kingdom
302 NON-SPECIFIC BACK PAIN, RETROPERITONEAL FIBROSIS AND AORTITIS-A SPECTRUM OF
IMMUNOLOGICAL DISEASE?
A.V. Kuttikat, A.R. Joshi, K. Chakravarty
Rheumatology, Barking, Havering & Redbridge Hospitals NHS Trust, Romford, Essex, United Kingdom
303 INFLIXIMAB IN A DIFFICULT CASE OF TAKAYASU'S ARTERITIS.
L.E. Coates 1 , A.K. Bhalla 1 , J. Ravindran 2 , D. Jayne 3 , C.L. Hall 4
1
Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, Bath and North East Somerset,
United Kingdom; 2 Rheumatology, Walsgrave NHS Trust, Coventry, Warwickshire, United Kingdom;
3
Renal Medicine, Addenbrooke's NHS Trust, Cambridge, Cambridgeshire, United Kingdom; 4 Renal and
Hypertension, Royal United Hospital, Bath, Bath and North East Somerset, United Kingdom
304 KAPOSI'S SARCOMA IN A PATIENT WITH GIANT CELL ARTERITIS-A CASE REPORT.
A.V. Kuttikat 1 , R. Islam 1 , A.R. Joshi 1 , I.T. Saeed 2 , K. Chakravarty 1
1
Rheumatology, Barking, Havering & Redbridge Hospitals NHS Trust, Romford, Essex, United
Kingdom; 2 Histopathology, Barking, Havering & Redbridge Hospitals NHS Trust, Romford, Essex,
United Kingdom
305 AN UNUSUAL CASE OF GIANT CELL ARTERITIS.
R.W. Marshall 1 , J.M. Ledingham 1 , K.R. MacKay 1 , F.C. McCrae 1 , M.J. Jeffrey 2
1
Rheumatology, Queen Alexandra Hospital, Cosham, Porstmouth, United Kingdom; 2 Pathology,
Queen Alexandra Hospital, Cosham, Porstmouth, United Kingdom
306 LARGE VESSEL VASCULITIS IN 41 YEAR OLD WHITE CAUCASIAN LADY WITH SARCOIDOSIS.
N.G. Shenker 1 , D.R. Blake 2
1
Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 2 School for
Health, University of Bath, Bath, United Kingdom
307 LIVEDOID VASCULOPATHY-A CASE REPORT.
A.R. Joshi 1 , A.V. Kuttikat 1 , D. Jayne 2 , K. Chakavarty 1
1
Rheumatology, Harold Wood Hospital, Romford, Essex, United Kingdom; 2 Nephrology,
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
67

308 ONCOGENIC HYPOPHOSPHATAEMIC OSTEOMALACIA SECONDARY TO A HUMERAL
OSTEOCHONDROMA PRESENTING WITH ACUTE PYROPHOSPHATE ARTHROPATHY OF THE
TEMPOROMANDIBULAR JOINT.
R.M. Smith 1 , A.J.K. Ostor 1 , J. Teir 1 , D.M. Adlam 2 , A.J. Crisp 1
1
Department of Rheumatology, Addenbrookes Hospital, Cambridge, Cambs, United Kingdom;
2
Department of Maxillofacial Surgery, Addenbrookes Hospital, Cambridge, Cambs, United Kingdom
309 CRESCENDO RAYNAUD'S PHENOMENON AS A PRESENTING FEATURE OF UNDERLYING
MALIGNANCY.
E.T. Middleton, D. Ashok, E. Baguley
Rheumatology Department, Hull Royal Infirmary, Hull, East Yorkhire, United Kingdom
310 SULFASALAZINE INDUCED PERIPHERAL NEUROPATHY.
N. Sathi, E. George
Rheumatology, Halton General Hospital, Runcorn, Cheshire, United Kingdom
311 METHOTREXATE INDUCED CUTANEOUS VASCULITIS.
J. Joseph 1 , S. Woodham 1 , I. Coutts 2 , J. Hughes 2
1
Rheumatology, Hillingdon Hospital, Uxbridge, Middlesex, United Kingdom; 2 Dermatology, Hillingdon
Hospital, Uxbridge, Middlesex, United Kingdom
312 AN UNUSUAL CAUSE OF JOINT PAIN IN A PATIENT WITH ULCERATIVE COLITIS.
M. Lloyd 1 , C. Ferrett 2 , A. Hatrick 3 , S. Hulme 4 , R. Bown 5
1
Department of Rheumatology, Frimley Park Hospital, Frimley, Surrey, United Kingdom; 2 Department of
Radiology, John Radcliffe Hospital, Oxford, United Kingdom; 3 Department of Radiology, Frimley Park
Hospital, Frimley, Surrey, United Kingdom; 4 Medical Centre, Oaklands, Yateley, Hants, United Kingdom;
5Department of Gastroenterology, Frimley Park Hospital, Frimley, Surrey, United Kingdom
313 PSEUDOMONAL SEPTIC ARTHRITIS OF THE WRIST.
C.J. Lapraik 1 , T. Marshall 1 , H.M.S. Williams 2
1
Dept of Rheumatology, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom;
2
Dept of Microbiology, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom
Scleroderma and related disorders
314 CIRCULATING LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-C IN
SYSTEMIC SCLEROSIS.
S. Chitale 1 , A. Herrick 1 , S. Kumar 2 , K. Edge 1 , F. Al-Mowlland 2
1
Department of Rheumatology, Rheumatic Diseases Centre, Hope Hospital, Salford, Lancashire, United
Kingdom; 2 Laboratory of Regenerative Medicine, University of Manchester, Manchester, Lancashire,
United Kingdom
315 CIRCULATING LEVELS OF ACTIVE BUT NOT TOTAL TGFß1 ARE REDUCED IN EARLY DIFFUSE
CUTANEOUS SYSTEMIC SCLEROSIS.
M. Dziadzio, R. Smith, G. Lindahl, C. Fonseca, D. Abraham, C. Black, C.P. Denton
Centre for Rheumatology, Royal Free Hospital, London, United Kingdom
316 EVALUATION OF CCL2 AS A POTENTIAL BIOMARKER OF PULMONARY VASCULAR DISEASE IN
LIMITED CUTANEOUS SYSTEMIC SCLEROSIS.
M.T. Carulli 1 , V.H. Ong 1 , D.J. Abraham 1 , G.J. Coghlan 2 , C.M. Black 1 , C.P. Denton 1
1
Centre for Rheumatology, Royal Free Hospital and UCL Medical School, Hampstead Campus, London,
United Kingdom; 2 Cardiology Department, National Pulmonary Hypertension Service, Royal Free Hospital,
London, United Kingdom
317 THE PATHOGENESIS OF SYSTEMIC SCLEROSIS - INSIGHTS FROM THE INNATE IMMUNE SYSTEM.
M.E. Anderson 1 , A. Cross 2 , S.W. Edwards 2 , L. Pazmany 1 , R.J. Moots 1
1
University of Liverpool Academic Rheumatology Group, University Hospital Aintree, Liverpool, United
Kingdom; 2 School of Biological Sciences, University of Liverpool, Liverpool, United Kingdom
68

318 COLLAGEN XV POLYMORPHISMS IN SYSTEMIC SCLEROSIS.
S.P. Pushpakom 1 , J.E. Worthington 2 , S. Kumar1, A.L. Herrick 3
1
Pathology, Medical School, University of Manchester, Manchester, United Kingdom; 2 Arthritis
Research Campaign- Epidemiology Unit, University of Manchester, Manchester, United Kingdom;
3
Rheumatic Diseases Centre, Hope Hospital, Salford, United Kingdom
319 INCIDENCE AND PREVALENCE OF SYSTEMIC SCLEROSIS (SSc) IN AN HMO IN ARGENTINA.
E.R. Soriano 1,2 , J. Rosa 1 , L. Narvaez Ponce 1 , C. Castel del Cid 1 , P.M. Imamura 1,2 , L.J. Catoggio 1,2
1
Rheumatology Unit, Servicio Clinica Medica, Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina; 2 Fundacion Pedro M Catoggio, Buenos Aires, Argentina
320 DIGITAL VASCULAR DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS WITH AND
WITHOUT CALCINOSIS.
S.A. Shetty, T.L. Moore, A.L. Herrick
University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford, United Kingdom
321 LOWER AND UPPER LIMB MACROVASCULAR DISEASE IS UNCOMMON IN SCLERODERMA
BUT IS AMENABLE TO ANGIOPLASTY.
N. Garg 1 , L.M. Shand 2 , R. Pathak 1 , F. Myint 1 , D. Baker 1 , C. Black 2 , C.P. Denton 2 , G. Hamilton 1
1
Department of Surgery, Royal Free Hospital, London, United Kingdom; 2 Centre for Rheumatology,
Royal Free Hospital, London, United Kingdom
322 DUAL WAVELENGTH (532 AND 633 nm) LASER DOPPLER IMAGING AND INFRA RED
THERMOGRAPHY OF MORPHOEA.
T.L. Moore 1 , S. Vij 1 , A.K. Murray 1 , M. Bhushan 2 , A.L. Herrick 1
1
University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford, United Kingdom;
2
Dermatology Centre, Hope Hospital, Salford, United Kingdom
323 A NOVEL APPROACH TO ANALYSING CHANGE IN SKIN SCLEROSIS IN DIFFUSE CUTANEOUS
SCLEROSIS: THE LATENT TRAJECTORY MODEL.
L.M. Shand 1 , M. Lunt 2 , A.J. Silman 2 , C.M. Black 1 , C.P. Denton 1
1
Centre for Rheumatology, Royal Free Hospital, London, United Kingdom; 2 ARC Epidemiology Unit,
University of Manchester, Manchester, United Kingdom
324 PERFORMANCE OF MEDSGER SEVERITY SCORE IN SEROLOGICAL SUBSETS OF
SCLERODERMA.
K. Solanki 1 , M. Chan 1 , S. Brown 1 , N. Waldron 1 , P. Owen 2 , C. Carmichael 2 , N. McHugh 1,2
1
Rheumatology, RNHRD, Bath, United Kingdom; 2 Bath Institute for Rheumatic Diseases, Bath, United
Kingdom
325 FREQUENCY OF CORONARY ARTERY DISEASE IN SYSTEMIC SCLEROSIS: APPLICATION OF
CURRENT PROBABILITY RISK ASSESSMENT.
M.R. Akram 1 , C.E. Handler 2 , M.H. Williams 1 , C.P. Denton 2 , C.M. Black 2 , J.G. Coghlan 1
1
Department of Cardiology, Royal Free Hospital, London, United Kingdom; 2 Department of
Rheumatology, Royal Free Hospital, London, United Kingdom
326 AUTONOMIC NERVOUS SYSTEM DYSFUNCTION IN SYSTEMIC SCLEROSIS.
R. Gupta 1 , R. Yadav 2 , M.M. Thabah 1 , R. Grover 1 , K.K. Deepak 2
1
Clinical Immunology & Rheumatology Sevice, Department of Medicine, All India Institute of Medical
Sciences, New Delhi, India; 2 Physiology Department, All India Institute of Medical Sciences, New
Delhi, India
327 SCLERODERMA OVERLAP SYNDROME IN INDIAN PATIENTS – SINGLE CENTRE STUDY.
R. Gupta, R. Grover, R. Anaja, S. Shankar, A. Kumar
Clinical Immunology & Rheumatology Services, Department of medicine, All India Institute of
Medical Sciences, New Delhi, India
69

328 MODERN TREATMENT ALGORITHMS IMPROVE SURVIVAL IN SYSTEMIC SCLEROSIS ASSOCIATED
PULMONARY HYPERTENSION.
M.H. Williams 1 , C. Das 2 , C.E. Handler 1 , M.R. Akram 1 , J. Davar 1 , C.P. Denton 2 , C.J. Smith 3 , C.M. Black 2 ,
J.G. Coghlan 1
1
Department of Cardiology, Royal Free Hospital NHS Trust, London, United Kingdom; 2 Department of
Rheumatology, Royal Free Hospital NHS Trust, London, United Kingdom; 3 Department of Primary Care
and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
329 INTRAVENOUS ILOPROST FOR THE TREATMENT OF RAYNAUDS: AN AUDIT.
L. Coates, M. Bakr, F. McCrae, R. Shaban, J. Ledingham, A. Thomas, R. Hull, K. MacKay
Rheumatology, Portsmouth Hospitals NHS Trust, Portsmouth, Hants, United Kingdom
Sjogren’s syndrome and related disorders
330 THE DISTRIBUTION OF THE ENDOGENOUS RETROVIRUSES HERV-K113 AND -K115 IN HEALTH
AND DISEASE: HERV-K113 AS A NOVEL RISK FACTOR FOR SJÖGREN'S SYNDROME.
D. Moyes 1 , A. Martin 1 , S. Sawcer 2 , N. Temperton 3 , D. Griffiths 4 , P. Venables 1
1
The Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom; 2 University of
Cambridge Department of Neurosciences, Addenbrooke's Hospital, Cambridge, United Kingdom; 3 Wohl
Virion Centre, University College, London, United Kingdom; 4 Moredun Research Institute, Penicuik,
United Kingdom
331 EFFECT OF SJÖGREN'S SYNDROME ON SENSES OF SMELL AND TASTE: IMPACT ON
QUALITY OF LIFE.
U.F. Kamel, R. Whitaker, P. Maddison
ENT, Ysbyty Gwynedd, Bangor, Gwynedd, United Kingdom; IMSCaR, University of Wales, Bangor, United
Kingdom; Rheumatology, Ysbyty Gwynedd, Bangor, United Kingdom
332 INTER-RATER RELIABILITY OF A NEW DAMAGE ASSESSEMENT TOOL IN PATIENTS WITH
IDIOPATHIC INFLAMMATORY MYOSITIS (IIM).
S.M. Sultan 1 , E. Allen 1 , R.G. Cooper 3 , S. Agarwal 2 , C.V. Oddis 4 , J. Vencovsky 5 , I. Lundberg 6 , P. Kiely 2 , M.G.
Hanna 7 , D.A. Isenberg 1
1
Rheumatology, University College London, London, United Kingdom; 2 St George's Hospital, London,
United Kingdom; 3 Hope Hospital, Manchester, United Kingdom; 4 University Of Pittsburgh School of
Medicine, Pittsburgh, United States; 5 Institute of Rheumatology, Prague, Czech Republic; 6 Karolinska
Institute, Stockholm, Sweden; 7 Hospital for Neurology and Neurosurgery, Queen's Square, London,
United Kingdom
333 ORAL CREATINE SUPPLEMENTS IMPROVE IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM) SIX
MONTH DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED TRIAL.
Y.-L. Chung 1 , H. Alexanderson 2 , N. Pipitone, C. Morrison, M. Dastmalchi, C. Stoll-Hallengren, S.E.
Richards, J.D. Bell, I.E. Lundberg, D.L. Scott
Rheumatology, GKT School of Medicine, Kings College, London, United Kingdom; Robert Steiner MR
Unit, MRC Clinical Science Centre, Imperial College, London, United Kingdom; Department of Medicine,
Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden; Rheumatology Unit, Malmö University
Hospital, Malmö, Sweden
334 THE DEVELOPMENT OF TWO SIMPLE, RELIABLE AND VALID TESTS TO ASSESS PROXIMAL
MUSCLE STRENGTH AND THEIR APPLICATION TO THE MANAGEMENT OF IDIOPATHIC MYOSITIS.
S. Agarwal, P.D.W. Kiely
Department of Rheumatology, St. George's Healthcare NHS Trust, London, United Kingdom
70

335 INTER-RATER RELIABILITY AND VALIDITY OF TWO DISEASE ACTIVITY ASSESSMENT TOOLS IN
PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS (IIM).
S.M. Sultan 1 , E. Allen 1 , P. Kiely 2 , R.G. Cooper 3 , C.V. Oddis 4 , J. Vencovsky 5 , I. Lundberg 6 , M. Dalmachi 6 ,
M. Hanna 7 , D.A. Isenberg 1
1
Department of Rheumatology, University College London, London, United Kingdom; 2 St George's
Hospital, London, United Kingdom; 3 Hope University Hospital, Manchester, United Kingdom;
4
University of Pittsburgh School of Medicine, Pittsburgh, United States; 5 Institute of Rheumatology,
Prague, Czech Republic; 6 Karolinska Institute, Stockholm, Sweden; 7 Hospital for Neurology and
Neurosurgery, Queen's Square, London, United Kingdom
SLE and antiphopholipid syndrome
336 IN VIVO EVIDENCE FOR APOPTOSIS IN THE BONE MARROW IN SLE.
A.L. Hepburn 1 , W.F. Ng 1 , M. Layton 2 , I.A. Lampert 3 , M. Botto 1 , J.C. Mason 1
1
Rheumatology, Hammersmith Hospital, London, United Kingdom; 2 Haematology, Hammersmith
Hospital, London, United Kingdom; 3 Histopathology, Hammersmith Hospital, London, United
Kingdom
337 THE Y-LINKED AUTOIMMUNE ACCELERATOR (YAA) GENE IS SUFFICIENT TO BREAK
IMMUNOLOGICAL TOLERANCE.
M.E.K. Haywood 1 , S.J. Rose 1 , J.M. Rankin 1 , S. Izui 2 , N.J. Rogers 1 , B.J. Morley 1
1
Rheumatology Section, Eric Bywaters Centre, Hammersmith Campus, Imperial College, London,
United Kingdom; 2 Department of Pathology, Centre Medical Universitaire, Geneva, Switzerland
338 COULD B CELLS HAVE THE POTENTIAL TO CONTROL LUPUS-LIKE SYNDROME IN MRL/lpr?
K. Chavez, M. Ehrenstein, J. Evans, C. Mauri
Centre For Rheumatology, Windeyer Institute, University College London, London, United Kingdom
339 SOLUBLE L-SELECTIN LEVELS CORRELATE WITH GENOTYPE AND A CLINICAL SUBSET OF
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).
A.I. Russell 1 , D.S. Cunninghame Graham 1 , J. Whittaker 2 , T.J. Vyse 1
1
Rheumatology, Imperial College, London, United Kingdom; 2 Epidemiology, Imperial College, London,
United Kingdom
340 THE ROLE OF CD4 T CELLS IN THE LOSS OF TOLERANCE IN A MURINE MODEL OF SLE.
N.J. Rogers 1 , L. Mendes da Costa Santos Gabriel 1 , C.T. Nunes 1 , J. Rose 2 , B.J. Morley 2
1
Immunology, Imperial College Hammersmith Campus, London, United Kingdom; 2 Rheumatology,
Imperial College Hammersmith Campus, London, United Kingdom
341 A PURIFIED HUMAN AUTOANTIBODY REQUIRES NUCLEOSOMES FOR BINDING TO dsDNA.
N. Lambrianides 1 , L. Mason 1 , J. Manson 1 , J. van der Vlag 2 , J. Burden 2 , D. Latchman 1 , D. Isenberg 1 ,
A. Rahman 1
1
Department of Medicine, University College London, London, United Kingdom; 2 Department of
Nephrology, University Hospital Nijmegen, Nijmegen, Netherlands
342 THE ROLE OF ANTI-NUCLEOSOME ANTIBODIES IN THE PATHOGENESIS OF SYSTEMIC LUPUS
ERYTHEMATOSUS.
J.J. Manson 1 , L.J. Mason 1 , J. Van der Vlag 2 , J.H.M. Berden 2 , D.A. Isneberg 1 , A. Rahman 1
1
Department of Rheumatology, University College London, London, United Kingdom; 2 Division of
Nephrology, University Medical Center, Nimegen, Netherlands
343 CYTOTOXIC EFFECTS INDUCED BY MINOCYCLINE SUPPORT A COMMON MYELOPEROXIDASE
MEDIATED PATHOGENIC MECHANISM FOR DRUG-INDUCED LUPUS.
B.M. Cox 1 , N.J. McHugh 2
1
Bath Institute for Rheumatic Diseases, Bath, United Kingdom; 2 Royal National Hospital for Rheumatic
Diseases, Bath, United Kingdom
71

344 PATIENTS' PERCEPTION OF SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY.
E.A. Sushchuk, A.V. Torgashina
Department of Hospital Therapeutics, Volgograd State Medical University, Volgograd, Russian Federation
345 AUTOIMMUNE LIVER DISEASE IN JUVENILE AND ADULT POPULATIONS WITH SYSTEMIC LUPUS
ERYTHEMATOSUS.
H. Tahir 1 , D. Sen 2 , C. Pilkington 3 , D. Isenberg 1
1
Rheumatology, University College London, London, United Kingdom; 2 Adolescent Rheumatology,
University College London, London, United Kingdom; 3 Paediatric Rheumatology, Great Ormond Street
Hospital for Sick Children, London, United Kingdom
346 AN AUDIT OF VACCINATION AND INFECTION PROPHYLAXIS IN SLE.
D.K. Roy, J. Shelmerdine, Y. Ahmad, R.M. Bernstein, I.N. Bruce
Rheumatism Research Centre, Manchester Royal Infirmary, Manchester, Greater Manchester, United
Kingdom
347 NON-CAUCASIAN ETHNICITY IS ASSOCIATED WITH HIGHER RATES AND A DIFFERENT PATTERN
OF DAMAGE IN A MULTIETHNIC UK LUPUS COHORT.
S. Abbas, J. Shelmerdine, Y. Ahmad, R. Bernstein, I.N. Bruce
Rheumatism Research Centre, Manchester Royal Infirmary, CMMCUHT, Manchester, United Kingdom
348 LUPUS NEPHRITIS IN AN AFROCARIBBEAN POPULATION IN BARBADOS.
C.H. Flower
Medicine, Queen Elizabeth Hospital, St. Michael, Barbados
349 VITAMIN D DEFICIENCY IN SLE.
T.C. Barnes1, R.C. Bucknall1, W.D. Fraser2
1
Rheumatic Diseases Unit, Royal Liverpool Univerisity Hospital, Liverpool, Merseyside, United Kingdom;
2
Department of Clinical Chemistry, University of Liverpool, Liverpool, Merseyside, United Kingdom
350 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), RHEUMATOID ARTHRITIS AND OTHER CONNECTIVE
TISSUE DISEASES – CLINICAL FEATURES AND SEROLOGICAL RESULTS IN OUTPATIENTS FROM SINGA-
PORE AND SYDNEY.
D.A. Kandiah
Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore,
Singapore
351 NEUROLOGICAL MANIFESTATIONS OF CONNECTIVE TISSUE DISEASES: CORRELATION WITH
SEROLOGICAL MARKERS.
D.A. Kandiah
Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore,
Singapore
352 TRANSFORMING GROWTH FACTOR BETA-1 (TGFß-1) ACTIVATION AND EARLY ATHEROSCLERO-
SIS IN SLE.
M. Jackson 1 , Y. Ahmad 2 , B. Coupes 1 , I.N. Bruce 2 , P.E.C. Brenchley 1
1
Renal Research Laboratories, MINT, Manchester Royal Infirmary, CMMCUHT, Manchester, United
Kingdom; 2 Rheumatism Research Centre, Manchester Royal Infirmary, CMMCUHT, Manchester, United
Kingdom
353 ANTICARDIOLIPIN ANTIBODIES (ACLA), DYSLIPIDAEMIA AND OXIDISED LOW DENSITY
LIPOPROTEIN (OX-LDL) IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).
M. El-Magadmi 1 , Y. Ahmad 1,2 , R.M. Bernstein 2 , M. Mackness 3 , P.N. Darrington 3 , I.N. Bruce 1,2
1
ARC Epidemiology Research Unit, The University of Manchester, Manchester, United Kingdom;
2
Rheumatism Research Centre, Manchester Royal Infirmary, Manchester, United Kingdom; 3 Department
of Medicine, The University of Manchester, Manchester, United Kingdom
72

354 PREVALENCE OF CONVENTIONAL AND LUPUS-SPECIFIC RISK FACTORS FOR CARDIOVASCU-
LAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - A CASE CONTROL
STUDY.
R. Bessant 1 , R. Duncan 2 , J. Swanton 1 , D.A. Isenberg 1 , C. Gordon 2 , A. Rahman 1
1
Centre for Rheumatology, University College London Hospitals, London, United Kingdom;
2
Department of Rheumatology, University of Birmingham, Birmingham, United Kingdom
355 THE ROSE ANGINA QUESTIONNAIRE POORLY DISCRIMINATES SUBCLINICAL
ATHEROSCLERSOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS.
S. Haque 1 , J. Shelmerdine 1 , Y. Ahmad 1 , I.N. Bruce 1 , H. Bodill 1 , L.S. Teh 2 , M. Pattrick 3
1
University of Manchester, Rheumatism Research Centre, Manchester Royal Infirmary, Manchester,
United Kingdom; 2 Department of Rheumatology, Blackburn Royal Infirmary, Blackburn, United
Kingdom; 3 Department of Rheumatology, North Manchester General Hospital, Manchester, United
Kingdom
356 ENDOTHELIAL DYSFUNCTION AND CIRCULATING MARKERS OF ENDOTHELIAL DAMAGE IN
SYSTEMIC LUPUS ERYTHEMATOSUS.
S.V. Shevchuk, M.A. Stanislavchuk, N.V. Zaichko
Rheumanology, Vinnycia National Medical University, Vinnycia, Ukraine
357 TREATMENT ADHERENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).
K. McElhone 1 , L.-S. Teh 1 , J. Walker 2 , J. Abbott 2
1
Rheumatology, Blackburn Royal Infirmary, Blackburn, Lancashire, United Kingdom; 2 Faculty of
Health, University of Central Lancashire, Preston, Lancashire, United Kingdom
358 THE LOW GLYCAEMIC INDEX DIET IN SYSTEMIC LUPUS ERYTHEMATOSUS: FEASIBILITY,
SAFETY AND TOLERABILITY.
S.I. Yeo, R.J. Davies, K. Avloniti, M. Lomer, S. Sangle, G.R.V. Hughes, D.P. D'Cruz
The Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
359 A PILOT STUDY OF A LOW GLYCAEMIC INDEX DIET IN SYSTEMIC LUPUS ERYTHEMATOSUS:
WEIGHT LOSS AND CARDIOVASCULAR RISK FACTORS.
R. Davies, S.I. Yeo, K. Avloniti, M. Lomer, G. Hughes, D. D'Cruz
The Lupus Research Unit,The Rayne Institute, St Thomas' Hospital, London, United Kingdom
360 A NOVEL, EFFICIENT, EXPRESSION SYSTEM OF DOMAIN I OF HUMAN BETA2
GLYCOPROTEIN I IN E.COLI.
Y. Ioannou 1 , I. Giles 1 , N. Lambrianides 2 , D.S. Latchman 2 , D.A. Isenberg 1 , A. Rahman 1
1
Centre for Rheumatology, University College London, London, United Kingdom; 2 Institute of Child
Health, University College London, London, United Kingdom
361 ARGININE RESIDUES ARE CRITICAL IN THE BINDING OF HUMAN MONOCLONAL
ANTIPHOSPHOLIPID ANTIBODIES TO ß2GLYCOPROTEIN I.
I. Giles1, N. Lambrianides 1 , Y. Ioannou 1 , D. Latchman 1 , P. Chen 2 , R. Chukwuocha 2 , D. Isenberg 1 ,
A. Rahman 1
1
Department of Medicine, University College London, London, United Kingdom; 2 Department of
Medicine, University of California at Los Angeles, Los Angeles, United States
362 SERONEGATIVE ANTIPHOSPHOLIPID (HUGHES) SYNDROME.
S.R. Sangle, D.P. D'Cruz, G.R.V. Hughes
Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
363 NON RENAL HYPERTENSION IN THE ANTIPHOSPHOLIPID SYNDROME.
S.R. Sangle, M.K. Kapoor, D.P. D'Cruz, G.R.V. Hughes
Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
73

364 VASCULITIS, ANTIPHOSPHOLIPID ANTIBODIES AND RENAL ARTERY STENOSIS.
S.N. Paul, S.R. Sangle, A.N. Bennett, G.R.V. Hughes, D.P. D'Cruz
Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Vasculitis
365 OUTCOMES IN THE FIRST YEAR IN POLYMYALGIA RHEUMATICA (PMR): RESULTS FROM A
MULTI-CENTRE PROSPECTIVE COHORT STUDY.
B. Dasgupta 1 , A. Hutchings 2 , J. Hollywood 1 , D. Lamping 2 , C. Pease 3 , K. Chakravarty 4 , B. Silverman 5 ,
B. Hazleman 5 , E. Choy 6 , D.G.I. Scott 7 , B. Bourke 8 , N. Gendi 9
1
Southend Hospital, Southend, United Kingdom; 2 LSHTM, London, United Kingdom; 3 Leeds General
Infirmary, Leeds, United Kingdom; 4 Harold Wood Hospital, Romford, United Kingdom; 5 Addenbrookes
Hospital, Cambridge, United Kingdom; 6 King's College, London, United Kingdom; 7 Norfolk & Norwich
Hospital, Norwich, United Kingdom; 8 St George's Hospital, London, United Kingdom; 9 Basildon Hospital,
Basildon, United Kingdom
366 THE DIFFICULTIES IN THE DEVELOPMENT OF HISTOLOGICAL SCORING FOR INFLAMED
TEMPORAL ARTERY IN GIANT CELL ARTERITIS.
A. Bharadwaj, B. Dasgupta, K. Wolfe, C. Nordborg, E. Nordborg
Rheumatology, Southend Hospital, Southend on Sea, Essex, United Kingdom; Pathology, Southend
Hospital, Southend-on-Sea, Essex, United Kingdom; Pathology, Sahlgrenska Hospital, Gothengberg,
Sweden; Medicine, Sahlgrenska Hospital, Gothenberg, Sweden
367 SUDDEN BLINDNESS AND ROLE OF PROTHROMBOTIC FACTORS IN GIANT CELL ARTERITIS-
A 'TRUE TO LIFE' OBSERVATIONAL STUDY.
A.R. Joshi 1 , A.V. Kuttikat 1 , G.M.B. Dawidek 2 , K. Chakravarty 1
1
Rheumatology, Harold Wood Hospital, Romford, Essex, United Kingdom; 2 Ophthalmology, Harold Wood
Hospital, Romford, Essex, United Kingdom
368 USEFULNESS OF TEMPORAL ARTERY BIOPSY IN THE DIAGNOIS OF GIANT CELL ARTERITIS.
S. Dahiya, K. Gaffney, P. Merry, D. Scott
Rheumatology, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom
369 ANTI-tRNA SYNTHETASE AND ANTIPHOSPHOLIPID ANTIBODIES MAY CONTRIBUTE TO
'FALSE-POSITIVE' ANCA TESTING.
J. Dunphy 1 , L. Phillips 1 , N. McHugh 1,2
1
BIRD Diagnostics, Bath Institute for Rheumatic Diseases, Bath, United Kingdom; 2 Rheumatology, RNHRD,
Bath, United Kingdom
370 ANTIPHOSPHOLIPID ANTIBODIES CONTRIBUTE TO DAMAGE IN PATIENTS WITH VASCULITIS.
R.D. Moco, C. Oliveri, S. Ferreira, M. Antunes, M.A. Khamashta, H.R. Graham, D.P. D'Cruz
The Lupus Research Unit, St. Thomas Hospital, London, United Kingdom
BHPR – audit/service delivery
371 DO ALL PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS IN DISTRESS NEED A DOCTOR?
A.G. Richards, S.M. Bintley-Bagot
Therapies Department, The Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
372 "I WANTED TO GIVE SOMETHING BACK": THE POSITIVE EFFECTS OF VOLUNTEERING AT A
COMMUNITY-BASED ARTHRITIS RESOURCE CENTRE.
E.D. Hale 1 , G.J. Treharne 1,2 , C. Gordhan 3 , P.A. Bacon 3 , G.D. Kitas 1,2,3
1
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United
Kingdom; 2 School of Psychology, University of Birmingham, Birmingham, United Kingdom; 3 Department
of Rheumatology, Division of Immunity and Infection, School of Medicine, University of Birmingham,
Birmingham, United Kingdom
74

373 "JOINING THE DOTS": ISOLATION, UNDERSTANDING AND INTEGRATED HEALTHCARE FOR
PATIENTS WITH LUPUS.
E.D. Hale 1 , G.J. Treharne 1,2 , D.L. Mitton 1,3 , S. Mole 1 , Y. Norton 4 , G.D. Kitas 1,2,5
1
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United
Kingdom; 2 School of Psychology, University of Birmingham, Birmingham, United Kingdom; 3 School of
Health Sciences, University of Birmingham, Birmingham, West Midlands, United Kingdom; 4 West
Midlands Branch, Lupus UK, Coseley, West Midlands, United Kingdom; 5 Department of
Rheumatology, Division of Immunity and Infection, School of Medicine, University of Birmingham,
Birmingham, United Kingdom
374 THE NATIONAL LIBRARY FOR HEALTH - TRAUMA, ORTHOPAEDICS AND MUSCULOSKELETAL
SPECIALIST LIBRARIES.
A.C. Redmond 1,2 , R. Armstrong 2 , A. Brockelhurst 2 , K. Dziedzic 2 , D. Pattison 2 , A. Hammond 2 ,
J.A.M. Gray 2
1
Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, W. Yorks, United Kingdom;
2
Trauma, Orthopaedics and Musculoskeletal Specialist Libraries, NHS National Program for IT,
London, United Kingdom
375 AN RETROSPECTIVE AUDIT OF SECONDARY HEALTH CARE UTILISATION OF PATIENTS
WITH FIBROMYALGIA.
S. Ryan, P. Dawes, M. Kirwan
Staffordshire Rheumatology Centre, The Haywood Hospital, Burslem, Stoke on Trent, United
Kingdom
376 BENCHMARKING THE NURSE CONSULTANT ROLE IN RHEUMATOLOGY.
S. Ryan 1 , A. Browne 2 , S. Hennell 3 , D. Home 4 , A. Wild 5 , D. Homer 6
1
Staffordshire Rheumatology Centre, Stoke on Trent, United Kingdom; 2 Royal Oldham Hospital,
Oldham, United Kingdom; 3 Wirral Hospital NHS Trust, Wirral, United Kingdom; 4 Department of
Rheumatology, West Middlesex University Hospital, Middlesex, United Kingdom; 5 Worcestershire
Acute Hospitals NHS Trust, Worcester, United Kingdom; 6 Department of Rheumatology, Selly Oak
Hospital, Birmingham, United Kingdom
377 TELEPHONE FOLLOW UP OF PATIENTS COMMENCING ORAL BISPHOSPHONATES.
G. Loghan, T.W. O'Neill
Department of Rheumatology, Hope Hospital, Salford, Manchester, United Kingdom
378 EVALUATION OF AN EVIDECE-BASED PHYSIOTHERAPY PROGRAMME FOR THE
MANAGEMENT OF PATIENTS WITH OSTEOARTHRITIS OF THE KNEE.
M.J. Domaille, R. Mascarenhas, N. Dayal, J.R. Kirwan
Rheumatology Centre, Bristol Royal Infirmary, Bristol, United Kingdom
379 SETTING UP A PATIENT REFERENCE GROUP TO INFORM SERVICE DELIVERY IN A
RHEUMATOLOGY UNIT.
A.E. Griffiths, J. Novak, S. Balshaw, M.P. Lynch, V.E. Abernethy, J.K. Dawson
Rheumatology Practice Development Unit, St Helens & Knowsley Hospitals NHS Trust, St Helens,
Merseyside, United Kingdom
380 CAN PIIINP HELP IN MONITORING RHEUMATOID ARTHRITIS PATIENTS ON METHOTREXATE?
M. Lloyd 1 , S. Burton 1 , U. David 2 , P. Cusick 3
1
Department of Rheumatology, Frimley Park Hospital, Frimley, Surrey, United Kingdom; 2 Department
of Clinical Biochemistry, Frimley Park Hospital, Frimley, Surrey, United Kingdom; 3 Audit Department,
Frimley Park Hospital, Frimley, Surrey, United Kingdom
75

381 AUDIT: BONE SCINTIGRAPHY USE IN THE INVESTIGATION OF FOOT PAIN IN THE OUT PATIENT
CLINIC OVER A 5 YEAR PERIOD.
E.A. Justice, P. Newton, M. Collins
Department of Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom; Department of
Radiology, New Cross Hospital, Wolverhampton, United Kingdom
382 RHEUMATOID ARTHRITIS PATIENT EDUCATION IN THE UK - WHAT IS ON OFFER AND HOW IS IT
DELIVERED?
Z. Cockshott 1 , S. Hewlett 1 , C. Almeida 1 , P. Richards 1 , R. Lowe 2 , J. Kirwan 1 , R. Study Group
1
Academic Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Psychology Dept, University of
Wales, Swansea, United Kingdom
383 MANAGEMENT OF KNEE OSTEOARTHRITIS IN PHYSIOTHERAPY OUTPATIENT DEPARTMENTS IN
THE UNITED KINGDOM AND NORTHERN IRELAND.
N.E. Walsh 1 , M.V. Hurley 2
1
University of the West of England, Bristol, United Kingdom; 2 King's College London, London, United
Kingdom
384 AUDIT OF AN EXERCISE PROGRAMME DESIGNED BY PATIENTS FOR PATIENTS WITH
INFLAMMATORY ARTHRITIS.
J. Binding, H. Murray, D. Fullerton, P. Green
Rheumatology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom
385 A RETROSPECTIVE ASSESSMENT OF THE VALUE OF EDUCATING NEW PATIENTS WITH
INFLAMMATORY JOINT DISEASE, BY NURSE SPECIALISTS, IN A GROUP SETTING.
L. Longstaff, J. Petherick, L. Thompson, J. Binding, C. Kelly
Rheumatology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom
386 A PICTORIAL INSTRUCTION TO AID METHOTREXATE DOSING.
L. Kerton, H. Timlin, G. Hamad, D. Collins, E. Price, L. Williamson
Great Western Rheumatology Unit, Great Western Hospital, Swindon, Wiltshire, United Kingdom
387 CAN GROUP PROGRAMMES FOR FIBROMYALGIA SAVE MONEY AND STILL BE
ACCEPTABLE FOR PATIENTS?
H. Brownett, M. Miles, D. Fletcher, S. Clarke
Department of Rheumatology, Weston Area Health Trust, Weston Super Mare, Somerset, United
Kingdom
388 IMPROVING TOLERANCE AND BIOAVAILABILITY OF METHOTREXATE BY SWITCHING FROM
ORAL TO SUBCUTANEOUS ROUTE OF ADMINISTRATION.
A. Breslin, C. Owen
Rheumatology, NWW.NHS Trust.Ysyty Gwynedd., Bagor, Gwynedd, United Kingdom
389 DISEASE CONTROL IN RHEUMATOLOGY PRACTITIONER CLINICS - HOW DO WE COMPARE?
L.M. Hawley, C.A. Dunne
Rheumatology, Christchurch Hospital, Christchurch, Dorset, United Kingdom
390 ARE WE NEGLECTING THE NEEDS OF OUR OLDER RA PATIENTS?
L. Martin, S. Griffith
Rheumatology, East Surrey Hospital, Redhill, Surrey, United Kingdom
391 PATIENT PREFERENCES IN CHOOSING ANTI-TNF THERAPIES.
S.P. Bennett, S. Sawyer, A. Baker, N.K. Arden, C.J. Edwards
Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton, United
Kingdom
76

392 PATIENT JOURNEY FROM PRE-ADMISSION TO FOLLOW-UP.
J. Novak, A.E. Griffiths, D. Dawson, Y. Hough, J. Carr, V.E. Abernethy, J.K. Dawson, M.P. Lynch
Rheumatology Practice Development Unit, St Helens & Knowsley Hospitals NHS Trust, St Helens,
Merseyside, United Kingdom
393 WHAT DO PATIENTS WITH KNEE OSTEOARTHRITIS WANT TO KNOW AND HOW SHOULD
WE TELL THEM?
H.G. Platten, C.J. Edwards, N.K. Arden
Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton,
Hampshire, United Kingdom
394 THE INCIDENCE OF ADVERSE EVENTS IN RHEUMATOLOGY PATIENTS ON DISEASE
MODIFYING THERAPY.
A. Campbell, T.A. O'Rourke, C. Brownsell, R. Wiswell, J.K. Dawson, M.P. Lynch, V.E. Abernethy
Rheumatology, St Helens and Knowsley NHS Trust, St Helens, Merseyside, United Kingdom
395 MEETING ARMA'S STANDARDS OF CARE FOR INFLAMMATORY ARTHRITIS: A MODEL
RHEUMATOLOGY RESOURCE CENTRE.
A. Topp 1 , J. Parkin 1 , H. Lapham 1 , P. Crook 1,2 , M. Grove 1,2 , F. Birrell 1,2,3
1
Rheumatology, Northumbria Healthcare NHS Trust, Newcastle, Tyne & Wear, United Kingdom;
2
Musculoskeletal Unit, Freeman Hospital, Newcastle, Tyne & Wear, United Kingdom;
3
Musculoskeletal Research Group, University of Newcastle upon Tyne, Newcastle, Tyne & Wear,
United Kingdom
396 DEVELOPMENT AND PILOTING OF AN ANNUAL REVIEW CLINIC FOR ESTABLISHED
RHEUMATOID ARTHRITIS.
G. Wilson, D.J. Walker, L.J. Kay
Department of Rheumatology, Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne,
United Kingdom
397 ACCURATE, LOCAL PATIENT DATA COLLECTION- IMPLICATIONS FOR SERVICE PLANNING.
J.T. Morgan 1 , N. Abd Ghafar 2 , E. Ashworth 2 , S. Lyle 1 , C. Rhys-Dillon 1 , J.C. Martin 1 , R.M.
Goodfellow 1
1
Rheumatology, Royal Glamorgan Hospital, Ynysmaerdy, Rhondda Cynon Taf, United Kingdom;
2
School of Medicine, Cardiff University, Cardiff, United Kingdom
398 CONCORDANCE WITH DMARDS AND BIOLOGICS.
A.Y.N. Lim, C. Ellis, A. Brooksby, K. Gaffney
Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom
399 PATIENT SATISFACTION WITH A COMBINED RHEUMATOLOGY PRACTITIONER AND
PHYSIOTHERAPIST ANKYLOSING SPONDYLITIS CLINIC.
P. Cornell, J. Haynes, S. Richards, P. Thompson
Rheumatology Dept, Poole Hospital NHS Trust, Poole, Dorset, United Kingdom
400 SETTING UP A COMMUNITY-BASED ARTHRITIS EDUCATION OUTREACH SERVICE:
A PROFILE OF THE INITIAL 4 MONTHS.
G.J. Treharne 1,2 , E.D. Hale 2 , C. Gordhan 3 , P.A. Bacon 3 , G.D. Kitas 1,2,3
1
School of Psychology, University of Birmingham, Birmingham, United Kingdom; 2 Department of
Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom;
3
Department of Rheumatology, Division of Immunity and Infection, School of Medicine, University
of Birmingham, Birmingham, United Kingdom
77

401 THE FIRST YEAR OF THE ONLY OPEN-ACCESS HOSPITAL-BASED LUPUS CLINIC IN THE UNITED
KINGDOM: LESSONS LEARNT AND FUTURE DIRECTIONS.
G.J. Treharne 1,2 , E.D. Hale 2 , Y. Norton 3 , A.E. Wild 4 , D.L. Mitton 2,5 , J. Morrey 2 , S. Mole 2 , J.P. Delamere 2 ,
K.M. Douglas 2 , N. Erb 2 , A.J. Whallett 2 , G.D. Kitas 1,2,6
1
School of Psychology, University of Birmingham, Birmingham, United Kingdom; 2 Department of
Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom; 3 West
Midlands Branch, Lupus UK, Coseley, West Midlands, United Kingdom; 4 Department of Rheumatology,
Worcester Acute Hospitals NHS Trust, Worcester, United Kingdom; 5 School of Health Sciences, University
of Birmingham, Birmingham, United Kingdom; 6 Department of Rheumatology, Division of Immunity and
Infection, School of Medicine, University of Birmingham, Birmingham, United Kingdom
402 QUALITY STANDARD AUDIT OF RHEUMATOLOGY OUTPATIENT LETTERS TO GENERAL
PRACTITIONERS.
C.S. Wijesooriya, A. Ball, D. Homer, S. Bowman, E. Rankin
Department of Rheumatology, University Hospital Birmingham, Birmingham, West Midlands, United
Kingdom
403 WHAT ARE THE BENEFITS OF A WEEKLY MULTI-DISCIPLINARY TEAM CLINIC FOR PATIENTS
WITH RHEUMATOID ARTHRITIS?
A. Worsley, D. Smith, C. Bateman, Z. Stableford, S. Wills
Rheumatology, Hope Hospital, Salford, United Kingdom
404 AN EVALUATION OF ENHANCED RHEUMATOLOGY SERVICES IN SOUTH BIRMINGHAM PRIMARY
CARE TRUST.
C. Moody 1 , D. Homer 2 , P. Jobanputra 2 , S. Jerome 1
1
Primary Care, South Birmingham Primary Care Trust, Birmingham, United Kingdom; 2 Department of
Rheumatology, Selly Oak Hospital, University Hospitals Birmingham, Birmingham, United Kingdom
405 PATIENTS TREATED WITH ANTI-TNF ATTENDING A RHEUMATOLOGY NURSE CLINIC: RESPONSE
AND OUTCOMES OF A SECOND OR A THIRD ANTI-TNF SWITCH.
E. Williams, A. Cox, A.M. Salih
Rheumatology, Warrington Hospital, Warrington, Cheshire, United Kingdom
406 AUDIT OF THE USE OF BIOLOGIC THERAPIES IN LIGHT OF NICE GUIDELINES.
A.A.G. Ginawi, L.J. Brett, K.S. Restarick, N.S.T. Gendi, A.K. Osman, J.A. Palit
Rheumatology, Basildon & Thurrock University Hospitals NHS Foundation Trust, Basildon, Essex, United
Kingdom
407 AN EVALUATION OF A STUDY DAY FOR THE ADMINISTRATION OF SUBCUTANEOUS
METHOTREXATE IN THE COMMUNITY.
J. Mooney, M. McGee
University of East Anglia, Norwich, Norfolk, United Kingdom; Norwich and Norfolk University hospital,
Norwich, Norfolk, United Kingdom
408 RHEUMATOLOGY YOUNG ADULT CLINIC PATIENTS-RELATIONSHIP BETWEEN DISEASE ACTIVITY
AND PATIENTS TAKING RESPONSIBILITY OF THEIR DISEASE.
C. Brownsell 1 , A. Clayton 1 , Y. Yough 1 , R. Wiswell 1 , S.L. Hennell 2 , R.E. Abernethy 1 , M.P. Lynch 1 ,
J.K. Dawson 1
1
Rheumatology Practice Development Unit, St Helens Hospital, St Helens, Merseyside, United Kingdom;
2
Rheumatology Department, Wirral Hospital NHS Trust, Wirral, Merseyside, United Kingdom
409 NICE GUIDELINE 36 -AN AUDIT OF THE APPRORIATENESS OF USE AND EFFICACY OF BIOLOGIC
DRUGS IN A DISTRICT GENERAL HOSPITAL.
K. Gadsby, M. Regan, S. O'Reilly
Department of Rheumatology, Derby Hospitals NHS Foundation Trust, Derby, United Kingdom
78

410 DEVELOPING A PHYSIOTHERAPY MODEL OF CARE FOR PATIENTS ATTENDING A DEDICATED
RHEUMATOLOGY DAY CASE UNIT.
C. Jeffries, R. Hull, C. Gray, A. Thomas, F. McCrae, J. Ledingham, K. MacKay, R. Shaban
Rheumatology Department, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom
411 DEVELOPMENT AND EVALUATION OF A POSTER TO AID PATIENT RECALL OF DISEASE
MODIFYING ANTI-RHEUMATIC DRUGS.
D.L. Mitton, K.M. Douglas, G.J. Treharne, E.D. Hale, R. Sandhu, N. Erb, G.D. Kitas
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands,
United Kingdom
412 SWITCHING OF INFLIXIMAB TO EITHER ETANERCEPT OR ADALIMUMAB -THE CANNOCK
EXPERIENCE.
S. Roskell, J. Barber, S. Venkatachalam, D. Mulherin, T.P. Sheeran, T. Price
Rheumatology, Cannock Chase Hospital, Cannock, Staffordshire, United Kingdom
413 THE PERSONAL IMPACT HAQ: SENSITIVITY TO CHANGE OF A MEASURE OF THE IMPACT
OF DISABILITY.
S. Hewlett 1 , M. Hehir 1 , J. Kirwan 1 , S. Tipler 2 , K. Kitchen 1
1
Academic Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Rheumatology Centre,
Bristol Royal Infirmary, Bristol, United Kingdom
BHPR - research
414 SENSITIVITY TO CHANGE OF THE RHEUMATOID ARTHRITIS SELF-EFFICACY SCALE (RASE).
S. Hewlett 1 , Z. Cockshott 1 , C. Almeida 1 , P. Richards 1 , R. Lowe 2 , R. Greenwood 3 , J. Kirwan 1 ,
R. Study Group
1
Academic Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Psychology, University of
Wales, Swansea, United Kingdom; 3 Research and Development, Bristol Royal Infirmary, Bristol,
United Kingdom
415 RHEUMATOLOGICAL EDUCATION FOR UNDERGRADUATE NURSING, PHYSIOTHERAPY AND
OCCUPATIONAL THERAPY STUDENTS IN THE UK.
C. Almeida 1 , S. Hewlett 1 , B. Clarke 2 , L. Kay 3 , S. Ryan 4 , A. Chadwick 5 , A. Hammond 6
1
Academic Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Faculty of Nursing,
University of West of England, Bristol, United Kingdom; 3 Musculo-Skeletal Unit, Freeman Hospital,
Newcastle, United Kingdom; 4 Staffordshire Rheumatology Centre, Haywood Hospital, Stoke on Trent,
United Kingdom; 5 Physiotherapy Studies, Keele University, Keele, United Kingdom; 6Rheumatology
Unit, Derbyshire Royal Infirmary, Derby, United Kingdom
416 MEASURING PROTECTIVE SENSATION IN THE FEET OF PATIENTS WITH RHEUMATOID
ARTHRITIS (RA).
O.S.L. Wilson 1,2 , J.R. Kirwan 1
1
Academic Rheumatology Unit, University of Bristol, Bristol, United Kingdom; 2 Podiatry Department,
Central Health Clinic, Towerhill, Bristol, United Kingdom
417 DISCRIMINATION OF THE NEUTRAL LOW BACK SITTING POSTURE IN PEOPLE WITH AND
WITHOUT LOW BACK PAIN, BEFORE AND AFTER A SHIFT OF WORK.
D.R. Phillips 1 , M.V. Hurley 2 , M.A. Mullee 3
1
School of Health Professions & Rehabilitation Sciences, University of Southampton, Southampton,
United Kingdom; 2 Rehabilitation Research Unit, King's College, London, United Kingdom; 3 Research
& Development Support Unit, University of Southampton, Southampton, United Kingdom
79

418 A PILOT STUDY TO DETERMINE THE PREVELANCE OF ERECTILE DYSFUNCTION IN MEN WITH
RHEUMATOID ARTHRITIS.
G. Grundy 1 , J.K. Dawson 1 , R.J. Moots 2 , S. Mpofu 1
1
Academic Rheumatology, University Hospital Aintree, Liverpool, United Kingdom; 2 Rheumatology
Practice Development Unit, St Helens and Knowsley Hospitals NHS Trust, St Helens, United Kingdom
419 AN ORIGINAL SPLINTING TECHNIQUE: BESPOKE NEOPRENE SPLINTS WITH THERMOPLASTIC
SUPPORT.
P. Renforth 1 , F. Birrell 1,2,3
1
Rheumatology, Northumbria Healthcare NHS Trust, Newcastle upon Tyne, Northumberland, United
Kingdom; 2 Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear, United Kingdom;
3
Musculoskeletal Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, Tyne &
Wear, United Kingdom
420 THE PREVALENCE OF DISABLING FOOT PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS.
M. Lohkamp 1 , G. Burrow 1 , T. McCarron 1 , W. Maclaren 2 , M. Granat 1
1
School of Health and Social Care, Glasgow Caledonian University, Glasgow, United Kingdom; 2 School of
Computing and Mathematical Sciences, Glasgow Caledonian University, Glasgow, United Kingdom
421 WHAT PATIENTS WITH RHEUMATOID ARTHRITIS REALLY WANT TO KNOW - AN ASSESSMENT
USING THE EDUCATIONAL NEEDS ASSESSMENT TOOL.
J. Hill 1 , A. Tennant 2 , A. Adebajo 3 , C. Hale 1
1
ACUMeN, University of Leeds, Leeds, W Yorkshire, United Kingdom; 2 Department of Musculoskeletal
Rehabilitation, University of Leeds, Leeds, W Yorkshire, United Kingdom; 3 Rheumatology Department,
Barnsley District Hospital, Barnsley, United Kingdom
422 OUTCOME IN LOW BACK PAIN: WHAT MATTERS TO THE PATIENTS?
R. Mullis, E. Hay, M. Lewis
Primary Care Sciences Research Centre, Keele University, Newcastle under Lyme, Staffordshire,
United Kingdom
423 MEASURING FATIGUE IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW OF THE SCALES.
M. Hehir, S. Hewlett, J. Kirwan
Academic Rheumatology, University of Bristol, Bristol, United Kingdom
424 A PRELIMINARY SURVEY OF PATIENTS' VIEWS IN RELATION TO THE USE OF SUBCUTANEOUS
METHOTREXATE IN THE MANAGEMENT OF INFLAMMATORY ARTHRITIS.
C.H. Marsden
Rheumatology, Mid Yorkshire NHS Trust, Wakefield, West Yorkshire, United Kingdom
425 WHY DO PATIENTS WITH RHEUMATOID ARTHRITIS USE COMPLEMENTARY THERAPIES?
G. Rose
Rheumatology Department, Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom
426 PEER AND PATIENT PERSPECTIVES OF THE ROLE OF THE NURSE CONSULTANT IN
RHEUMATOLOGY.
C. Thwaites, S. Ryan, A. Hassell, D. Home
School of Nursing and Midwifery, Keele University, Keele, Staffs, United Kingdom; Department of
Rheumatology, Staffordshire Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, Staffs, United
Kingdom; Department of Rheumatology, Staffordshire Rheumatology Centre, Haywood Hospital,
Stoke-on-Trent, Staffs, United Kingdom; Dept of Rheumatology, West Middlesex University Hospital NHS
Trust, London, United Kingdom
80

427 A RANDOMISED CONTROLLED PILOT STUDY OF INFLAMMATORY ARTHRITIS PATIENTS
ATTENDING AN INDIVIDUAL OR A GROUP SESSION FOR INFORMATION ON ANTI- RHEUMATIC
DRUGS: COMPARING DIFFERENCES IN CONCORDANCE WITH TREATMENT, PATIENT SATISFAC-
TION, TIME TAKEN AND DRUG SURVIVAL.
D. Homer, P. Nightingale, P. Jobanputra
Rheumatology, UHB NHS Trust, Birmingham, United Kingdom; Wolfson Centre, UHB NHS Trust,
Birmingham, United Kingdom; Rheumatology, UHB NHS Trust, Birmingham, United Kingdom
428 PARTICIPATING IN CLINICAL TRIALS: PATIENTS' EXPERIENCES OF THE INFORMED
CONSENT PROCESS. A LITERATURE REVIEW.
S.L. Grieve
Clinical Trials Unit, Bath Institute for Rheumatic Diseases, Bath, United Kingdom; Royal National
Hospital for Rheumatic Diseases, Bath, United Kingdom
429 WALKING THE LINE: EXPECTATIONS AND INTENTIONS IN QUALITATIVE RESEARCH
INTERVIEWS IN RHEUMATOLOGY.
E.D. Hale 1 , G.J. Treharne 1,2 , D.L. Mitton 1,3 , S. Mole 1 , Y. Norton 4 , C. Gordhan 5 , P.A. Bacon 5 ,
G.D. Kitas 1,2,5
1
Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands,
United Kingdom; 2 School of Psychology, University of Birmingham, Birmingham, United Kingdom;
3
School of Health Sciences, University of Birmingham, Birmingham, United Kingdom; 4 West
Midlands Branch, Lupus UK, Coseley, West Midlands, United Kingdom; 5 Department of
Rheumatology, Division of Immunology and Infection, School of Medicine, University of
Birmingham, Birmingham, United Kingdom
430 PATIENT PERCEPTIONS OF EMPOWERMENT/SELF ACTUALISATION WHEN TAKING PART IN A
PARENTERAL METHOTREXATE SELF-ADMINISTRATION PROGRAMME.
J.M. White, C.A. Hale
Rheumatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United
Kingdom; School of Healthcare Studies, University of Leeds, Leeds, West Yorkshire, United
Kingdom; ACUMeN, University of Leeds, Leeds, West Yorkshire, United Kingdom
431 AN INFORMATION GATEWAY FOR THE FOOT IN RHEUMATIC DISEASES.
A.E. Williams 1,2 , C.J. Nester 2 , A. Mainwaring 3 , M. Berry 2
1
Directorate of Podiatry, University of Salford, Salford, Manchester, United Kingdom; 2 Centre for
Rehabilitation and Human Performance Research, University of Salford, Salford, Manchester, United
Kingdom; 3 Directorate of Podiatry, Salford Royal Hospitals NHS Trust, Salford, Manchester, United
Kingdom
432 THE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS: SPLINT AND ORTHOTIC
PROVISION - RESULTS OF A SUREY FROM EIGHT PHYSIOTHERAPY DEPARTMENTS.
F. Keogan 1 , N. Kennedy 2
1
Physiotherapy Department, Beaumont Hospital, Dublin, Ireland; 2 Department of Physiotherapy,
University of Limerick, Limerick, Ireland
81

Exhibition Floor Plan
82

Exhibitor Details
StandNo Company
2 Janssen-Cilag Ltd
3 Actelion Pharmaceuticals UK Ltd
4 Genzyme Biosurgery
5 Institute of Healthcare Research
6-13 Merck Sharp & Dohme Ltd
15 Abbott Laboratories
16 Roche Products Ltd
17 Servier Laboratories Ltd
18 Cyber-café, sponsored by Novartis
20 Wyeth
21 Schering-Plough Ltd
22 Novartis Pharmaceuticals UK Ltd
23 Pfizer Ltd
24 Alliance for Better Bone Health
27 Q-Med (UK) Ltd
30 Clinovia Ltd
31 Graphnet Health Ltd
32 Wisepress Online Bookshop
33 Dynamic Imaging Ltd
34 Healthcare at Home
35 OUP
36 TRB Chemedica UK Ltd
37 BSR Biologics Register (BSRBR)
39 Oxford Immunotec Ltd
41 Eli-Lilly & Co Ltd
42 Vertec Scientific Ltd
43 The Scleroderma Society
44 DJ Orthopedics
45 ERAN
46 Birmingham Arthritis Resource Centre
47 Musculoskeletal specialist Library (NLH)
48 4S Dawn Clinical Software
49 Uptodate
50 Kyphon Europe
51 Medac UK
52 BSR
53 ARMA
54 Arthritis Research Campaign
55 BHPR
56 Arthritis Care
57 National Rheumatoid Arthritis Society
64 RCN
65 Raynaud's and Scleroderma Association
66 NASS
67 Lupus UK
68 British Sjogren's Syndrome Association
69 Children's Chronic Arthritis Association
70 BSPAR
4S Dawn Clinical Software (stand 48)
Some key problems with monitoring DMARD therapy are:
• Time consumed in monitoring of laboratory test results, which must be carried out in an exacting manner.
• Not forgetting to follow up on actions decided for the patient.
• Auditing therapy management.
Dawn DMARD software overcomes this by:
• Rigorously monitoring test results automatically.
• Produces electronic alerts
• Providing an auditing/report writing facility.
Abbott Laboratories (stand 15)
Abbott Immunology is hosting a satellite symposium to support their anti-TNF therapy on Wednesday, 20th April,
20.00 - 21.30 in Hall four at the ICC. "Broadening horizons in anti-TNF therapy" will be chaired by Professor Paul
Emery and includes a panel of rheumatology experts. Express your views and join the interactive debate.
For further information, visit the Abbott Immunology stand (15) in the main hall.
Actelion (stand 3)
Actelion is an independent biopharmaceutical company discovering, developing and marketing drugs for unmet medical
n e e d s . For more information contact Actelion on 0208 987 3333 or visit www.actelion.com
The Alliance for Better Bone Health (stand 24)
The Alliance for Better Bone Health (Procter and Gamble / sanofi-aventis) is delighted to support this conference. The
Alliance is committed to the timely identification and treatment of postmenopausal osteoporosis, to ensure patients
experience significant reductions in the risk of debilitating fractures. sanofi-aventis also pro-actively researches and
promotes significant advances in the treatment of adult patients with active rheumatoid arthritis.
83

Arthritis Care (stand 56)
Arthritis Care is the UK’s largest voluntary organisation for people with all types of arthritis. Our aim is to empower people
to take control of their arthritis, their organisation and their lives. We offer a range of services including helplines,
publications, self-management and hotels. We also campaign to ensure the voice of people with arthritis is heard at both
a national and local level.
Arthritis Research Campaign (stand 54)
The Arthritis Research Campaign (arc) is the fourth-largest medical research charity in the UK with an annual income of £25
million. arc funds research into all forms of arthritis and related conditions, and also provides information to the public
(including more than 80 patient booklets) and health professionals. arc also funds a variety of fellowships and bursaries.
ARMA (stand 53)
The Arthritis and Musculoskeletal Alliance (ARMA) is the UK umbrella organisation bringing together 28 members including
support groups, research organisations and medical/non-medical professionals’ societies. Visit our stand to pick up copies of
the Standards of Care on osteoarthritis, inflammatory arthritis and back pain, find out how you can use the Standards to help
improve services in your area; and share good practice in delivering services. Also find out more about the work of ARMA and
its member organisations, and about policy developments in the musculoskeletal community.
BHPR (stand 55)
The BHPR was formed in 1985 to bring together health professionals whose major interests lay in the management of
people with rheumatic diseases. The aim of the BHPR is to encourage a multi-disciplinary approach to the management of
people with rheumatic diseases. To provide a forum through which health professionals can exchange knowledge, skills
and experience. To generate greater awareness of the contribution of health professionals.
Birmingham Arthritis Resource Centre/Dudley Arthritis Information Service For You (stand 46) – “Our
fundamental aim is to promote ‘self care’ and ‘self management’, supporting people with chronic and painful conditions to
cope with their problems. We encourage patients to take an active role in managing their care. Knowledge about their
specific conditions can enable approaches that prevent these conditions from getting worse and reduce the disability arising
from incurable disease”.
BSPAR (stand 70)
The British Society for Paediatric and Adolescent Rheumatology (BSPAR) is the professional body that represents doctors,
nurses, occupational therapists, physiotherapists and other health care professionals who care for children and young people
with arthritis and other Rheumatic conditions.
BSPAR is responsible for setting clinical standards, promoting research and educating patients, parents and future
generations of rheumatology clinicians. www.bspar.org.uk
British Sjögren’s Syndrome Association (stand 68)
The British Sjögren's Syndrome Association is a registered charity and self help organisation dedicated to providing mutual
support and information to individuals affected by Sjögren's Syndrome - the second most common auto-immune disease
after Rheumatoid arthritis. We aim to educate patients, GPs, dentists and other medical professionals about the condition,
raise awareness surrounding its existence and symptoms and support research into its cause and treatment.
BSR (stand 52)
The British Society for Rheumatology (BSR) is a professional medical society with 1,400 members. We are committed to
advancing knowledge and practice in the field of rheumatology. Visit the BSR stand to find out more about the society's
work in promoting arthritis and musculoskeletal conditions as a health priority and pick up other useful information
including copies of BSR's new draft clinical guidelines.
BSR Biologics Register (BSRBR) (stand 37)
The British Society for Rheumatology Biologics Register (BSRBR) is a prospective observational cohort study of all patients
receiving anti-TNFα therapy for rheumatic conditions in the UK. The BSRBR collect data on all anti-TNFα_ patients on a
6-monthly basis (for at least five years) via the rheumatologist. The aim of this data collection is to monitor changes to
drug therapy, disease activity and the occurrence of adverse events. A comparison cohort of similar patients receiving
conventional therapy is being collected at the same time.
84

Children’s Chronic Arthritis Association (stand 69)
CCAA is the leading charity run by parents and professionals to provide help and information for children with
arthritis, their families and professionals involved with their care. We offer emotional and practical support to
maximize the choices and opportunities and raise awareness of childhood arthritis in the community.
We provide a national support network of parents and we host an educational weekend for the whole family.
Clinovia Ltd (stand 30)
Clinovia is Britain’s most experienced home healthcare company providing flexible care and service programmes that
encompass drug compounding and deliver y, specialist nursing care and clinical support, reporting and monitoring.
Our partnership approach helps healthcare providers to meet patient care targets and reduce waiting lists, whilst
ensuring patients nationwide receive quality clinical care in the comfort and convenience of their own home.
DJ Orthopedics (stand 44)
dj Orthopedics is a global orthopaedic company specialising in the design, manufacture and marketing of products
that rehabilitate soft tissue, protect against injury and assist in the treatment of osteoarthritis of the knee.
The DonJoy (trademark) range of osteoarthritis bracing presented at this meeting includes the newly introduced OA
Everyday and the OAdjuster. These are designed to help relieve the pain associated with unicompartmental
osteoarthritis.
Dynamic Imaging (stand 33)
Dynamic Imaging manufactures and distributes a range of ultrasound scanners that are ideal for use in the
Rheumatology clinic. Simple to use but powerful in their diagnostic capabilities these systems can be used for the early
diagnosis of erosions, synovitis, rotator cuff pathology, and guided injections. Dynamic Imaging is a major supporter of
ultrasound training courses.
Eli Lilly & Co Ltd (stand 41)
Eli Lilly and Company, founded in Indianapolis in 1876, is one of the world's largest research-based pharmaceutical
companies, dedicated to creating and delivering innovative pharmaceutical healthcare solutions that enable people to
live longer, healthier and more active lives.
To assist clinicians in their therapeutic management of Osteoporosis, Lilly has two products each catering for different
patient needs, - Raloxifene can be used in the early post menopausal stage, whilst Teriparatide was recently launched
for the treatment of severe osteoporosis. For additional information, please come and talk to us at stand 41.
ERAN (stand 45)
The Early Rheumatoid Arthritis Network (ERAN) has been recognised as part of the sponsored National Clinical Audit
Programme (Commission for Health – CH).
Make sure you are involved in this rapidly expanding Network. Come and visit stand 45 for more information or
contact Wendy Garwood on +44 (0)1753 480400 or wgarwood@phlexglobal.com
Genzyme Biosurgery (stand 4)
Synvisc ® is the viscosupplement clinically proven to relieve the pain and immobility of knee OA for up to 12 months.
Now also clinically proven and approved for use in patients with symptomatic hip OA, Synvisc is effective in all stages
of joint pathology, and is particularly indicated for patients where symptoms are not controlled by conservative
measures, where NSAID's are contraindicated, or where surgery should be delayed or avoided.
Graphnet Health Ltd (stand 31)
Blood Monitoring and Rheumatology Solution.
Graphnet’s blood Monitoring and Rheumatology solution provides improved patient safety with crucial Blood
monitoring including DNA’s, Out of range, and Significant changes that can be individualised to the patient.
Our solution refreshes dated legacy systems with full access to historical data, Improves performance and productivity
by automating, streamlining and optimizing complex clinical processes. Complete multidisciplinary clerking and
workflow which is commissioned, specified and tailored to your needs matching your workflow and documentation
whilst supporting audit, research and relevant registers. It reduces duplication and effort whilst providing
pre-population of data, reducing errors and improving information.
85

Healthcare at Home (stand 34)
Healthcare at Home is by far the UK’s largest and most experienced provider of acute therapy in the home. In addition
to early discharge programmes, specialist outpatient treatment services and outreach home chemotherapy, we offer a
broad range of clinical services. These include clinical trials, pharmacy and full logistical and customer support. All of
our services are designed to provide the highest quality patient care.
Institute of Healthcare Research (stand 5)
IHR is a data collection agency involved in long-term studies. Our aim is to develop relationships with physicians in
the UK, Germany, Spain, France and Italy. Data is collected continuously, in strict confidence, to the highest standards
in the industry. In return, Physicians are rewarded through our Medical Incentives Plan – attendance at conferences, a
selection of gifts, donations to charity – you decide!!
Janssen-Cilag Ltd (stand 2)
Janssen-Cilag Ltd is a research based company marketing medicines across a wide range of therapeutic areas and has
a number of specialist products that have dramatically improved patient care. Janssen-Cilag Ltd holds particularly
strong positions in anaesthesia, gastroenterology, dermatology, HRT, psychiatry, neurology, urology and biotechnology.
Kyphon Europe (stand 50)
Kyphon’s vision is to improve patients’ quality of life through revolutionising the practice of medicine.
BALLOON KYPHOPLASTY is a minimally invasive orthopaedic procedure to treat Vertebral Compression Fractures.
The technique is designed to reduce and stabilise the fracture in a controlled way, to correct vertebral body deformity
and to provide significant pain reduction and improve parameters contributing to Quality Of Life.
WWW.KYPHON-EU.COM
Lupus UK (stand 67)
LUPUS UK is the only national charity for patients with lupus offering support through our voluntary network of over
30 Regional Groups. Our priorities are to increase lupus awareness amongst the public and the medical profession,
provide support to our members, and raise valuable funds towards research and Lupus Nurses. Tel:01708 731251
(24 hour answerphone) website www.lupusuk.com
Medac UK (stand 51)
Medac is an innovative German pharmaceutical company with experience in oncology, haematology, fibrinolysis and
automimmune disease. SST ® treats dry mouth by locally stimulating saliva production.
Medac is working with Central Homecare Limited on a new project. CHL provide a bespoke home delivery service
for a wide range of rheumatology drugs. The service includes prescription management, a choice of delivery times
and clinical waste collection.
Merck Sharp & Dohme Limited (MSD) (stand 6-13)
Merck Sharp & Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey,
USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide
range of innovative pharmaceutical products to improve human health.
Musculoskeletal Specialist Library (NLH) (stand 47)
The Musculoskeletal Specialist Library was launched in November 2003. It has been created and is maintained and
regularly updated by a team which includes representatives from all the professional groups involved in the care of
those suffering from musculoskeletal disorders. The site is intended primarily to support clinicians and allied health
professionals and is part of the NHS National Library for Health.
NASS (stand 66)
NASS was founded in 1976 to provide patient education and support. It has donated over 100,000 guidebooks,
mainly to rheumatologists and physiotherapists, produces a twice-yearly membership journal, and other publications.
It has over 100 branches treating 1,500 patients with supervised remedial physiotherapy one evening a week, also a
video and DVD of home exercises. At the moment NASS is actively engaged in the topic of anti-TNF.
86

National Rheumatoid Arthritis Society (stand 57)
NRAS is a patient led charity focussing specifically on Rheumatoid Arthritis
Key Aims
• To provide advice, information and support to people with RA, their families and carers
• To facilitate the networking of people with RA and encourage self-help
• To raise public and government awareness of Rheumatoid Arthritis
• To campaign for more funding and better use of existing resources in the treatment of Rheumatoid Arthritis
Novartis Pharmaceuticals (stand 22)
As a world leader in pharmaceuticals, our goal is to provide a broad portfolio of innovative and effective products and
services to patients through healthcare professionals around the world.
Our current portfolio includes over 40 marketed products. Novartis also has more than 75 projects in various stages of
clinical development including the investigation of treatments for arthritis & bone disorders.
Oxford Immunotec Ltd (stand 39)
The Oxford Immunotec high sensitivity, in vitro T SPOT-TB test for active and latent tuberculosis is particularly
suitable for immunosuppressed populations and extrapulmonary TB. It is very specific with no cross-reactivity to
BCG or M. avium.
T SPOT-TB can identify TB contacts, and those who are regularly screened, including healthcare workers, HIV patients,
Cancer, transplant and immuno-suppressed patients, including anti-TNF alpha therapies, immigrants and prisoners.
Oxford University Press (stand 35)
Rheumatology is an international peer reviewed journal publishing the highest quality clinical and scientific papers,
and is the official publication of the British Society for Rheumatology. With an impact factor of 3.760 and
extremely rapid online and print publication times, Rheumatology is one of the leading journals in the field.
To pick up your free copy, visit the Oxford University Press booth at stand 35.
Pfizer UK (stand 23)
Pfizer discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and
many of the world's best-known consumer treatments. In 2003, Pfizer's net contribution to UK Government was over
£190 million; with a research and development spend of over £600 million.
Q-Med (stand 27)
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces, markets
and sells medical implants. All products are based on the company’s patented NASHA technology - Non-Animal
Stabilized Hyaluronic Acid. So far, approximately 3,500,000 treatments have been carried out with Q-Med’s
NASHA-products. Website: www.durolane.com. Email: info.uk@q-med.com
The Raynaud’s & Scleroderma Association (stand 65)
The Raynaud's & Scleroderma Association are launching several new scleroderma patient leaflets. A new publication,
The Lungs in Scleroderma, will also be available together with a range of Health Professional booklets. The
Association aims to promote a greater awareness and understanding of these conditions and to raise funds for
research and welfare projects. To be added to our mailing list visit Stand No 65.
Roche Products Ltd. (stand 16)
Roche is one of the world’s leading research-based healthcare groups. With the aim of enhancing people’s health and
quality of life, our core businesses in pharmaceuticals and diagnostics provide innovative products and services for the
prevention, diagnosis and treatment of disease. In the UK, Roche employs around 1,800 people in prescription and
over the counter medicines and diagnostics. Together, our businesses in the UK strive to make a real difference to
healthcare, the UK’s health services and, most importantly, people’s lives. Visit our website at www.rocheuk.com.
Royal College of Nursing Rheumatology Forum (stand 64)
The Royal College of Nursing Rheumatology Forum (RCNRF) supports nurses in raising awareness of musculoskeletal
conditions in order to enhance the provision of high quality services in all care settings. Among many other activities
the committee represents nurses on working parties and lobbying to improve standards of care - working with others
& umbrella organisation the Arthritis and Musculoskeletal Alliance (ARMA). www.rcn.org.uk
87

Schering-Plough Immunology Ltd (stand 21)
Schering-Plough Ltd is one of the world’s leading pharmaceutical corporations.
Schering-Plough Immunology invites you to Stand 21 to find out more information about the treatment of rheumatoid
arthritis, ankylosing spondylitis & psoriatic arthritis, and to our Satellite Symposium on Wednesday evening.
Schering-Plough would like to wish all the BSR and BHPR delegates an enjoyable conference and look forward to meeting you.
The Scleroderma Society (stand 43)
3 Caple Rd, Harlesden, London NW10 8AB
Tel: 020 8961 4912
info@sclerodermasociety.co.uk
www.sclerodermasociety.co.uk
Charity Registration No: 286736
The Scleroderma Society was founded in 1982. Our aim is to help people with scleroderma and their families to obtain
appropriate support/information and fund medical research. Scleroderma is a rare connective tissue disease and the Society
helps people with scleroderma/members to feel less isolated through group meetings, quarterly newsletters, telephone and
email helpline and web message board. Patient information leaflets available at our stand.
Servier Laboratories (stand 17)
Servier Laboratories is an independently owned pharmaceutical company committed to research, investing over 25% of
annual turnover to it. Servier has over 16,000 employees worldwide including 2,500 in research and development
Servier’s commitment to the management of osteoporosis is evident with the introduction of the first DABA, dual action
bone agent. Visit the Servier stand to find out more information.
TRB Chemedica (stand 36)
TRB Chemedica specialises in the manufacture of a variety of highly purified, non-animal sourced, Hyaluronic Acid based
products. Ostenil is for the relief of OA pain in large joints, for example the knee and hip & Ostenil mini is for the relief of OA
pain in the small joints, for example, the upper and lower limbs and the facet joints of the lumbar spine.
UpToDate (stand 49)
UpToDate Putting Clinical Information into Practise
UpToDate is a web based clinical resource which is also available via CD Rom and in a Pocket PC format.
UpToDate gives you succinct information on more than 6,000 clinical topics. It offers current, fully referenced,
comprehensive information which is easily navigated. Synthesized, evidenced based information which can be
applied directly to patients.
To evaluate UpToDate for yourself please come to stand 49 to arrange a 30day pass to UpToDate free of charge.
www.UpToDate.com
Vertec Scientific Ltd (stand 42)
Vertec Scientific Ltd, Hologic Bone Density Systems, launch the latest advances in Vertebral Imaging, Radiologic Vertebral
Assessment (RVA), Paediatric Database and QDR Mobility, from the leader in Bone Densitometry assessment.
Please come and visit our stand for a demonstration on the latest technology in Osteoporosis Assessment.
Wisepress Online Bookshop (stand 32)
Wisepress Online Bookshop is pleased to present a display of titles selected especially for the British Society for
Rheumatology Annual Meeting from the world’s leading publishing houses. All titles can be bought or ordered at the
congress or via our website: www.wisepress.co.uk. Whatever your book requirements, Wisepress will be happy to help.
Wyeth Pharmaceuticals (stand 20)
Tel: 01628 604377
Fax: 01628 666368
Wyeth welcomes all delegates to Birmingham and invites you to visit us at our stand.
Wyeth is one of the UK's leading pharmaceutical companies with a significant commitment to clinical research. Wyeth is
committed to working in partnership with Government, healthcare professionals and patient support organisations to
continue to enhance the quality of life for as many people as possible.
Worldwide, the company focuses on finding groundbreaking medical therapies, and has a broad portfolio of leading
products across a wide range of therapy areas, including rheumatological disease.
88

Abstract Reviewers
The BSR Heberden Committee was expanded substantially for the purposes of abstract
assessment to ensure that every abstract was peer reviewed, blind, by at least 4 reviewers.
The Heberden Committee is extremely grateful for the assistance of everyone that gave up
their time to review abstracts, and acknowledges them accordingly:
Dr David Abraham
Dr Wilhelm Aicher
Dr Simon Allard
Prof Rieke Alten
Prof Berliner
Dr Rupa Bessant
Dr Fraser Birrell
Dr Simon Bowman, Heberden Committee
Dr Paul Bowness, Heberden Committee
Dr Matt Brown
Dr Marwan Bukhari, Heberden Committee
Dr Jiri Chard
Prof Yuti Chernajovsky, Heberden Committee
Dr Ernest Choy
Dr Gavin Clunie
Dr David Collins, Heberden Committee
Dr Andy Cope
Prof Jane Dacre
Dr Bhaskar Dasgupta
Dr Joyce Davidson
Dr David D’Cruz
Dr Chris Denton
Dr Oliver Distler
Prof Mike Doherty
Dr Krysia Dziedzic, Heberden Committee
Dr Sally Edmonds, Heberden Committee
Dr Christoph Fiehn
Dr Helen Foster
Dr Simon Frostick
Prof Hill Gaston, Heberden Committee
Dr Caroline Gordon
Prof Wolfgang Gross
Dr Alan Hakim
Dr Frances Hall
Dr John Halsey
Dr Alison Hammond
Prof Dorian Haskard
Dr Andy Hassell
Prof Elaine Hay
Dr Ariane Herrick
Dr Rod Hughes
Dr Richard Hull
Dr Mike Hurley
Dr Nigel Hurst
89
Dr Charles Hutton
Dr Rachel Jeffery, Heberden Committee
Dr Adrian Jones, Heberden Committee
Prof Kaltwasser
Dr Lesley Kay
Dr Gernot Keyszer
Dr Munther Khamashta
Dr George Kitas, Heberden Committee
Dr Lange
Dr Alison Leak, Heberden Committee
Dr Raashid Luqmani
Prof Peter Maddison, Heberden Committee
Prof Bernhard Manger
Prof Elisabeth Märker-Hermann
Mrs Candy McCabe
Dr Dennis McGonagle
Dr Julie McHale
Prof Robert Moots, Heberden Committee
Dr Ulf Muller-Ladner
Dr Elena Neumann
Dr Thomas Pap
Dr Laslo Pazmany
Prof H-H Peter
Prof Costantino Pitzalis
Dr Karim Raza
Dr Mageed Rizgar
Dr Joerg Schedel
Prof Schneider
Dr Schulze-Koops
Prof Rainer Straub
Prof Swoboda
Prof Deborah Symmons
Dr Alister Taggart
Dr Paul Thompson
Dr Jon Tobias, Heberden Committee
Dr Gareth Treharne
Dr Patrick Venables
Dr David Walker
Dr Richard Watts, Heberden Committee
Dr Gerry Wilson
Dr Jane Worthington
Dr Adam Young
Prof Zink

Acknowledgements
The British Society for Rheumatology would like to thank the following companies for
their contribution to the success of the 2005 Annual Meeting, in particular for support
in the areas listed below:
Abbott for their support of the BSR Innovations in Rheumatology Awards.
MSD for their support of the BSR Young Investigator Awards.
Novartis for sponsoring the provision of a cyber-café in the exhibition hall.
Pfizer for sponsoring the delegate bags and speakers CD-ROMs.
Wyeth for sponsoring the registration staff and badges, and for organising the fun run.
Abbott, MSD and Schering Plough for supporting the provision of educational
satellite symposia for delegates.
Additionally, we would like to thank all exhibitors for their continued support in
providing added depth and colour to the BSR Annual Meeting through an
interactive exhibition.
BSR, 41 Eagle Street, London WC1R 4TL
Telephone: +44 (0) 207 242 3313 Fax: +44 (0) 207 242 3277
Email: conferences@rheumatology.org.uk
Website: www.rheumatology.org.uk
A Company limited by guarantee with charitable status
VAT No. 404 5637 66 Company Reg. No. 3470316 Charity Reg. No. 1067124